tyrosine has been researched along with tirofiban in 960 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 94 (9.79) | 18.2507 |
| 2000's | 589 (61.35) | 29.6817 |
| 2010's | 261 (27.19) | 24.3611 |
| 2020's | 16 (1.67) | 2.80 |
| Authors | Studies |
|---|---|
| Duggan, ME; Egbertson, MS; Halczenko, W; Hartman, GD; Laswell, WL; Lynch, RJ; Manno, PD; Naylor, AM; Smith, RL; Zhang, G | 1 |
| Cook, JJ; Holahan, MA; Lynch, JJ; Lynch, RJ; Mellott, MJ; Ramjit, DR; Sitko, GR; Stabilito, II; Stranieri, MT; Zhang, G | 1 |
| Gilbert, JD; Hand, EL; Hichens, M; Olah, TV; Yuan, AS | 1 |
| Arnout, J; Barrett, JS; De Lepeleire, I; Deckmyn, H; Gould, RJ; Hand, E; Murphy, G; Panebianco, D; Peerlinck, K; Vermylen, J | 1 |
| Chang, CT; Duggan, ME; Egbertson, MS; Gould, RJ; Halczenko, W; Hartman, GD; Laswell, WL; Lynch, JJ; Lynch, RJ; Manno, PD | 1 |
| Bruttger, O; Cook, NS; Hagenbach, A; Pally, C | 1 |
| Arnout, J; Barrett, J; De Lepeleire, I; Deckmyn, H; Farrell, D; Goldberg, M; Hand, E; Panebianco, D; Peerlinck, K; Vermylen, J | 1 |
| Ambrose, J; Cohen, M; Fitzpatrick, V; Herrmann, HC; Kereiakes, DJ; Kleiman, NS; McKee, DB; Palabrica, T; Rodriguez, S; Sax, FL; Sutton, JM; Weaver, WD | 1 |
| Tcheng, JE | 4 |
| Anderson, KM; Coller, BS; Weisman, HF | 1 |
| Anderson, HL; Edmunds, LH; Gikakis, N; Gorman, JH; Gould, RJ; Hiramatsu, Y; Marcinkiewicz, C; Niewiarowski, S | 1 |
| Ellis, JD; Gilbert, JD; Hand, EL | 1 |
| Verheugt, FW | 1 |
| Gawaz, M; Neumann, FJ; Schömig, A | 1 |
| Karlberg, KE; Martinsson, A; Mattsson, E; Nyqvist, O; Rasmanis, G; Sylvén, C | 1 |
| Ikeda, Y; Kondo, K; Nakashima, M; Umemura, K | 1 |
| Moliterno, DJ; Steinhubl, SR | 1 |
| Adgey, AA | 2 |
| Snapinn, SM | 1 |
| Ferguson, JJ; Lau, TK | 1 |
| Badimon, JJ; Chesebro, JH | 1 |
| Armstrong, PW; Braunwald, E; Califf, RM; Gibler, WB; Hamm, CW; Maseri, A; Simoons, ML; Van de Werf, F | 1 |
| Marwick, C | 1 |
| Aoki, T; Honda, S; Okubo, M; Seki, J; Senzaki, K; Takahashi, F; Takasugi, H; Tanaka, A; Tomiyama, Y | 1 |
| Cohen, DJ; Deckelbaum, LI; Gibson, CM; Goel, M; Harris, KE; King, SB; Piana, RN | 1 |
| Clem, JR; Falls, S | 1 |
| Béguin, S; de Zwaan, C; Hemker, HC; Keularts, IM | 1 |
| Braunwald, E; Cannon, CP; Demopoulos, LA; Gormley, GJ; Robertson, DH; Weintraub, WS | 1 |
| Liron, M | 1 |
| Lindenfeld, J | 1 |
| Aoki, T; Honda, S; Kurata, Y; Matsuzawa, Y; Seki, J; Shiraga, M; Tomiyama, Y | 1 |
| Lincoff, AM | 1 |
| Kleiman, NS; Ramanathan, A | 1 |
| Dykun, Y; Ronner, E; Simoons, ML; van den Brand, MJ; van der Wieken, LR | 1 |
| Kleiman, NS | 1 |
| Alexander, JH; Harrington, RA | 1 |
| Goa, KL; McClellan, KJ | 1 |
| Frojmovic, M; Théroux, P; Xiao, Z | 1 |
| Barr, E; Becker, ER; Boccuzzi, SJ; Burnette, J; Cannon, CP; Cohen, DJ; Culler, SD; Demopoulos, L; Ellis, SG; Feeny, D; Kosinski, A; Krumholz, H; Mahoney, E; Robertson, D; Spertus, JA; Weintraub, WS | 1 |
| Faul, JD; Huang, J; Lucchesi, BR; Rebello, SS | 1 |
| Hensley, S | 1 |
| Bakhos, M; Fareed, J; Jeske, WP; Lewis, BE; Leya, F; Walenga, JM; Wallis, DE | 1 |
| Al-Mousa, EN; Arshad, MN; Campsey, M; Gandhi, R; Gibson, CM; Marble, SJ; Mattson, S; Mesley, R; Moynihan, JL; Murphy, S; Ryan, KA; Swanson, J | 1 |
| Bergquist, PA; Cook, J; Forsyth, RJ; Holahan, M; Hunke, WA; Kenney, RR; Manas, D; Reed, RA | 1 |
| Kaluza, G; Kleiman, NS; Mazur, W | 1 |
| Colombo, A; Dangas, G | 1 |
| Hillegass, WB; Newman, AR; Raco, DL | 1 |
| Adachi, T; Kimura, Y; Marukawa, K; Matsumoto, Y; Okumura, H; Tani, T | 1 |
| Fisher, I; Ritter, JM; Robinson, P | 1 |
| Holmes, MB; Schneider, DJ; Sobel, BE | 1 |
| Chanu, B | 1 |
| Phillips, J; Stouffer, GA; Subbarao, VD | 1 |
| Klein, WW | 1 |
| Kiowski, W; Meyer, BJ; Szucs, TD | 1 |
| Edmunds, LH; Gorman, JH; Hiramatsu, Y; Rao, AK; Sun, L | 1 |
| Bergquist, PA; Han, RY; Hunke, WA; Kenney, RR; Zimmerman, J | 1 |
| Abbottsmith, CW; Broderick, TM; Hattemer, C; Kereiakes, DJ; Lacock, P; Mueller, M; Roth, EM; Runyon, JP; Schneider, J; Shimshak, T; Whang, D | 1 |
| Adgey, AA; Mathew, TP | 1 |
| Despotis, GJ; Moon, MR; Skubas, NJ; Vlasnic, JJ | 1 |
| Dunn, A | 1 |
| Harrington, RA | 1 |
| Juran, NB | 1 |
| Dyke, CM | 1 |
| Chase, SL | 1 |
| Sax, FL; Snapinn, SM; Théroux, P; Zhao, XQ | 1 |
| Boccuzzi, SJ; Burnette, J; Cohen, DJ; Cook, JR; Culler, S; Kosinski, AS; Weintraub, WS | 1 |
| Bhatia, D; Dyke, C | 1 |
| Arison, B; Balani, SK; Cui, D; Duncan, CA; Ellis, JD; Gorham, LM; Polsky, SL; Prueksaritanont, T; Ramjit, HG; Slaughter, DE; Theoharides, AD; Vickers, S; Vyas, KP | 1 |
| Farmer, JA; Frangogiannis, NG; Lakkis, NM | 1 |
| Akkerhuis, KM; Boersma, E; Califf, RM; Simoons, ML; Théroux, P; Topol, EJ | 1 |
| Deu, A; Goldmann, B; Hamm, CW; Heeschen, C; Langenbrink, L; White, HD | 1 |
| Bell, DM | 1 |
| Abbottsmith, CA; Anderson, LC; Blanck, C; Broderick, TM; Howard, W; Kereiakes, DJ; Lacock, P; Mueller, M; Roth, EM; Schneider, J; Whang, D | 1 |
| Atar, S; Birnbaum, Y; Luo, H; Nagai, T; Siegel, RJ | 1 |
| Borzak, S; Cohen, M; Deckelbaum, LI; Diodati, JG; Harris, KE; Huynh, T; Laramée, P; Lo, MW; Sax, FL; Squire, IB; Théroux, P; Thornton, AR; Weber, S; White, HD | 1 |
| Ali, A; Grady, KJ; Patil, S; Schreiber, TL | 1 |
| Wallentin, L | 1 |
| Abbottsmith, CW; Broderick, T; Howard, WL; Kereiakes, DJ; Martin, LH; McDonald, M; Roth, EM; Schneider, J; Shimshak, T; Whang, DD | 1 |
| Lincoff, AM; Roe, MT; Sapp, SK | 1 |
| Borchardt, RT; Camenisch, G; Hugger, E; Sane, DC; Wang, B; Wang, W; Wheeler, GL; Zhang, H | 1 |
| Doerr, G; Fleck, E; Graefe, M; Graf, K; Grill, M; Kappert, K; Kintscher, U; Schmidt, G; Wollert-Wulf, B | 1 |
| Desai, M; Lucore, CL | 1 |
| Galli, M; Maggioni, AP; Tavazzi, L; Vassanelli, C | 1 |
| Mohammad, SF; Solen, KA; Sukavaneshvar, S | 1 |
| Amidon, JB; Amidon, TM; Benson, JM; Coffler, D | 1 |
| Feldman, DN; Jayasundera, TG; Marmur, JD | 1 |
| Cohen, M | 3 |
| Zidar, JP | 1 |
| Herrmann, HC | 2 |
| Blennerhassett, J; Burnett, JR; McConnell, W; O'Leary, PC; Vasikaran, SD | 1 |
| Agostoni, P; Biondi-Zoccai, GG | 1 |
| Califf, RM; Lincoff, AM; Topol, EJ | 1 |
| Ikeda, Y | 1 |
| Collard, CD; Lewis, W | 1 |
| Broderick, TM; Kereiakes, DJ; Runyon, JP; Shimshak, TM | 1 |
| Byrne, KH; Hanlon, SJ; MacCallum, EM | 1 |
| Collinson, J; Flather, M; Gomma, A; Purcell, H | 1 |
| Chen, JC; Ishimaru, S; Powell, LL; Serna, DL; Wang, D; Wilson, SE; Yomo, T | 1 |
| Ferguson, JJ | 2 |
| Morais, J | 1 |
| Blankenship, JC; Dasgupta, H; Demko, SL; Frey, CM; Menapace, FJ; Wood, GC | 1 |
| De Rosa, V; Polimeno, S | 1 |
| Ball, S; Becker, RC; Li, Y; Spencer, FA | 1 |
| Chadow, HL; Giarraffa, L; Gunsburg, MY; Hauptman, RE; Rafii, SE; Strom, JA; VanAuker, M | 1 |
| Eto, K; Goto, S; Handa, S; Ichikawa, N; Isshiki, T; Kim, JY; Nagaoka, Y; Sakakibara, M; Shimazaki, T; Yoshida, M | 1 |
| Cheung, S; Mithani, V; Watson, RM | 1 |
| Anderson, HV; Assali, AR; Fujise, K; Ghani, M; Rosales, OR; Schroth, G; Sdringola, S; Smalling, RW; Westbrook, LA | 1 |
| Blankenship, JC; Frey, CM; Memon, MA; Menapace, FJ; Wood, GC | 1 |
| Jang, IK; Sabatine, MS | 1 |
| Bozarth, JM; Forsythe, MS; Mousa, SA; Slee, A | 1 |
| Mak, KH; Moliterno, DJ | 1 |
| Holmes, DR | 1 |
| Bhatt, DL; Topol, EJ | 1 |
| Chae, CU; Giugliano, R; Hahn, SS; Jang, IK; Januzzi, JL; Lewandrowski, K; Theroux, P | 1 |
| Barnard, MR; Frelinger, AL; Furman, MI; Krueger, LA; Mascelli, MA; Michelson, AD; Nakada, MT | 1 |
| Blankenship, JC; Iliadis, EA | 1 |
| Moliterno, DJ; Topol, EJ | 2 |
| Braunwald, E; Califf, RM; Cannon, CP; Fox, KA; Fuster, V; Gibler, WB; Harrington, RA; King, SB; Kleiman, NS; Theroux, P; Topol, EJ; Van de Werf, F; White, HD; Willerson, JT | 1 |
| Shepard, RW | 1 |
| Alexander, J; Barr, E; Ghannam, AF; Pharand, C; Sax, FL; Snapinn, S; Théroux, P | 1 |
| Rasmanis, G; Sylvén, C | 1 |
| Agustí, A; Araujo, R | 1 |
| Deckelbaum, LI; Dodge, JT; Dotani, I; Gibson, CM; Goel, M; King, SB; Marble, SJ; Murphy, SA | 1 |
| Bigonzi, F; Cohen, M; Danchin, N; Fox, KA; Gensini, GF; Gurfinkel, EP; Huber, K; Le-Louer, V; Maritz, F; Timerman, A; Vittori, L; White, H | 1 |
| Mitka, M | 1 |
| Montalescot, G | 2 |
| Droullé, C; Garnotel, R; Hézard, N; Metz, D; Nguyen, P; Potron, G | 1 |
| Hamm, C | 1 |
| Bachmann, LM; Golder, S; Kleijnen, J; McDonagh, MS; ter Riet, G | 1 |
| Hetzer, R; Koster, A; Kuppe, H; Loebe, M; Mertzlufft, F | 1 |
| Binder, WD; Brown, DF; Nadel, ES; Reisner, AT | 1 |
| Bach, F; Fischer, T; Hetzer, R; Koster, A; Kukucka, M; Kuppe, H; Loebe, M; Mertzlufft, F; Meyer, O | 1 |
| Lakkis, NM; Nguyen-Ho, P | 1 |
| Alexander, J; Barr, E; Dupuis, J; Gervais, P; Grandmont, D; Huynh, T; Kouz, S; Laramée, P; Pesant, Y; Sax, FL; Théroux, P | 1 |
| Berkowitz, SD | 1 |
| Goldberg, L; Mekel, J | 1 |
| Kondo, K | 1 |
| Husted, SE; Rasmussen, S | 1 |
| Brown, DL; Chang, CJ; Fann, CS | 1 |
| Cannon, CP; Cohen, MC; Hochman, JS; Lucore, CL; O'Rourke, RA; Popma, JJ | 1 |
| Danchin, N | 1 |
| Bala, M; Barber, BL; Lage, MJ; McCollam, PL; Scherer, J | 1 |
| Bassand, JP | 2 |
| Ganz, P; Kirshenbaum, JM; Liu, CB; Piana, RN; Popma, JJ; Rogers , C; Selwyn , AP; Simon, DI | 1 |
| Rodrigues, HL | 1 |
| Gawaz, M; Hochholzer, W; Neumann, FJ; Pogatsa-Murray, G; Schömig, A | 1 |
| Jordan, RE; Marciniak, SJ; Mascelli, MA | 1 |
| Hézard, N; Metz, D; Nguyên, P; Potron, G; Tassan-Mangina, S | 1 |
| Ahmad, S; Fareed, J; Jeske, WP; Ma, Q; Walenga, JM | 1 |
| Auer, J; Berent, R; Eber, B; Maurer, E; Mayr, H; Weber, T | 1 |
| Goldmann, BU; Hamm, CW | 1 |
| Schrör, K | 1 |
| Holmes, MB; Kabbani, SS; Schneider, DJ; Sobel, BE; Terrien, CM; Watkins, MW | 1 |
| Ambrose, JA; Barua, RS; Coppola, J; Dominguez, A; Doss, R; Duvuri, S; Geagea, JM; Giedd, K; Hawkey, MC; Nguyen, TH; Palla, V; Saha, DC | 1 |
| Willerson, JT; Wu, KK | 1 |
| Berger, PB; Braden, GA; Casterella, PJ; Dangas, G; Gallo, R; Holmes, DR; Jia, G; Kereiakes, DJ; Lincoff, AM; Moliterno, DJ; Navetta, FI; Popma, JJ; Sane, DC; Saucedo, JF; Steinhubl, SR; Talley, JD; Tcheng, JE; Teirstein, PS; Theroux, P | 1 |
| Nurden, P | 1 |
| Adam, PC; Evemy, KL; Pemberton, J | 1 |
| Proimos, G | 1 |
| Vernon, SM | 1 |
| Braunwald, E; Cannon, CP; DeLucca, PT; Demopoulos, LA; DiBattiste, PM; Frey, MJ; Gibson, CM; Lakkis, N; Neumann, FJ; Robertson, DH; Vicari, R; Weintraub, WS | 1 |
| Bertrand, M; Cohen, DJ; Cohen, EA; Demopoulos, L; DiBattiste, PM; Grines, CL; Herrmann, HC; Moliterno, DJ; Neumann, FJ; Powers, ER; Stone, GW; Topol, EJ | 1 |
| Throckmorton, DC | 1 |
| Boden, WE; McKay, RG | 2 |
| Böck, K; Calais, P; Herrlinger, JD; Schommer, B; Schröder, J | 1 |
| Bergquist, PA; Hunke, WA; Manas, D; Reed, RA | 1 |
| Stone, GW | 1 |
| Ali, M; Carville, D; George, S; Guyer, K; Lakkis, NM; Thomas, E | 1 |
| Kurz, HI; Lasala, JM; Taniuchi, M | 1 |
| Lele, M; Sajid, M; Stouffer, GA; Wajih, N | 1 |
| Becker, RC; Li, YF; Spencer, FA | 2 |
| Bilheimer, D; Blazing, MA; Braunwald, E; Califf, RM; De Lemos, JA; Dyke, CK | 1 |
| Ito, H; Kimura, Y; Ozeki, Y; Sudo, T | 1 |
| Schrör, K; Weber, AA | 1 |
| Jang, IK; Januzzi, JL; Sabatine, MS; Snapinn, S; Théroux, P | 1 |
| Arjmand, R; Arjomand, H; Fischer, HA; Sokil, AB; Wolf, NM | 1 |
| Cemri, M; Cengel, A; Dörtlemez, O; Ozdemir, M; Timurkaynak, T; Yalçin, R | 1 |
| Caputo, RP; Esente, P; Giambartolomei, A; Reger, M; Simons, A; Wagner, S | 1 |
| Bertel, O; Genoni, M; Maloigne, M; Turina, M; Zeller, D | 1 |
| Lassila, R | 1 |
| Breddin, HK; Esslinger, HU; Graff, J; Harder, S; Kirchmaier, CM; Klinkhardt, U; Westrup, D | 1 |
| Corno, A; Horisberger, J; Marty, B; Mueller, X; von Segesser, LK | 1 |
| Caglar, N; Dagdelen, S; Ergelen, M; Soydinc, S | 1 |
| Becker, RC; Denier, D; Gouveia, W; Kimmelstiel, C; MacIsaac, DA; Miele, R; Phang, R; Rand, W; Rehman, A; Rhofiry, J | 1 |
| Chae, CU; Jang, IK; Januzzi, JL; Sabatine, MS | 1 |
| Amerigo, L; Cannizzaro, S; Castello, A; D'Alfonso, G; Pasquale, PD; Sarullo, FM | 1 |
| Doggrell, SA | 1 |
| Bala, M; Lage, MJ; McCollam, PL | 1 |
| Bautista, FJ; Garabito, MJ; Jimenez, L; Perez-Rodrigo, I; Santos-Rubio, MD | 1 |
| Lorenz, TJ; O'Shea, JC; Strony, J; Tcheng, JE | 1 |
| Gazewood, J | 1 |
| Anderson, HV; Assali, AR; Fujise, K; Ghani, M; Hale, S; Moustapha, A; Rosales, OR; Salloum, J; Schroth, G; Sdringola, S; Smalling, RW | 1 |
| Badimon, JJ; Delfin, JA; Jayasundera, T; Lev, EI; Marmur, JD; Osende, JI; Richard, MF; Robbins, JA; Rodriguez, O; Sharma, SK | 1 |
| Popma, JJ; Suk, J | 1 |
| Bartsch, G; Baumann, M; Borberg, H; Otto, C; Schmid-Schönbein, H; Schreiner, T; Schwandt, P | 1 |
| Bertrand, M; Braunwald, E; Hamm, CW | 1 |
| Aulich, A; Junghans, U; Seitz, RJ; Siebler, M; Wittsack, HJ | 1 |
| Aulich, A; Freund, HJ; Junghans, U; Seitz, RJ; Siebler, M | 1 |
| Cannizzaro, S; Di Pasquale, P; Giambanco, F; Giubilato, A; Paterna, S; Sarullo, FM; Scalzo, S; Vitrano, MG | 1 |
| Galli, M; Vassanelli, C | 1 |
| Merlini, PA; Rossi, ML | 2 |
| Bizzarri, F; Davoli, G; Frati, G; Lucidi, M; Muzzi, L; Neri, E; Scolletta, S; Toscano, T; Tucci, E | 1 |
| Bauer, M; Fischer, T; Hetzer, R; Koster, A; Krabatsch, T; Kukucka, M; Kuppe, H; Meyer, O | 1 |
| Kini, AS; Mitre, CA; Reich, D; Sharma, SK | 1 |
| Kereiakes, DJ; Kukielka, G; Lorenz, T; Mueller, MN; Nanniazzi-Alaimo, L; Phillips, DR; Young, JJ | 1 |
| Davie, AP; McMurray, JJ | 1 |
| Houghton, AR; Hudson, I; Patel, M | 1 |
| Fröhlich, E; Möckel, M; Störk, T | 1 |
| Galli, M | 1 |
| Albuquerque, A | 1 |
| Chew, DP; Moliterno, DJ | 1 |
| Antman, EM; Braunwald, E; McCabe, CH; Morrow, DA; Snapinn, SM; Theroux, P | 1 |
| Campbell, P | 1 |
| Bakhai, A; Flather, M; Perez de Arenaza, D | 1 |
| Alston, SM; Goodman, PD; Hall, MW; Solen, KA | 1 |
| Scarborough, RM | 1 |
| Fink, GR; Freund, HJ; Junghans, U; Ritzl, A; Seitz, RJ; Siebler, M; Wittsack, HJ | 1 |
| Jiang, J; Sane, DC; Wang, B; Wang, W | 1 |
| Sajid, M; Stouffer, GA | 1 |
| Banaszewski, M; Konopka, A; Stepinska, J; Szajewski, T | 1 |
| Aggarwal, A; DiBattiste, PM; Kabbani, SS; Schneider, DJ; Sobel, BE; Terrien, EF | 1 |
| Johnson, K | 1 |
| Kondo, K; Umemura, K | 1 |
| Adamian, M; Collins, MB; Dangas, G; Iakovou, I; Kobayashi, Y; Lansky, AJ; Leon, MB; Mehran, R; Moses, JW; Polena, S; Roubin, GS; Stone, GW | 1 |
| Cercek, B; Finkelstein, A; Kaul, S; Rukshin, V; Shah, PK; Tsang, V | 1 |
| Bickel, C; Fallen, H; Henkel, B | 1 |
| Brattström, A; Meyners, W; Peters, S; Trümmel, M | 1 |
| Leclerc, JR | 1 |
| Stevens, M | 1 |
| Bertrand, M; Cohen, DJ; Cohen, EA; Cohen, M; DiBattiste, PM; Grines, CL; Herrmann, HC; Moliterno, DJ; Moses, JW; Neumann, FJ; Powers, ER; Stone, GW; Topol, EJ; Wolski, K | 1 |
| DiBattiste, PM; Jang, IK; Januzzi, JL; Snapinn, SM; Theroux, P | 1 |
| DiBattiste, PM; Herrmann, HC; Hirshfeld, JW; Kapoor, S; Klugherz, BD; Kolansky, DM; Magness, K; Swierkosz, TA; Tardiff, DC; Valettas, N; Wilensky, RL | 1 |
| Hantgan, RR; Jerome, WG; Nagaswami, C; Stahle, MC; Weisel, JW | 1 |
| Jacoski, MV; Jennings, LK; White, MM | 1 |
| Bertrand, M; Demopoulos, LA; DiBattiste, PM; Grines, CL; Harris, KE; Herrmann, HC; Meier, B; Moliterno, DJ; Powers, ER; Roffi, M; Topol, EJ | 1 |
| Kereiakes, DJ; Young, JJ | 2 |
| Henry, RG; Little, JW; McIntosh, BA; Miller, CS | 1 |
| Bhatt, DL; Chew, DP | 1 |
| Dauterman, KW; Dodge, JT; Dotani, MI; Gibson, CM; Marble, SJ; Michaels, AD; Murphy, SA | 1 |
| Cucchiara, BL; Hurst, RW; Liebeskind, DS; McGarvey, ML; Pollard, JR; Schwartz, ED | 1 |
| Bobek, J; Farmer, J; Lakiss, N; Lakkis, N | 1 |
| Caron, A; Merhi, Y; Mousa, SA; Théorêt, JF | 1 |
| Califf, RM; Kandzari, DE | 1 |
| Jacobs, C; Kelm, M; Meila, D; Scharf, RE; Schrör, K; Strauer, BE; Weber, AA; Weber, S; Zotz, RB | 2 |
| Barlage, S; Pfeiffer, A; Rothe, G; Schmitz, G; Wimmer, A | 1 |
| Ahmad, S; Fareed, J; Hoppensteadt, DA; Ma, Q; Messmore, HL; Schultz, CL; Untch, B; Walenga, JM | 1 |
| Aster, RH; Bougie, DW; Curtis, BR; Levine, S; Lind, RN; Malik, M; Pereira, J; Wilker, PR; Wuitschick, ED | 1 |
| Bonz, AW; Ertl, G; Harre, K; Held, S; Kochsiek, N; Lengenfelder, B; Meesmann, M; Neyses, L; Schanzenbächer, P; Strotmann, J; Turschner, O; Voelker, W; Wacker, C; Waller, C | 1 |
| Fisher, EA; Kamran, M; Kini, AS; Lee, P; Marmur, JD; Perez, N; Richard, M; Sharma, SK; Suleman, J | 1 |
| Bock, A; Leitsch, T; Schimmer, M; Schultheiss, HP; Seligmann, C; Simsek, Y | 1 |
| Boekstegers, P; Habazettl, H; Horstkotte, J; Krombach, F; Kupatt, C; Wichels, R | 1 |
| Bigonzi, F; Borzak, S; Cohen, M; Frey, MJ; Harris, K; Lis, J; Mukherjee, R; Senatore, F; Théroux, P; Van Mieghem, W; White, HD | 1 |
| Brener, SJ; Cannon, CP; Demopoulos, LA; DiBattiste, PM; Gibson, CM; Murphy, SA | 1 |
| Batchelor, WB; Califf, RM; Cantor, WJ; Davidian, M; DiBattiste, PM; Dillard, P; Gretler, D; Harrington, RA; Huang, Y; Larsen, RL; Mantell, RM; Ohman, EM; Sketch, MH; Tcheng, JE; Tolleson, TR; Zhang, D; Zidar, JP | 1 |
| Adgey, AA; Belardi, JA; Bunt, T; Herrmann, HC; Juergens, CP; Levy, RD; Macaya, C; Menten, J; Meyer, BJ; Soler-Soler, J; Tarnesby, G; White, HD | 1 |
| Ardissino, D; Bassand, JP; Borzi, L; Demopoulos, LA; DiBattiste, PM; Harris, KA; Herrmann, HC; Macaya, C; Moliterno, DJ; Neumann, FJ; Stone, GW; Topol, EJ; Yakubov, SJ; Yeung, AC | 1 |
| Alpert, JS; Antman, EM; Beasley, JW; Braunwald, E; Califf, RM; Cheitlin, MD; Faxon, DP; Fuster, V; Gibbons, RJ; Gregoratos, G; Hiratzka, LF; Hochman, JS; Jacobs, AK; Jones, RH; Kereiakes, D; Kupersmith, J; Levin, TN; Pepine, CJ; Schaeffer, JW; Smith, EE; Smith, SC; Steward, DE; Theroux, P | 1 |
| Ambrosini, V; Battaglia, S; Cioppa, A; Lo Muzio, L; Rubino, P; Salemme, L; Sorropago, G; Tesoria, T | 1 |
| Alexander, C; Becker, ER; Cannon, CP; Chu, H; Cook, JR; Culler, S; Demopoulos, LA; DiBattiste, PM; Jurkovitz, CT; Kosinski, AS; Mahoney, EM; Nag, S; Robertson, DH; Weintraub, WS | 1 |
| Adelmeijer, J; De Groot, PG; Lisman, T; Moschatsis, S; Nieuwenhuis, HK | 1 |
| Barbera, FA; Dorsam, RT; Feuerstein, GZ; Friedman, SM; Gibbs, S; Lauver, A; Savion, N; Varon, D; Wang, H; Wang, X | 1 |
| Braunwald, E; Cannon, CP; Demopoulos, LA; DiBattiste, PM; Gibson, CM; McCabe, CH; Morrow, DA; Murphy, SA; Sabatine, MS | 1 |
| Braunwald, E; Cannon, CP; DiBattiste, PM; Januzzi, JL; Murphy, S; Weintraub, W | 1 |
| Brinkman, WT; Chaikof, EL; Najibi, S; Terramani, TT | 1 |
| Aggarwal, A; Aguirre, F; DiBattiste, PM; Herrmann, HC; Kabbani, SS; Lakkis, N; Schneider, DJ; Wan, Y | 1 |
| Blindt, R; Bosserhoff, AK; Demircan, L; Hanrath, P; Krott, N; Vogt, F; vom Dahl, J | 1 |
| Braunwald, E; Cannon, CP; Demopoulos, LA; DiBattiste, PM; Glaser, R; Herrmann, HC; Murphy, SA | 1 |
| Carrasco Martín, C; Casado, S; Córdoba, M; Farré, J; García-Mendez, A; Jiménez Mateos-Caceres, P; López-Farré, A; Millás, I; Molero, L; Navarro, F | 1 |
| Anderson, HV; Assali, AR; Fujise, K; Ghani, M; Moustapha, A; Rosales, OR; Salloum, J; Schroth, G; Sdringola, S; Smalling, RW | 1 |
| Carrozza, JP; Cohen, DJ; Pinto, DS; Sperling, RT; Tu, TM | 1 |
| Christopoulos, CG | 1 |
| Aggarwal, A; Aguirre, F; DiBattiste, PM; Herrmann, HC; Kabbani, SS; Lakkis, N; Lo, MW; Schneider, DJ; Yin, KC | 1 |
| Bauer, M; Chew, DP; Habazettl, H; Hamm, CW; Hausmann, H; Hetzer, R; Koster, A; Kuebler, W; Kuppe, H | 1 |
| Ioannidis, JP; Karvouni, E; Katritsis, DG | 1 |
| Cristofaro, RD; Crocchiolo, R; Landolfi, R; Renda, G; Rocca, B | 1 |
| DiBattiste, PM; Jang, Ik; Januzzi, JL; Sabatine, MS; Servoss, SJ; Theroux, P; Wan, Y | 1 |
| Aguanno, JJ; Glover, EN; Schumacher, JR; Schussler, JM; Vish, NA; Wheelan, KR; Wissinger, LA | 1 |
| Ackman, M; Humphries, K; Jackevicius, C; Kertland, H; Shalansky, SJ; Tsuyuki, R; Virk, R | 1 |
| Alves, VL; Nannizzi-Alaimo, L; Phillips, DR | 1 |
| Boussaada, R; Chérif, A; Ezzar, T; Mechmèche, R; Messaoudi, H; Mourali, S | 1 |
| Tsakiris, DA | 1 |
| Antman, EM; Sabatine, MS | 1 |
| Jordan, RE; Kereiakes, DJ; Nakada, MT; Nedelman, MA; Sassoli, PM; Tam, SH | 1 |
| Carter, AJ; DiBattiste, PM; Fearon, WF; Herity, NA; Hiatt, BL; Huston, M; Lee, DP; Rezaee, M; Schreiber, D; Yeung, AC | 1 |
| Bertram, U; Bode, C; Moser, M; Peter, K; Ruef, J | 1 |
| Azarbal, B; Cercek, B; Finkelstein, A; Kaul, S; Rukshin, V; Shah, PK; Tsang, V | 1 |
| Belcher, PR; Menys, VC; Muriithi, EW | 1 |
| Hobbach, HP; Schuster, P | 1 |
| Baglini, R; Capuano, C; Danzi, GB; Sesana, M | 2 |
| Boura, J; Dixon, SR; Grines, CL; Harjai, KJ; Karatepe, M; Moses, JW; Moussa, I; O'Neill, WW; Roubin, GS; Soffer, D | 1 |
| Ali, A; Gardin, JM; Hashem, M; Kazmouz, G; Rosman, HS; Schrieber, TL | 1 |
| Goldschmidt-Clermont, PJ; Kandzari, DE; Mayes, CE; Phillips, HR | 1 |
| Bonz, AW; Ertl, G; Held, S; Jacobs, M; Lengenfelder, B; Strotmann, J; Voelker, W | 1 |
| Brown, DL; Green, SJ; Kaplan, RC; Ravi, KL; Sanborn, TA; Sherman, W; Slater, JN; Vakili, BA | 1 |
| Cannon, CP; Demopoulos, LA; DiBattiste, PM; Gibson, CM; Lorenz, DP; Marble, SJ; Murphy, SA; Pinto, DS | 1 |
| Brown, DL | 1 |
| Bauer, M; Fischer, T; Gruendel, M; Koster, A; Kuebler, WM; Kuppe, H; Mappes, A | 1 |
| Akdemir, R; Uyan, C | 1 |
| Goto, S | 1 |
| Junghans, U; Siebler, M | 1 |
| Amikam, S; Gruberg, L | 1 |
| Bailey, S; Eles, G; Jarmolowski, C; Tan, WA; Toursakissian, B; Wholey, MH | 1 |
| Qureshi, AI | 1 |
| Böhm, M; Fries, R | 1 |
| Bowbrick, VA; Mikhailidis, DP; Stansby, G | 1 |
| Hamzavi, M; Junghans, U; Ringleb, PA; Schranz, C; Seitz, RJ; Siebler, M | 1 |
| Foster, DA; McCollam, PL; Riesmeyer, JS | 1 |
| Casserly, IP; Chew, DP; Cohen, DJ; DiBattiste, PM; Hamm, C; Jia, G; Lakkis, N; Lange, RA; Meier, B; Moliterno, DJ; Stone, GW; Topol, EJ | 1 |
| Heitzer, T; Köke, K; Meinertz, T; Munzel, T; Ollmann, I | 1 |
| Boersma, E; Westerhout, CM | 2 |
| Dambrink, JH; de Boer, MJ; de Vries, ST; Gosselink, AT; Hoorntje, JC; Miedema, K; Suryapranata, H; van 't Hof, AW; Zijlstra, F | 1 |
| Bekeredjian, R; Bertram, U; Bode, C; Kuecherer, HF; Moser, M; Nordt, TK; Peter, K; Ruef, J; Straub, A | 1 |
| Blazicek, H; Domanovits, H; Galehr, E; Jilma, B; Jilma-Stohlawetz, P; Mayr, F; Reiter, RA | 1 |
| Auer, J; Berent, R; Eber, B; Lassnig, E; Maurer, E; Weber, T | 1 |
| Goto, S; Handa, M; Handa, S; Ikeda, Y; Li, M; Ruggeri, ZM; Tamura, N | 1 |
| Cakmak, M; Cam, N; Okmen, E; Tartan, Z | 1 |
| Chang, HW; Chen, MC; Chen, SM; Fang, CY; Hsieh, YK; Wu, CJ; Yip, HK | 1 |
| Blankenship, JC; Demopoulos, L; DiBattiste, PM; Ellis, SG; Ghazzal, Z; Herrmann, HC; Martin, JL; Moliterno, DJ; Ross, MJ; Topol, EJ; White, J | 1 |
| White, CJ | 1 |
| Jeng, SS; Wang, MS | 1 |
| Gil, RJ; Rzezak, J | 1 |
| Bestehorn, HP; Bollwein, H; Dirschinger, J; Kastrati, A; Mehilli, J; Neumann, FJ; Pogatsa-Murray, G; Schmitt, C; Schömig, A; Seyfarth, M | 1 |
| Abu-Shanab, JR; Dobesh, PP; Gowda, S; Haikal, MY; Lakamp, JE; Lanfear, SL | 1 |
| Casten, R; Dunkley, S; Evans, S; Jepson, N; Lindeman, R | 1 |
| Berger, PB; Bhatt, DL; Chan, AW; DiBattiste, PM; Moliterno, DJ; Sapp, SK; Stone, GW; Topol, EJ; Wolski, K; Yakubov, SL | 1 |
| Campbell, ME; Tcheng, JE | 1 |
| Caputo, RP; Carrozza, JP; Cutlip, DE; Dua, V; Garringer, J; Giri, S; Ling, FS; Ricciardi, MJ | 1 |
| Alemao, E; Bakhai, A; Ben-Joseph, R; Collinson, JR; Flather, MD; Itzler, R; Normand, C; Stevens, W | 1 |
| Bigonzi, F; Cohen, M; Danchin, N; Gensini, GF; Gurfinkel, EP; Hecquet, C; Huber, K; Krzeminska-Pakula, M; Maritz, F; Santopinto, J; Timerman, A; Vittori, L; White, HD | 1 |
| Antman, EM; Bates, ER; Cohen, M; Every, NR; Ferguson, JJ; Harrington, RA; Pepine, CJ; Theroux, P | 1 |
| Huynh, T; Snapinn, S; Theroux, P; Wan, Y | 1 |
| Barnard, MR; Dae, MW; Frelinger, AL; Furman, MI; Krueger, LA; Michelson, AD | 1 |
| Boden, WE; Cannon, CP; Januzzi, JL; Theroux, P | 1 |
| Besta, F; Gawaz, M; Massberg, S; Mueller, I; Thomas, P | 1 |
| Cohen, M; Gensini, GF; Gurfinkel, EP; Hecquet, C; Huber, K; Krzeminska-Pakula, M; Maritz, F; Santopinto, J; Timerman, A; Vittori, L | 1 |
| Cochran, K; DeMartini, TJ; Grassman, ED; Lewis, BE; Leya, F; O Brien, J; Steen, LH | 1 |
| Aquilina, M; Branzi, A; Gaiba, W; Marrozzini, C; Marzocchi, A; Neri, S; Ortolani, P; Palmerini, T | 1 |
| Chang, HW; Chen, CJ; Chen, SM; Cheng, CI; Fang, CY; Hsieh, YK; Hung, WC; Wu, CJ; Yang, CH; Yip, HK | 1 |
| Aydin, M; Bilge, M; Gursurer, M; Ozdemir, H; Ozeren, A; Savranlar, A | 1 |
| Derhaschnig, U; Jilma, B; Marsik, C; Pachinger, C; Schweeger-Exeli, I | 1 |
| Baris, N; Duman, C; Ercan, E; Onbasili, OA; Tengiz, I | 1 |
| Cam, N; Okmen, E; Ozen, E; Sanli, A; Tartan, Z; Uyarel, H | 1 |
| Adgey, AA; Manoharan, G | 1 |
| Harrington, RA; Nguyen, CM | 1 |
| Akin, Y; Biyikoglu, SF; Guray, U; Korkmaz, S; Yilmaz, MB | 1 |
| Ben-Yehuda, O; DeMaria, AN; Kunichika, H; Kunichika, N; Lafitte, S; Peters, B | 1 |
| Dai, W; Kloner, RA | 1 |
| Atar, S; Birnbaum, Y; Chen, M; Kobal, S; Luo, H; Miyamoto, T; Neuman, Y; Siegel, RJ | 1 |
| Jovanovic, V; Junghans, U; Seitz, RJ; Siebler, M; Straub, S; Wittsack, HJ | 1 |
| Antman, EM; Braunwald, E; Cannon, CP; Demopoulos, LA; DiBattiste, PM; Giugliano, RP; McCabe, CH; Morrow, DA; Murphy, SA; Sabatine, MS; Weintraub, WS | 1 |
| Carrillo, J; Delgado, L; García, H; Gaspar, J; Gaxiola, E; González, H; Leyva, JL; Lupi, E; Martínez-Ríos, MA; Martínez-Sánchez, C; Peña-Duque, MA; Rosas, M | 1 |
| Antman, EM; Braunwald, E; Cannon, CP; Demopoulos, LA; DiBattiste, PM; Gibson, CM; Giugliano, RP; McCabe, CH; Morrow, DA; Murphy, SA; Rifai, N; Sabatine, MS; Wiviott, SD | 1 |
| Abrams, CS; Cines, DB | 1 |
| Gill, DS; Ng, K; Ng, KS | 1 |
| Chai, HT; Chang, HW; Chen, CJ; Chen, MC; Chen, YH; Fu, M; Hang, CL; Wang, CP; Wu, CJ; Yeh, KH; Yip, HK; Yu, TH | 1 |
| Demir, M; Fareed, J; Gül, C; Iqbal, O; Kürüm, T; Ozbay, G; Vural, O | 1 |
| Bolton, ED; Braunstein, JB; Chiles, KA; Faraday, N; Gerstenblith, G; Heldman, AW; Schulman, SP | 1 |
| Cam, N; Dayi, S; Okmen, E; Sanli, A; Tartan, Z; Uyarel, H | 1 |
| Haerten, K; Krabbe, C; Raiber, M | 1 |
| Corominas, N; Ferrer, E; Ortiz, J; Perez, J; Ribas, J; Sanz, G | 1 |
| DiBattiste, PM; Jang, IK; Januzzi, JL; Servoss, SJ; Snapinn, SM; Theroux, P; Wan, Y; Zhao, XQ | 1 |
| Carotenuto, R; Chieffo, C; Corsini, F; Corsini, G; Martone, A; Melorio, S; Romano, S; Schioppa, M; Sideri, F; Vetrano, A | 1 |
| Chang, HW; Chen, CJ; Chen, MC; Chen, SM; Cheng, CI; Hung, WC; Kuo, FY; Wu, CJ; Yang, CH; Yip, HK | 1 |
| De Caterina, R; Zimarino, M | 1 |
| Derhaschnig, U; Jilma, B; Pachinger, C | 1 |
| Chang, Y; Choi, CJ; Gimelli, G; Harding, S; Inglessis, I; Jang, IK; Walters, D; Wong, P | 1 |
| Ferrari, E; Menabue, L; Saladini, M | 1 |
| Aydin, M; Bilge, M; Ozeren, A; Ozkökeli, M; Unalacak, M | 1 |
| Kirch, W; Köhler, A; Koster, A; Oertel, R | 1 |
| Ardissino, D; Brennan, DM; Buratti, S; Menozzi, A; Merlini, PA; Moliterno, DJ; Rossi, M; Topol, EJ | 1 |
| Abdel-Aty, H; Al-Saadi, N; Friedrich, MG; Messroghli, DR; Schulz-Menger, J; Taylor, AJ | 1 |
| Dale, GL; Hamilton, SF; Miller, MW; Thompson, CA | 1 |
| Cook, SL; Garza, L; Jacoski, MV; Jennings, LK; Matin, Z; McGrew, FA; Ramanathan, KB; Saucedo, JF; Wolford, DC | 1 |
| Büttner, HJ; Neumann, FJ | 1 |
| Boersma, E; Bunt, T; Dambrink, JH; de Boer, MJ; de Winter, R; Ernst, N; Hollak, F; Hoorntje, JC; Jap, W; Marcel Gosselink, AT; Petronio, S; Suryapranata, H; van 't Hof, AW; Zijlstra, F | 1 |
| Koehler, B; Meyners, W; Peters, S; Trümmel, M | 1 |
| Courval, M; Diodati, JG; Lesperance, B; Palisaitis, DA; Pharand, C | 1 |
| Antman, EM; Braunwald, E; Gibson, CM; Giugliano, RP; Harrington, RA; Morrow, DA; Murphy, SA; Roe, MT; Sabatine, MS | 1 |
| Hennebry, TA; Saucedo, JF | 1 |
| Junghans, U; Meisel, S; Moll, M; Seitz, RJ; Siebler, M; Wittsack, HJ | 1 |
| Katori, N; Kelly, AB; Levy, JH; Sato, N; Szlam, F; Tanaka, KA | 1 |
| Day, JR; Haskard, DO; Landis, RC; Malik, IS; Nadra, I; Poullis, M; Taylor, KM; Weerasinghe, A | 1 |
| Carotenuto, R; Catanzaro, M; Chieffo, C; Corsini, F; Corsini, G; De Lucia, R; Di Donna, V; Izzo, A; Sorbo, R; Vetrano, A | 1 |
| Baglini, R; Berra Centurini, P; Capuano, C; Danzi, GB; Mauri, L; Sesana, M | 1 |
| Ansani, L; Barbieri, D; Bettini, A; Campo, G; Cicchitelli, G; Ferrari, F; Ferrari, R; Guardigli, G; Malagutti, P; Parrinello, G; Percoco, G; Soukhomovskaia, O; Valgimigli, M | 1 |
| Barbieri, D; Ferrari, F; Ferrari, R; Guardigli, G; Parrinello, G; Percoco, G; Soukhomovskaia, O; Valgimigli, M | 1 |
| Ardissino, D; Bilheimer, DW; Blazing, MA; Braunwald, E; Califf, RM; de Lemos, JA; DiBattiste, PM; Fox, KA; Gardner, LH; Hasselblad, V; Lewis, EF; Palmisano, J; Pfeffer, MA; Ramsey, KE; Snapinn, SM; Verheugt, FW; White, HD | 1 |
| Dobrzycki, S; Gajewska-Bachórzewska, H; Gugała, K; Kochman, W; Korecki, J; Kralisz, P; Mezyński, G; Musiał, W; Nowak, K; Poniatowski, B; Prokopczuk, P; Zuk, J | 1 |
| Goto, S; Ishida, H; Tamura, N | 1 |
| Allie, AA; Allie, DE; Allie, SD; Chaisson, GA; Fail, PS; Hebert, CJ; Keller, VA; Khan, MA; Khan, MH; Lirtzman, MD; Mitran, EV; Stagg, SJ; Vitrella, DA; Walker, CM; Wyatt, CH | 1 |
| Brener, SJ; Lincoff, AM; Moliterno, DJ; Steinhubl, SR; Topol, EJ; Wolski, KE | 1 |
| Bachorzewska-Gajewska, H; Chlopicki, S; Dobrzycki, S; Gugala, K; Kochman, W; Korecki, J; Kralisz, P; Mezynski, G; Musial, WJ; Niewada, M; Nowak, KS; Poniatowski, B; Prokopczuk, P | 1 |
| Angioi, M; Carteaux, JP; de Maistre, E; Fohlen-Walter, A; Lecompte, T; Moulin, F; Mulot, A; Sghaier, M | 1 |
| Domanovits, H; Frossard, M; Fuchs, I; Hsieh, K; Jilma, B; Laggner, AN; Leitner, JM; Losert, H; Schreiber, W; Vlcek, M | 1 |
| Braunwald, E; Cannon, CP; Demopoulos, LA; DiBattiste, PM; Gibson, CM; Murphy, SA; Singh, KP | 1 |
| Akkus, MN; Aytacoğlu, B; Camsari, A; Cicek, D; Cin, VG; Doven, O; Kanik, A; Katircibasi, MT; Pekdemir, H; Sucu, N | 1 |
| Angioli, P; Baldassarre, S; Bolognese, L; Burali, A; Ducci, K; Falsini, G; Liistro, F | 1 |
| Barcin, C; Iyisoy, A; Kursaklioglu, H | 1 |
| Dambrink, JH; de Boer, MJ; Ernst, NM; Gosselink, AT; Hoorntje, JC; Miedema, K; Ottervanger, JP; Slingerland, RJ; Suryapranata, H; van 't Hof, AW; Zijlstra, F | 1 |
| Ito, H; Miyakoda, G; Mori, T | 1 |
| Antman, EM; Braunwald, E; Cannon, CP; Morrow, DA; Sabatine, MS; Theroux, P | 1 |
| Brouse, SD; Wiesehan, VG | 1 |
| Chew, D; Gruendel, M; Jurmann, M; Koster, A; Kuppe, H; Merkle, F; Oertel, R | 1 |
| Bilheimer, DW; Blazing, MA; Brady, WE; Braunwald, E; Califf, RM; de Lemos, JA; Fox, KA; Lewis, EF; Palmisano, J; Pfeffer, M; Ramsey, KE; White, HD; Wiviott, SD | 1 |
| Aster, RH; Bougie, DW; Curtis, BR | 1 |
| Hamm, CW; Heeschen, C; Lantelme, NH; Mitrovic, V; White, HD | 1 |
| Akbulut, M; Arslan, N; Dagli, N; Durukan, P; Gundogdu, O; Ilkay, E; Ozbay, Y | 1 |
| Gandhi, PJ; Silva, MA | 1 |
| Cannon, CP; Dibattiste, PM; Gibson, CM; Karha, J; Murphy, SA | 1 |
| Albuquerque, FC; Deshmukh, VR; Fiorella, DJ; Flaster, M; Frey, J; McDougall, CG; Spetzler, RF; Wallace, RC | 1 |
| Deutsch, HJ; Feldmann, C | 1 |
| Goldmann, BU; Heitzer, T; Munzel, T; Nowak, G; Ostad, MA; Warnholtz, A | 1 |
| Azar, RR; Badaoui, G; Germanos, M; Kassab, R; Klaymé, S; Naman, R; Salamé, E; Sarkis, A | 1 |
| Bayturan, O; Bilge, AR; Eser, E; Seküri, C; Tezcan, UK; Tikiz, H; Utük, O | 1 |
| Graf, C; Nkoulou, R; Perrenoud, JJ; Trombert, V | 1 |
| Atwater, BD; Mahaffey, KW; Roe, MT | 1 |
| Ahn, YK; Cho, JG; Hong, SN; Hong, YJ; Jeong, MH; Kang, DK; Kang, JC; Kim, JH; Kim, KH; Kim, W; Lee, SH; Lee, YS; Lim, JH; Lim, SY; Moon, Y; Park, HW; Park, JC; Rhew, JY; Yun, KH | 1 |
| Aoki, T; Maeda, M; Matsuoka, N; Mihara, K; Moriguchi, A; Mutoh, S | 1 |
| Aster, RH | 1 |
| Eberli, FR; Hess, OM; Locher, S; Meier, B; Remondino, A; Rey, C; Seiler, C; Togni, M; Tüller, D; Wenaweser, P; Windecker, S | 1 |
| Berger, PB; DiBattiste, PM; Lennon, R; Lubbe, D; Orford, JL; Talreja, D | 1 |
| Mazurov, AV; Naimushin, YA | 2 |
| Erkoc, R; Eryonucu, B; Tuncer, M | 1 |
| Cannizzaro, S; Di Pasquale, P; Paterna, S | 1 |
| Coull, BM; McDonagh, PF; Ritter, LS; Stempel, KM | 1 |
| Baysan, O; Erinc, K; Isik, E; Ozkan, M; Sag, C; Uzun, M; Yokusoglu, M | 1 |
| Bailey, LA; Sistino, JJ; Uber, WE | 1 |
| Dambrink, JH; de Boer, MJ; Gosselink, AT; Hoorntje, JC; Ottervanger, JP; Suryapranata, H; Timmer, JR; van 't Hof, AW; Zijlstra, F | 1 |
| DiBattiste, PM; Huynh, T; Pharand, C; Piazza, N; Snapinn, SM; Theroux, P; Wan, Y | 1 |
| Frick, A; Gebauer, A; Hinder, M; Miller, B; Paccaly, A; Shukla, U; Simcox, K | 1 |
| Badar, J; Covic, L; Jacques, S; Kimmelstiel, C; Kuliopulos, A; Waxman, S; Weintraub, A | 1 |
| Ardissino, D; Menozzi, A; Merlini, PA | 1 |
| Chang, ST; Cheng, NJ; Chung, CM; Yang, TY | 1 |
| Gehl, HB; Giannitsis, E; Katus, HA; Kulke, C; Lehrke, S; Lima, JA; Merten, C; Richardt, G; Schuster, L; Steen, H; Wiegand, UK | 1 |
| Bosco, A; Dunkley, S; Kidson-Gerber, G | 1 |
| Ansani, L; Barbieri, D; Bettini, A; Boersma, E; Campo, G; Cicchitelli, G; Ferrari, F; Ferrari, R; Guardigli, G; Malagutti, P; McFadden, EP; Merlini, F; Parrinello, G; Percoco, G; Valgimigli, M | 1 |
| Ilveskero, S; Lassila, R | 1 |
| Dambrink, JH; de Boer, MJ; De Luca, G; Ernst, N; Gosslink, AT; Hoorntje, JC; Ottervanger, JP; Smit, JJ; Suryapranata, H; van 't Hof, AW | 1 |
| Matzdorff, A; Voss, R | 1 |
| Berger, PB; Best, PJ; Chan, AW; DiBattiste, PM; Herrmann, HC; Kristensen, SD; Moliterno, DJ; Topol, EJ; White, J | 1 |
| Cohen, EA; Fort, S; Godin-Edgecombe, M; Madan, M; Naqvi, SZ; Paradiso-Hardy, FL; Phillips, AM; Radhakrishnan, S; Reis, M; Shanmugasegaram, S; Sparling, C | 1 |
| Goodman, CN; Kaul, S; Klibanov, AL; Lindner, JR; Sakuma, T; Sari, I | 1 |
| Chun, KJ; Hong, TJ; Jeong, JH; Kim, JH; Park, YH; Shin, YW | 1 |
| Baumann, PQ; Schneider, DJ; Sobel, BE; Whitaker, DA | 1 |
| Hursting, MJ; Patel, K | 1 |
| Concannon, MJ; Farias, CL; Kazmier, FR; Puckett, CL; Yates, YJ | 1 |
| Le Pen, C; Lilliu, H | 1 |
| Aronson, D; Beyar, R; Boulos, M; Grenadier, E; Gruberg, L; Hammerman, H; Kapeliovich, M; Lavi, S; Markiewicz, W | 1 |
| Young, JJ | 1 |
| Biscione, C; Crea, F; De Vita, M; Maria Leone, A; Mongiardo, R; Niccoli, G; Rebuzzi, A | 1 |
| Aroney, CN; Gunasekara, AP; Walters, DL | 1 |
| Allie, AA; Allie, DE; Allie, SE; Barker, EA; Chaisson, G; Fail, PS; Hebert, CJ; Keller, VA; Khan, MA; Khan, MH; Lirtzman, MD; McElderry, MW; Mitran, EV; Stagg, SJ; Vivekananthan, K; Walker, CM; Wyatt, CH | 1 |
| Bocksch, W; Dietz, R; Kühnle, Y; Möckel, M; Nibbe, L; Strohm, S; Vollert, J | 1 |
| Antman, EM; Braunwald, E; Califf, RM; de Lemos, JA; DiBattiste, P; Gibson, CM; Harrelson, L; McCabe, C; Ohman, EM; Oliverio, RL; Van de Werf, F | 1 |
| Baum, H; Braun, S; Dibra, A; Dirschinger, J; Hadamitzky, M; Kastrati, A; Mehilli, J; Schömig, A; Schühlen, H | 1 |
| Chang, M; Dangas, G; Ellis, SG; Kao, J; Laufer, N; Mehran, R; Russell, ME; Stone, GW; Tannenbaum, MA; Teirstein, PS; Watkins, M | 1 |
| Ardissino, D; Bassand, JP; Bertrand, ME; Herrmann, HC; Kristensen, SD; McClure, RR; Moliterno, DJ; Mukherjee, D; Neumann, FJ; Stone, GW; Topol, EJ; Yakubov, SJ | 1 |
| Jain, D; Khattab, AA; Kurowski, V; Richardt, G; Richter, C; Toelg, R; Wiegand, UK | 1 |
| Shanmugam, G | 1 |
| Cellerini, M; Gensini, G; Inzitari, D; Mangiafico, S; Nencini, P | 1 |
| Bucha, E; Nowak, G; Schumann, A | 1 |
| Bhatt, DL; Duffy, B | 1 |
| Badia, T; Bellandi, F; Dabizzi, RP; De Servi, S; Leoncini, M; Maioli, M; Politi, A; Toso, A | 1 |
| El Gaylani, N; Osman, F; Pitt, M; Qaisar, S | 1 |
| De Luca, L; Sardella, G | 1 |
| Dirksen, MT; Kiemeneij, F; Laarman, GJ; Ronner, E; Slagboom, T; van der Wieken, LR; van der Wouw, PA; van Heerebeek, L | 1 |
| Buckland, RJ; Holgate, CE; Judge, HM; Storey, RF | 1 |
| Feuring, M; Ganschow, A; Harenberg, J; Losel, R; Peiter, A; Ruf, A; Schultz, A; Wehling, M | 1 |
| Cardaioli, P; Giordan, M; Magro, B; Maronati, L; Rigatelli, G; Roncon, L; Zonzin, P | 1 |
| Hölschermann, H; Jacobi, F; Jung, A; Krombach, C; Tillmanns, H; Weinand, F | 1 |
| Jafary, FH | 1 |
| Dunkley, S; Evans, S; Gaudry, L; Jepson, N | 1 |
| Grebe, M; Matzdorff, A; Pralle, H; Tillmanns, H; Voss, R | 1 |
| Chen, JL; Chen, ZJ; Gao, RL; Jing, ZC; Meng, L; Tian, Y; Wu, YJ; Yang, WX; Yang, YJ; You, SJ; Zhao, JL | 1 |
| Bukow, SC; Daffertshofer, M; Hennerici, MG | 1 |
| Baumann, PQ; Keating, FK; Schneider, DJ; Sobel, BE; Whitaker, DA | 1 |
| Goto, S; Ishida, H; Ruggeri, ZM; Tamura, N | 1 |
| Gao, RL; Jing, ZC; Meng, L; Wang, YW; Wu, YJ; Yang, WX; Yang, YJ; You, SJ; Zhao, JL | 1 |
| Baglini, R; Capuano, C; Danzi, GB; Mauri, L; Predolini, S; Sesana, M | 1 |
| Huxtable, LM; Rakkar, AN; Tafreshi, MJ | 1 |
| Chung, TW; Tsai, WJ; Yang, MC | 1 |
| Angioli, P; Baldassarre, S; Bolognese, L; Burali, A; Cosmi, F; Ducci, K; Falsini, G; Liistro, F; Taddei, T; Tarducci, R | 1 |
| Glaser, R; Glick, HA; Herrmann, HC; Kimmel, SE | 1 |
| Ben-Yehuda, O | 1 |
| Aster, RH; Bougie, DW; Chong, BH; Curtis, BR; Dunkley, S; Greinacher, A; Warkentin, TE | 1 |
| Capuano, C; Danzi, GB; Mauri, L; Sesana, M; Sozzi, FB | 1 |
| Akgul, O; Cam, N; Erdem, I; Kasikcioglu, H; Okmen, E; Samur, H; Simsek, D; Tartan, Z; Unal Dayi, S; Uyarel, H; Uzunlar, B | 1 |
| Kecskés, M; Losonczy, H; Nagy, A; Pótó, L; Szabó, C; Tóth, O | 1 |
| Bruckner-Tuderman, L; Heino, J; Kainulainen, T; Nissinen, L; Parikka, M; Salo, T; Tasanen, K | 1 |
| Dorsch, MP; Montague, D; Patterson, C; Rodgers, JE | 1 |
| Barutcu, I; Boztosun, B; Gunes, Y; Kirma, C | 1 |
| Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Andreadou, I; Georgiadou, P; Iliodromitis, EK; Kremastinos, DT; Kyrzopoulos, S; Mademli, K; Markantonis-Kyroudis, S | 1 |
| Angiolillo, D; Arora, U; Atar, D; Malinin, A; Pokov, A; Serebruany, V | 1 |
| Brown, BG | 1 |
| Akbulut, T; Akgoz, H; Bilsel, T; Ciloglu, F; Dayi, SU; Ergelen, M; Sayar, N; Terzi, S; Yesilcimen, K | 1 |
| Chen, SM; Fang, CY; Fu, M; Guo, GB; Hsieh, YK; Wu, CJ; Yip, HK | 1 |
| Azevedo, R; Beierlein, W; Dietz, K; Straub, A; Wendel, HP; Ziemer, G | 1 |
| Dambrink, JH; de Boer, MJ; Ernst, NM; Gosselink, AT; Hoorntje, JC; Kolkman, JJ; Ottervanger, JP; Slingerland, RJ; Smit, JJ; Suryapranata, H; van 't Hof, AW | 1 |
| Bonizzoni, E; De Servi, S; Dellavalle, A; Leoncinie, M; Mariani, M; Poletti, F; Politi, A; Vandoni, P | 1 |
| Dambrink, JH; de Boer, MJ; Gosselink, M; Hoorntje, JC; Miedema, K; Ottervanger, JP; Rasoul, S; Suryapranata, H; van 't Hof, AW; Zijlstra, F | 1 |
| Akbulut, T; Bilsel, T; Emre, A; Ersek, B; Oz, D; Sayar, N; Terzi, S; Ucer, E; Yesilcimen, K | 1 |
| Cohen, DJ; Hu, T; McClure, R; Moliterno, DJ; Mukherjee, D; Roffi, M; Shishehbor, MH; Stone, GW; Topol, EJ | 1 |
| Buckland, R; Judge, HM; Sastry, P; Siotia, A; Storey, RF | 1 |
| Ganter, MT; Hamiel, CR; Hofer, CK; Klaghofer, R; Tucci, MA; Zollinger, A | 1 |
| Marubini, E; Rebora, P; Reina, G | 1 |
| Cengel, A; Taçoy, G; Timurkaynak, T; Yalçin, R | 1 |
| Cay, S; Korkmaz, S; Topaloğlu, S | 1 |
| Ahrens, I; Bassler, N; Bode, C; Chen, YC; Fitzgerald, D; Hagemeyer, CE; Kenny, D; Meade, G; Moran, N; Peter, K; Schwarz, M; Stoll, P; Ylanne, J | 1 |
| Braun, S; Dietrich, W; Eicken, A; Kostolny, M; Lange, R; Schreiber, C | 1 |
| Demirkan, B; Guray, U; Guray, Y; Korkmaz, S | 1 |
| Aguiar, C; Almeida, M; de Araujo Goncalves, P; Ferreira, J; Pereira Machado, F; Raposo, L; Seabra-Gomes, R; Teles, R | 1 |
| Blazing, MA; Braunwald, E; Califf, RM; de Lemos, JA; Morrow, DA; Rifai, N; Sabatine, MS; Shui, A; Wiviott, SD | 1 |
| Jennings, LK | 1 |
| Alexander, KP; Chen, AY; Gibler, WB; Hochman, JS; Newby, LK; Ohman, EM; Peterson, ED; Redberg, RF; Roe, MT; Schwartz, JB | 1 |
| Burns, G; Meola, S; Mohammad, S; Solen, K; Sukavaneshvar, S | 1 |
| Alessi, MC; Barbou, F; Bonnet, JL; Cuisset, T; Frère, C; Hovasse, T; Quilici, J; Said, LN | 1 |
| Radke, PW; Schunkert, H | 1 |
| Münzel, TF; Post, F | 1 |
| Köprülü, D; Tuhta, AG; Yeşildağ, O | 1 |
| Del Pace, S; Scheggi, V | 1 |
| Beer, JH; Deckmyn, H; Forestier, M; Pontiggia, L; Steiner, B; Ulrichts, H | 1 |
| Anselmi, M; Campo, G; Catozzi, L; Cicchitelli, G; Ferrari, R; Gemmati, D; Malagutti, P; Percoco, G; Scapoli, G; Tognazzo, S; Valgimigli, M; Vassanelli, C | 1 |
| Connor, JH; Connor, RF; Hantgan, RR; Mousa, SA; Stahle, MC | 1 |
| Berger, P; Blankenship, JC; Herrmann, H; Kalyanasundaram, A; McClure, R; Moliterno, D | 1 |
| Ligon, RW; Markwell, SJ; Mishkel, GJ; Moore, AL | 1 |
| Gershlick, A; Jeilan, M; Richardson, G | 1 |
| Cui, L; Ge, YG; Li, WM; Liu, Y; Ni, ZH; Wang, HS; Wang, LF; Xu, L; Yang, XC | 1 |
| Dambrink, JH; de Boer, MJ; Gosselink, AT; Hoorntje, JC; Ottervanger, JP; Rasoul, S; Suryapranata, H; van 't Hof, AW | 1 |
| Fontana, P | 1 |
| Topaz, O | 1 |
| Mukherjee, D; Roffi, M | 1 |
| Balbarini, A; Ciabatti, N; Cortese, B; De Carlo, M; De Caterina, R; Gistri, R; Levantino, M; Maselli, D; Petronio, AS | 1 |
| Clofent-Sanchez, G; Coste, P; Harizi, H; Jais, C; Nurden, A; Nurden, P | 1 |
| Boeken, U; Feindt, P; Gams, E; Kurt, M; Litmathe, J | 1 |
| Cannon, CP; Chen, AY; Gibler, WB; Gibson, CM; Greenbaum, AB; Harrington, RA; Hoekstra, JW; Newby, LK; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Tricoci, P | 1 |
| Song, Y | 1 |
| Fallon, AM; Hanson, SR; Marzec, UM; Yoganathan, AP | 1 |
| Blancas Gómez-Casero, R; Chana García, M; González Manzanares, JL; López Matamala, B; Martín Delgado, C; Martínez Díaz, C; Nevado Losada, E; Serrano Castañeda, J; Yáñez Parareda, E | 1 |
| Agostoni, P; Anselmi, M; Arcozzi, C; Bolognese, L; Campo, G; Cohen, DJ; Colangelo, S; de Cesare, N; Ferrari, R; Ferrario, M; Hamon, M; Malagutti, P; Parrinello, G; Pasquetto, G; Percoco, G; Prati, F; Rodriguez, AE; Sheiban, I; Valgimigli, M; Vassanelli, C; Vranckx, P | 1 |
| Chang, LT; Chua, S; Hang, CL; Lee, FY; Sheu, JJ; Wu, CJ; Yang, CH; Yeh, KH; Yip, HK; Youssef, AA | 1 |
| Hauptmann, KE; Hochadel, M; Ischinger, T; Janicke, I; Jung, J; Mark, B; Mudra, H; Schramm, A; Seggewiss, H; Senges, J; Zahn, R; Zeymer, U | 1 |
| Arcozzi, C; Barbieri, D; Campo, G; Carletti, R; Ferrari, F; Ferrari, R; Malagutti, P; Parrinello, G; Percoco, G; Valgimigli, M | 1 |
| Arora, R; Deo, D; Deshpande, NV; Hiremath, JS; Hiremath, MS; Joseph, J; Khan, A; Mardikar, HM; Mathew, R; Moliterno, DJ; Mukherjee, D | 1 |
| Choi, M; Kettritz, R; Luft, FC; Rolle, S; Salanova, B; Wellner, M | 1 |
| Avci, A; Boztosun, B; Kirma, C; Olcay, A | 1 |
| Aoun, N; Azar, R; Kadri, Z; Moussa, R; Sarkis, A | 1 |
| Holmes, CE; Madsen, NJ; Schneider, DJ; Serrano, FA; Sobel, BE | 1 |
| Arcozzi, C; Campo, G; Cohen, DJ; Dulisse, B; Ferrari, R; Isogai, PK; Mittmann, N; Percoco, G; Seung, SJ; Squasi, P; Valgimigli, M | 1 |
| Ge, YG; Li, WM; Lian, Y; Ma, LX; Ni, ZH; Wang, HS; Wang, LF; Xia, K; Xu, L; Xue, YL; Yang, XC; Zhang, DP | 1 |
| Delgado, C; Fernández-Perez, GC; Rodríguez-Pérez, J; Vázquez, M; Vázquez-Lima, A; Velasco, M | 1 |
| Augoustides, JG | 1 |
| Blazing, MA; Braunwald, E; Califf, RM; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Bachorzewska-Gajewska, H; Dobrzycki, S; Kochman, W; Korecki, J; Kralisz, P; Musial, WJ; Nowak, K; Poniatowski, B; Prokopczuk, P; Sienkiewicz, J; Sitniewska, E; Zuk, J | 1 |
| Chung, TL; Holton, LH; Pumplin, DW; Rodriguez, ED; Silverman, RP; Taylor, JA | 1 |
| Banerjee, S; Chen, S; Ho, C; Labinaz, M; Martin, J; Mensinkai, S | 1 |
| Blue, R; Coller, BS; Jirousková, M; Karan, C; Murcia, M | 1 |
| Birkenmaier, C; Goebl, M; Gottschalk, O; Jansson, V; Metz, P; Schmitt-Sody, M; Veihelmann, A; von Schulze Pellengahr, C; Zysk, S | 1 |
| Ardissino, D; Bolognesi, MG; Dangas, G; Fahy, M; Gobbi, G; Ippolito, L; Mehran, R; Merlini, PA; Ruenes, R; Solinas, E; Vitale, M | 1 |
| Koehler, B; Peters, S; Truemmel, M | 1 |
| Dambrink, JH; de Boer, MJ; Gosselink, AT; Hoorntje, JC; Kolkman, JJ; Ottervanger, JP; Slingerland, RJ; Smit, JJ; Suryapranata, H; van 't Hof, AW | 1 |
| Bittmann, I; Brandl, U; Brenner, P; Burdorf, L; Erhardt, M; Hammer, C; Jöckle, H; Michel, S; Mordstein, V; Reichart, B; Rössle, M; Schmoeckel, M; Thein, E | 1 |
| Atmaca, Y; Erol, C; Ozdol, C | 1 |
| Arslan, U; Balcioglu, S; Timurkaynak, T; Turkoglu, S | 1 |
| Emiroglu, M; Gulmez, SE; Heper, AO; Kaya, B; Serel, S | 1 |
| Blazing, M; Cannon, CP; Gersh, B; McLean, DS; Ravid, S; Shui, A | 1 |
| Agarwal, A; Cavusoglu, E; Manjappa, N; Marmur, JD; Poludasu, S | 1 |
| Shen, J; Zhang, Q; Zhang, RY | 1 |
| Boden, WE; Hoekstra, J; Miller, CD | 1 |
| Cazenave, JP; Désaubry, L; Laeuffer, P; Riché, S | 1 |
| Kim, DJ; Lee, KO; Lee, KY; Seo, KD | 1 |
| Anderson, JL; Bair, TL; Burke, JL; Casterella, PJ; Horne, B; May, HT; Muhlestein, JB; Pearson, RR; Revenaugh, JR | 1 |
| Dietz, K; Peter, K; Schiebold, D; Schoenwaelder, SM; Straub, A; Wendel, HP; Ziemer, G | 1 |
| di Spilimbergo, SS; Padula, E; Penzo, M; Rampazzo, A; Squaquara, R | 1 |
| Azcona, L; Farré, J; Fernández-Ortiz, A; López-Farré, AJ; Macaya, C; Romero, J; Sacristán, D; Zamorano-León, JJ | 1 |
| Fan, WZ; Fu, XH; Geng, W; Gu, XS; Hao, GZ; Hao, QQ; Jia, XW; Jiang, YF; Li, SQ; Wu, WL | 1 |
| Bolognese, L; Campo, G; Colangelo, S; de Cesare, N; Ferrari, R; Ferrario, M; Moreno, R; Nazzaro, MS; Parrinello, G; Pasquetto, G; Percoco, G; Piva, T; Prati, F; Rodriguez, AE; Sheiban, I; Valgimigli, M; Vassanelli, C | 1 |
| Agnelli, D; Ottani, F | 1 |
| Acartürk, E; Bozkurt, A; Tasal, A | 1 |
| Higman, DJ; Imray, CH; Jarvi, K; Marshall, C; Tiivas, CA; van Dellen, D | 1 |
| Jagroop, IA; Mikhailidis, DP | 1 |
| Allegretto, N; Barbera, F; Bird, JE; Giancarli, MR; Ogletree, ML; Schumacher, WA; Seiffert, D; Wong, P | 1 |
| Hu, J; Shen, J; Shen, WF; Yang, ZK; Zhang, JS; Zhang, Q; Zhang, RY; Zhang, X; Zheng, AF | 1 |
| Kent, TA; Mandava, P; Thiagarajan, P | 1 |
| Juergens, CP; Winter, JP | 1 |
| Barlocco, F; D'Urbano, M; De Servi, S; Fetiveau, R; Poli, A; Savonitto, S; Vandoni, P | 1 |
| Angiolillo, DJ; Campo, G; Colangelo, S; de Cesare, N; Ferrari, F; Ferrari, R; Furgieri, A; Hamon, M; Kubbajeh, M; Meliga, E; Parrinello, G; Percoco, G; Repetto, A; Sabatè, M; Tumscitz, C; Valgimigli, M; Vranckx, P | 1 |
| Becker, RC; Cannon, CP; Goodman, SG; Gutterman, D; Guyatt, GH; Harrington, RA; Lincoff, AM; Popma, JJ; Steg, G | 1 |
| Carteaux, JP; Durand, M; Hacquard, M; Lecompte, T | 1 |
| Acar, G; Nacar, AB; Sökmen, G; Tuncer, C | 1 |
| Dembo, L; Lovett, M; O'Driscoll, G; Thomas, MD; Wood, C | 1 |
| Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH | 1 |
| Ciborowski, M; Dobrzycki, S; Rusak, T; Tomasiak, M; Winnicka, K | 1 |
| Chen, L; Gai, LY; Jin, J; Li, HY; Li, RB; Lin, L; Liu, CX; Liu, HB; Ren, YH; Wang, CY; Wang, HY; Wang, Y; Xin, YH; Xu, XL; Yang, TS | 1 |
| Dambrink, JH; Dill, T; Funck, RC; Giannitsis, E; Hamm, C; Heestermans, T; Ottervanger, JP; Stella, P; Suryapranata, H; Ten Berg, J; van Houwelingen, G; van Werkum, W; Van't Hof, AW | 1 |
| Banerjee, S; Blazing, MA; Braunwald, E; Brilakis, ES; Califf, RM; Cannon, CP; de Lemos, JA; Morrow, DA; Murphy, SA; Sabatine, MS; Wiviott, SD | 1 |
| Chen, SW; Huang, LP; Huang, WG; Wang, LX; Wei, JR; Wu, TG; Zhao, J; Zhao, Q | 1 |
| Böhm, M; Girndt, M; Link, A; Rbah, R; Selejan, S | 1 |
| Iavelov, IS | 1 |
| Chang, HW; Han, MH; Kang, HS; Kim, JE; Kwon, BJ; Roh, HG; Yoon, SW | 1 |
| Simsek, V; Timurkaynak, T; Turkoglu, S | 1 |
| Biondi-Zoccai, G; Lotrionte, M; Sheiban, I | 1 |
| Giannitsis, E; Ivandic, BT; Katus, HA; Keck, F; Kurz, K; Lehrke, S; Staritz, P | 1 |
| Binetti, N; Franco, N; Gordini, G; Guiducci, V; Magnavacchi, P; Manari, A; Marinucci, L; Marra, S; Marrozzini, C; Marzocchi, A; Piovaccari, G; Reggiani, ML; Saia, F; Sangiorgio, P; Taglieri, N | 1 |
| Kim, DJ; Lee, KO; Lee, KY; Song, TJ | 1 |
| Basani, RB; Bennett, JS; Degrado, WF; Kowalska, MA; Poncz, M; Soto, CS; Thornton, MA; Zhu, H | 1 |
| Bosković, A; Dragnić, S; Knezević, B; Musić, L; Nikolić, G | 1 |
| Jörres, A; Storm, C | 1 |
| Chen, YD; Li, WM; Liu, PD; Song, LY; Zhao, YJ; Zhou, LJ | 1 |
| Si, LY; Wang, HL; Xu, Q | 1 |
| Chamorro, A; Díez-Marqués, ML; Griera, M; Rodríguez-Puyol, D; Rodríguez-Puyol, M; Ruiz-Torres, MP | 1 |
| Cavusoglu, E; Lazar, J; Marmur, JD; Poludasu, S | 1 |
| Zijlstra, F | 1 |
| Beiras-Fernandez, A; Jiru, P; Kowert, A; Reichart, B; Schmoeckel, M; Spannagl, M; Weis, M | 1 |
| Valgimigli, M; van 't Hof, AW | 1 |
| Ottervanger, JP; Remijn, JA; Slingerland, RJ; Smit, JJ; van 't Hof, AW; van Oeveren, W; Zijlstra, F | 1 |
| Bildirici, U; Celikyurt, U; Ural, E | 1 |
| Andreotti, F; Brancati, M; Burzotta, F; Crea, F; De Vita, M; Giammarinaro, M; Leone, AM; Mazzari, MA; Niccoli, G; Porto, I; Schiavoni, G; Talarico, GP; Todaro, D; Trani, C | 1 |
| Biagini, E; Conrotto, F; Giacometti, P; Guiducci, V; Manari, A; Marrozzini, C; Marzocchi, A; Piovaccari, G; Reggiani, ML; Rocchi, G; Saia, F; Taglieri, N; Tondi, S | 1 |
| Cunha, MS; da Silva, JC; Ferreira, MC; Machado, FA; Nakamoto, HA | 1 |
| Cassetti, E; De Luca, G; Marino, P; Ucci, G | 1 |
| Brener, SJ | 2 |
| Chen, LL; Li, WW; Lin, YL; Luo, YK; Zheng, XC | 1 |
| Duran, NE; Kocabay, G; Ozkan, M; Yildiz, M | 1 |
| Koulouris, S; Manolis, AS; Pastromas, S; Sakellariou, D | 1 |
| Akima, S; Blyth, K; Chapman, JR; Favaloro, E; Hawthorne, WJ; Mudaliar, Y; O'Connell, PJ; Patel, A | 1 |
| Angiolillo, DJ; Brugaletta, S; Campo, G; Colangelo, S; de Cesare, N; Ferrari, R; Furgieri, A; Hamon, M; Meliga, E; Parrinello, G; Percoco, G; Repetto, A; Sabatè, M; Valgimigli, M; Vranckx, P | 1 |
| Choe, YH; Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Kim, JH; Lee, SH; Lee, SY; Song, YB | 1 |
| Danzi, GB; Marzocchi, A | 1 |
| Merlini, PA; Valgimigli, M | 1 |
| Savonitto, S | 1 |
| Hantgan, RR; Stahle, MC | 1 |
| Chiariello, M; D'andrea, C; Esposito, G; Piscione, F | 1 |
| Jia, D; Li, Y; Nie, X; Yan, Z; Zhao, Y; Zhou, Y; Zhou, Z | 1 |
| Avşar, O; Batyraliev, TA; Fettser, DV; Pershukov, IV; Preobrazhenskiĭ, DV; Sidorenko, BA; Vural, A | 2 |
| Eriksson, AC; Whiss, PA | 1 |
| Cheng, WJ; Guo, YH; Li, YP; Liu, T; Liu, YY; Ma, HY; Shi, DM; Xie, Y; Zhao, YX; Zhou, YJ | 1 |
| De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW | 1 |
| Beresford-Cleary, NJ; Chelliah, R; Connolly, TM; Cortas, K; Daga, S; Feuerstein, GZ; Fox, KA; Lucking, AJ; Newby, DE; Tattersall, L | 1 |
| Bizzarri, F; Frati, G | 1 |
| Glahn, J; Philipps, J; Rother, J; Schwarze, M; Thomalla, G | 1 |
| Alam, M; Bobek, J; Delarosa, A; Dokainish, H; Gonzalez, R; Lakkis, N | 1 |
| Biondi-Zoccai, G; Bolognese, L; Briguori, C; Campo, G; Danzi, GB; Hamm, C; King, SB; Moliterno, DJ; Okmen, E; Saia, F; Tebaldi, M; ten Berg, J; Topol, EJ; Valgimigli, M; van't Hof, AW | 1 |
| Bhasin, A; Chai, HT; Chang, LT; Chen, CJ; Chen, SM; Chung, SY; Hang, CL; Hsieh, YK; Sun, CK; Wu, CJ; Yang, CH; Yip, HK; Youssef, AA | 1 |
| Ding, FH; DU, R; Hu, J; Shen, J; Shen, WF; Zhang, Q; Zhang, RY; Zhang, X; Zhao, LP | 1 |
| Guo, YH; Li, YP; Liu, T; Liu, YY; Ma, HY; Shi, DM; Xie, Y; Zhao, YX; Zhou, YJ | 1 |
| Akdemir, R; Cagirci, G; Karakurt, O; Kilic, H | 1 |
| Aboujaoudé, S; Azar, RR; Badaoui, G; Barakett, V; Germanos, M; Hamdan, R; Kassab, R; Salamé, E; Sarkis, A | 1 |
| Briguori, C; Caccavale, M; D'Andrea, D; Focaccio, A; Golia, B; Librera, M; Ricciarelli, B; Tavano, D; Visconti, G | 1 |
| Ricci, Z; Ronco, C | 1 |
| De Luca, G; Marino, P; Navarese, E | 1 |
| Cuturello, D; Gaudio, C; Missiroli, B; Papalia, F; Puddu, PE; Saladini, A; Schiariti, M | 1 |
| Allen, DJ; Freedman, J; Gyulkhandanyan, AV; Leytin, V; Mutlu, A; Mykhaylov, S | 1 |
| Aitken, EW; Harper, MT; Jones, ML; Poole, AW; Williams, CM | 1 |
| Fu, GQ; Jia, KY; Lei, LC; Ma, ZM; Peng, JJ; Ren, LH; Ye, HM | 1 |
| Bates, ER; Chetcuti, S; Grossman, PM; Gurm, HS; Meier, P; Tamhane, U | 1 |
| Aroney, CN; Bett, JH; Perrin, EJ; Ray, MJ; Walters, DL; Wood, P | 1 |
| Barlocco, F; Caracciolo, M; D'Urbano, M; De Servi, S; Klugmann, S; Mariani, G; Nichelatti, M; Savonitto, S | 1 |
| Collins, MB; Dangas, G; Hooper, WC; Kreps, EM; Lansky, AJ; Leon, MB; Mehran, R; Moses, JW; Saltzman, AJ; Stone, GW; Weisz, G | 1 |
| Boiti, C; Borutti, G; Cazzaniga, M; Falaschi, F; Maestroni, A; Mandelli, C; Manganaro, D; Monzani, V; Rossi, P; Torgano, G; Zecca, B; Zilioli, E | 1 |
| Campo, G; Cangiano, E; Cavazza, C; Ferrari, R; Fileti, L; Frangione, A; Luccarelli, S; Valgimigli, M | 1 |
| Dai, K; Li, S; Liu, G; Shi, Q; Wang, Y; Wang, Z; Zhang, W | 1 |
| Agnelli, D; Al-Kayyali, S | 1 |
| Jafary, FH; Rahman, N | 1 |
| Purdy, PD; Rickert, KL; Welch, BG | 1 |
| Juwana, YB; Ottervanger, JP; Suryapranata, H; van 't Hof, AW | 1 |
| Doraiswamy, VA | 1 |
| Erden, I; Ordu, S; Ozhan, H | 1 |
| Dong, L; Shu, X; Zhang, F | 1 |
| Cakici, M; Davutoglu, V; Ercan, S; Sari, I; Yuce, M | 1 |
| Chen, SC; Cheng, PW; Chuang, YH; Li, PC; Ruan, JL | 1 |
| Bolsin, S; Conroy, M; Osborne, C | 1 |
| Chi, YP; Li, QX; Li, SY; Li, WZ; Song, L; Wang, J; Wu, Z; Yan, HB; Zhang, XJ; Zhao, HJ; Zheng, B | 1 |
| Armstrong, PW; Aylward, PE; Betriu, GA; Granger, CB; Holmes, DR; Huber, K; Montalescot, G; van 't Hof, AW; Westerhout, CM; Widimsky, P | 1 |
| Boersma, E; Dill, T; Hamm, C; Heestermans, T; Koopmans, PC; Mosterd, A; Stella, PR; ten Berg, JM; van 't Hof, AW; van Houwelingen, G; van Werkum, JW | 1 |
| Waksman, R | 1 |
| Catapano, O; De Vita, M; Galvani, M; La Vecchia, L; Ottani, F; Tarantino, F | 1 |
| Belle, L; Bonnefoy, E; Capel, O; Debaty, G; Dubien, PY; El Khoury, C; Mercier, C; Perret, T; Savary, D; Serre, P | 1 |
| Cuturello, D; Missiroli, B; Puddu, PE; Saladini, A; Schiariti, M | 1 |
| Tebaldi, M; Valgimigli, M | 1 |
| Aytekin, V; Catakoğlu, AB; Demiroğlu, C; Erciyes, D; Erdim, R; Görmez, S; Gülbaran, M; Karabay, KO | 1 |
| Abbott, JD | 1 |
| Alonso, JJ; Alonso-Briales, JH; Ancillo, P; Bethencourt, A; Bosa, F; de Prado, AP; Fernández-Avilés, F; Gimeno, F; López-Messa, J; San Román, JA; Sánchez, PL; Sanchis, J; Santos, I; Sanz, JJ | 1 |
| Lin, X; Liu, Y; Ni, Z; Wan, X; Yang, X; Zhang, L; Zhang, Z | 1 |
| Corbi, P; Hajj-Chahine, J; Jayle, C; Tomasi, J | 1 |
| Basak, S; Bhattacharya, R; Das Baksi, S; Dutta, D; Gangopadhyay, S; Pani, A; Sarkar, RN | 1 |
| Dambrink, JH; Dill, T; Hamm, C; Heestermans, AA; Ottervanger, JP; Suryapranata, H; ten Berg, J; Timmer, JR; van 't Hof, AW; van Werkum, JW | 1 |
| Chen, SD; Chung, TW; Huang, YY; Sheu, SH; Tseng, CC; Wang, SS; Yang, MC | 1 |
| Dill, T; Hamm, C; Heestermans, T; Ottervanger, JP; Slingerland, R; Smit, JJ; ten Berg, J; van 't Hof, AW; van Werkum, JW | 1 |
| Brugaletta, S; Campo, G; Colangelo, S; de Cesare, N; Ferrari, R; Fileti, L; Furgieri, A; Meliga, E; Russo, F; Valgimigli, M | 1 |
| Sachithanandan, A | 1 |
| Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hermanides, RS; Kolkman, JJ; Ottervanger, JP; Stella, PR; Ten Berg, JM; van 't Hof, AW; van Houwelingen, KG | 1 |
| Biondi-Zoccai, G; Lioy, E; Rasoul, S; Romagnoli, E; Sciahbasi, A; Stone, GW; Valgimigli, M; van't Hof, A | 1 |
| Chen, LY; Hsin, HT; Liao, PC; Lin, PC; Wu, CF | 1 |
| Chiu, YW; Hsu, CN; Hung, CS; Kao, HL; Lee, JK; Lin, MS; Liu, CP | 1 |
| Handa, M; Ikeda, Y; Okamura, Y; Watanabe, N; Yoshida, H | 1 |
| Birhan Yilmaz, M; Caldir, V; Refiker Ege, M | 1 |
| Boersma, E; Dill, T; Gosselink, AT; Hamm, C; Heestermans, T; Kochman, W; Koopmans, PC; Mosterd, A; Stella, PR; ten Berg, JM; van 't Hof, AW; van Houwelingen, G; van Werkum, JW; van Zoelen, AB; Zijlstra, F | 1 |
| Chi, YP; Li, QX; Li, SY; Li, WZ; Liu, C; Song, L; Wang, J; Wu, Z; Yan, HB; Zhang, XJ; Zhao, HJ; Zheng, B | 1 |
| Dambrink, JH; Dill, T; Hamm, C; Hermanides, RS; Kolkman, E; Ottervanger, JP; Ten Berg, JM; van 't Hof, AW; van Houwelingen, G | 1 |
| Heindl, B; Körner, M; Leibig, M; Ney, L | 1 |
| Brazier, JE; Fox, KA; Schwenkglenks, M; Szucs, TD | 1 |
| Anselmi, M; Biondi-Zoccai, G; Boccuzzi, G; Bolognese, L; Campo, G; de Cesare, N; Díaz Fernández, JF; Ferrari, R; Malagutti, P; Moreno, R; Parrinello, G; Penzo, C; Ribichini, F; Rodriguez, AE; Russo, F; Valgimigli, M | 1 |
| Anselmi, M; Bolognese, L; Bressers, M; Bristot, L; Campo, G; Colangelo, S; De Cesare, N; Gambetti, S; Garcia-Garcia, HM; Garg, S; Monti, M; Moreno, R; Parrinello, G; Rodriguez, AE; Sarno, G; Serruys, PW; Valgimigli, M | 1 |
| Dziegielewski, P; Fu Zhu, L; Harris, J; Seikaly, H; Singh, P | 1 |
| Boes, L; Bonz, AW; Ertl, G; Lengenfelder, B; Stoerk, S; Strotmann, J; Voelker, W | 1 |
| Oberstrass, H; Ringelstein, A; Seitz, RJ; Siebler, M; Wittsack, HJ | 1 |
| Cheng, CF; Cheng, WT; Kikuchi, T; Lian, WS; Lin, H | 1 |
| Canga, Y; Durmuş, G; Ilhan, E; Karataş, MB; Kırbaş, V; Osmonov, D | 1 |
| Dündar, C; Erkol, A; Gibson, CM; İzgi, A; Kırma, C; Oduncu, V; Pala, S; Tigen, K | 1 |
| Alame, G; Cazenave, JP; Freund, M; Gachet, C; Gaertner, S; Hechler, B; Leguay, C; Petitou, M | 1 |
| Latour, RA; Sivaraman, B | 1 |
| Bongo, AS; Cavallino, C; Lazzero, M; Lupi, A; Rognoni, A; Sansa, M; Secco, GG | 1 |
| Chu, KM; Han, CL; Li, YH; Lin, GM | 1 |
| Moliterno, DJ | 1 |
| Armstrong, PW; Bolognese, L; Braunwald, E; Califf, RM; Durand, E; Giugliano, RP; Harrington, RA; Hasselblad, V; Kong, DF; Moliterno, DJ; Newby, LK; Prabhakaran, D; Rasoul, S; Stone, GW; Théroux, P; Tricoci, P; Van de Werf, F; White, HD | 1 |
| Schneider, DJ | 1 |
| Cardenal, R; Diaz, JF; Gomez-Manchero, A; Sanchez-Gonzalez, C | 1 |
| Cakmak, M; Karabulut, A | 1 |
| Boersma, E; de Boer, MJ; Dill, T; Hamm, C; Hermanides, RS; Ottervanger, JP; Stella, PR; ten Berg, JM; van 't Hof, AW; van Houwelingen, G | 1 |
| Valgimigli, M | 1 |
| Dambrink, JH; de Boer, MJ; Gosselink, AT; Hamm, C; Heestermans, T; Koopmans, P; Mosterd, A; ten Berg, JM; van 't Hof, AW; van Houwelingen, G; van Werkum, JW; Zijlstra, F | 1 |
| Biondi Zoccai, G; Bollati, M; Giraudi, E; Millesimo, G; Moretti, C; Omedè, P; Sciuto, F; Sheiban, I | 1 |
| Baik, SK; Hwang, JC; Kwon, JH; Shin, SH; Weon, YC | 1 |
| Andronati, SA; Grygorash, RY; Kabanov, VM; Kabanova, TA; Khristova, TM; Krysko, AA; Krysko, OL; Kuz'min, VE; Polishchuk, PG; Samoylenko, GV; Varnek, AA | 1 |
| Fiebach, JB; Hamann, G; Hennerici, MG; Junghans, U; Röther, J; Schneider, D; Seitz, RJ; Siebler, M; Villringer, A; von Reutern, GM; Witte, OW | 1 |
| Bolognese, L; Campo, G; Colangelo, S; de Cesare, N; Díaz Fernández, JF; Ferrari, R; Gambetti, S; Moreno, R; Nazzaro, MS; Parrinello, G; Penzo, C; Piva, T; Prati, F; Ribichini, F; Rodriguez, AE; Russo, F; Sheiban, I; Valgimigli, M; Vassanelli, C | 1 |
| Atalar, E; Canpolat, U; Sunman, H; Yorgun, H | 1 |
| Hu, J; Jin, HG; Lu, L; Qiu, JP; Shen, J; Shen, WF; Yang, ZK; Zhang, Q; Zhang, RY; Zhao, LP; Zhu, TQ | 1 |
| Eisenberg, MJ; Friedland, S; Shimony, A | 1 |
| Ge, YG; Li, WM; Ni, ZH; Wang, HS; Wang, LF; Xu, L; Yang, XC; Zhang, DP | 1 |
| Chen, R; Gao, L; Gao, W; Li, LJ; Lu, CY; Tian, JW; Xue, Q; Zhai, JY; Zhang, YX; Zhou, SH | 1 |
| Breet, NJ; Dambrink, JH; Gosselink, AT; Hamm, C; Hermanides, RS; Ottervanger, JP; ten Berg, JM; van 't Hof, AW; van Houwelingen, KG; van Werkum, JW | 1 |
| Bolognese, L; Bramucci, E; Campo, G; Colangelo, S; Corrada, E; De Cesare, N; E Rodriguez, A; Ferrante, G; Ferrari, R; Moreno, R; Nazzaro, MS; Pasquetto, G; Piva, T; Prati, F; Presbitero, P; Sheiban, I; Valgimigli, M; Vassanelli, C | 1 |
| Chilton, R | 1 |
| Baik, SK; Lee, JH; Oh, SJ; Park, KP | 1 |
| Badenhorst, PN; Lamprecht, S; Meiring, SM; Roodt, JP; van Rensburg, WJ | 1 |
| De Caterina, R; Grove, EL; Huber, K; Kristensen, SD; Moliterno, DJ; Neumann, FJ; Würtz, M | 1 |
| Candemir, B; Erol, C; Gerede, M; Kaya, CT; Kilickap, M; Kumbasar, D; Ozcan, OU; Ozdemir, AO; Ozdol, C | 1 |
| Batur, MK; Demirkol, S; Kurt, IH; Ünal, I | 1 |
| Allen, A; Armstrong, N; Di Nisio, M; Kleijnen, J; Lang, SH; Manning, N; Misso, K | 1 |
| Baroni, M; Musumeci, G; Rossini, R | 1 |
| Shen, WF | 1 |
| Dambrink, JH; Gosselink, AT; Hamm, C; Hermanides, RS; Ottervanger, JP; Stella, PR; ten Berg, JM; van 't Hof, AW; van Houwelingen, G | 1 |
| Guo, J; Xi, Y; Xu, M | 1 |
| Bristot, L; Campo, G; Ferrari, R; Gambetti, S; Monti, M; Parrinello, G; Tebaldi, M; Valgimigli, M | 1 |
| Steinhubl, SR | 1 |
| Janzen, MC; Lakings, DB; Schneider, DJ | 1 |
| Berger, A; Freeman, A | 1 |
| Aster, RH; Bougie, DW; Rasmussen, M; Zhu, J | 1 |
| Ren, XN; Wang, LF; Wang, MS; Xu, L | 1 |
| Kern, MJ; Seto, A | 1 |
| Hu, H; Huang, ZS; Jiang, L; Jiang, YZ; Liu, P; Ouyang, HW; Song, XH; Zeng, CL; Zhu, LJ | 1 |
| Balling, G; Martin, K; Neuray, M; Schreiber, C | 1 |
| Aksakal, E; Inci, S; Karakelleoğlu, S; Sevimli, S | 1 |
| Bang, OY; Byun, HS; Jeon, P; Kim, GM; Kim, JW; Kim, KH | 1 |
| Chalouhi, N; Hasan, D; Jabbour, P; Kung, D | 1 |
| Cho, YD; Han, MH; Jung, KH; Kang, HS; Kim, JE; Lee, JY; Seo, JH | 1 |
| Davutoglu, V; Ercan, S; Ozer, O; Sari, I; Yuce, M | 1 |
| Teke, D; Teke, HÜ | 1 |
| Akpınar, TS; Besısık, SK; Elcioglu, OC; Ozkok, A; Sezer, M; Tufan, F; Umman, S | 1 |
| Bellandi, F; Cutlip, D; De Luca, G; Dudek, D; Emre, A; Gabriel, HM; Gibson, CM; Gyongyosi, M; Huber, K; Maioli, M; Noc, M; Rakowski, T; Secco, GG; van 't Hof, AW; Zeymer, U; Zorman, S | 1 |
| Controtto, F; Cristofori, R; D'Amico, M; Grasso, C; Marra, S; Pennone, M; Scacciatella, P | 1 |
| Bayır, PT; Duyuler, S; Topaloğlu, S; Uygur, B | 1 |
| Bennett, JS; Hook, KM | 1 |
| Akpinar, I; Aydin, M; Dogan, SM; Elri, T; Karabag, T; Salihoglu, YS; Sayin, MR | 1 |
| Chen, C; Peng, JJ; Ren, LH; Wang, ZY; Ye, HM | 1 |
| Fan, W; Fu, X; Geng, W; Gu, X; Hao, G; Jiang, Y; Li, S; Li, W; Wang, X; Wang, Y; Wu, W; Xue, H; Yang, Z; Zhao, Y | 1 |
| Alexandrov, AV; Bavarsad Shahripour, R | 1 |
| Akpinar, I; Aydin, M; Cil, C; Dogan, SM; Karabag, T; Sayin, MR | 1 |
| Coner, A; Müderrisoğlu, H; Okyay, K; Yıldırır, A | 1 |
| Berger, PB; Califf, RM; Chiswell, K; Hasselblad, V; Pieper, KS; Williams, JB | 1 |
| Bellomo, G; Camaro, C; De Luca, G; Di Giovine, G; Marino, P; Pergolini, P; Restifo, M; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
| Dursunoglu, D; Gür, S; Sari, I; Taskoylu, O | 1 |
| Bendszus, M; Hacke, W; Hametner, C; Kellert, L; Ringleb, P; Rohde, S; Stampfl, S | 1 |
| Ding, FH; DU, R; Hu, J; Qiu, JP; Shen, WF; Yang, ZK; Zhang, JS; Zhang, Q; Zhang, RY; Zhu, TQ | 1 |
| Arystanova, AZh; Balli, M; Batyraliev, TA; Fettser, DV; Kagliian, KÉ; Samko, AN; Serchelik, A; Sidorenko, BA; Tekin, K; Turkmen, S | 1 |
| Gao, C; Hu, D; Li, M; Liu, H; Wang, X; Yang, H; Zhang, Y; Zhu, Z | 2 |
| Ballesteros Ortega, D; Blancas Gómez-Casero, R; Castro Gallego, O; Chana García, M; Estébanez Montiel, B; López Matamala, B; Marina Martínez, L; Martín Parra, C; Martínez González, O; Prieto Valderrey, F; Quintana Díaz, M; Vigil Escribano, D | 1 |
| Omar, HR | 1 |
| Acikel, S; Arslantas, U; Cimen, T; Dogan, M; Ertem, AG; Yeter, E | 1 |
| Jeong, HW; Jin, SC | 1 |
| Gao, YX; Li, L; Li, Y; Sun, TW; Yu, XZ; Yuan, YQ; Zhao, XY | 1 |
| Bae, HJ; Chung, JW; Han, MK; Jang, MS; Jung, C; Kim, JH; Kim, KJ; Kwon, OK; Lee, J; Lee, JS; Noh, WY; Oh, CW; Yang, MH | 1 |
| Altay, S; Ekmekci, A; Eren, M; Golcuk, Y; Gunay, E; Velibey, Y | 1 |
| Guo, M; Jia, Z; Liang, HQ; Song, Y; Zhang, YQ | 1 |
| Altay, S; Golcuk, Y; Gunay, E; Terzi, S; Velibey, Y; Yesilcimen, K | 1 |
| Liu, XH; Qu, Y; Shen, H; Xia, JG | 1 |
| Chen, Y; Chi, Y; Liu, C; Song, L; Wang, J; Wang, S; Yan, H; Zhao, B; Zhao, H; Zhou, P | 1 |
| El-Jack, S | 1 |
| Dong, P; Li, Z; Liu, X; Wang, H; Wang, S; Xing, S; Yang, X; Zhai, Q; Zhang, H | 1 |
| Ding, FH; Hu, J; Jiang, L; Jin, HG; Lu, L; Qiu, JP; Shen, WF; Shen, Y; Yang, ZK; Zhang, Q; Zhang, RY; Zhu, TQ | 1 |
| Chen, MH; Qin, T; Xie, L | 1 |
| Aksu, U; Ayan, A; Demirelli, S; Koza, Y; Lazoglu, Z; Senocak, H; Seven, B; Simsek, Z; Tas, MH | 1 |
| Fedyanin, AA; Gafarova, MA; Khokhlova, MD; Kryukova, DV; Lyubin, EV; Muravyov, AV; Rikova, SY; Shahnazarov, AA; Skryabina, MN; Sokolova, IA | 1 |
| Xie, Q; Zhang, J; Zhang, T; Zhu, J | 1 |
| Gao, CY; Hu, DY; Li, MW; Liu, HZ; Qi, DT; Wang, XP; Wang, XQ; Yang, HH; Zhang, Y; Zhu, ZY | 1 |
| Fahy, M; Kirtane, AJ; Lee, EA; Mehran, R; Nazif, TM; Parise, H; Stone, GW | 1 |
| Chen, M; Li, FO; Li, Q; Miao, GB; Tong, ZC; Wei, Y; Zhang, JJ; Zhao, H | 1 |
| Chen, YD; Dong, W; Guo, JC; Qi, GX; Qian, G; Yang, M | 1 |
| Aytekin, V; Karabay, KO; Yildiz, O | 1 |
| Chen, Y; Gao, CY; Li, MW; Rao, LX; Zhao, XM; Zhu, ZY | 1 |
| Asanin, M; Brdar, N; Djuricic, N; Krljanac, G; Lasica, R; Marinkovic, J; Mrdovic, I; Perunicic, J; Savic, L | 1 |
| Abraha, I; Ciccone, A; Cozzolino, F; Motto, C; Santilli, I | 1 |
| Li, L; Liu, Y; Su, Q | 1 |
| Du, J; Li, W; Liu, Y; Ni, Z; Wang, H; Wang, L; Xia, K; Xu, L; Yang, X; Zhang, D | 1 |
| Arif Yalcin, A; Biyik, I; Celik, O; Erturk, M; Faruk Akturk, I; Murat Caglar, I; Oner, E; Sarikamis, C; Turhan Caglar, N; Uzun, F | 1 |
| Acikel, M; Aksakal, E; Bakirci, EM; Karal, H; Kaya, A; Kurt, M; Sevimli, S; Tanboga, IH; Topcu, S | 1 |
| Li, W; Liu, Y; Ni, Z; Wang, H; Wang, L; Xia, K; Xu, L; Yang, X; Zhang, D | 1 |
| Austin, D; Christie, J; de Belder, MA; Hennigan, B; Mackay, DF; Morley, R; Oldroyd, KG; Pell, JP | 1 |
| Angiolillo, DJ; Antonelli, M; Biglioli, F; Boni, L; Bovenzi, F; Bozzani, A; Bramucci, E; Buffoli, F; Capodanno, D; Castiglioni, B; Comel, A; Cremonesi, A; Crescini, C; D'Angelo, F; De Servi, S; Dionigi, G; Droghetti, A; Francetti, L; Gadda, F; Guagliumi, G; Lettieri, C; Lettino, M; Lorini, L; Musumeci, G; Parolari, A; Piccaluga, E; Ravelli, P; Rossini, R; Salvi, L; Savonitto, S; Scarone, P; Setacci, C; Staurenghi, G; Trabattoni, D; Valdatta, L; Visconti, LO | 1 |
| Baik, SK; Hwang, YH; Kang, DH; Kim, YS; Kim, YW; Park, SP | 1 |
| Brener, SJ; Sattur, S; Stone, GW | 1 |
| Brinjikji, W; Cloft, HJ; Kallmes, DF; Morales-Valero, SF; Murad, MH | 1 |
| Akpek, M; Arinc, H; Baktir, AO; Ergin, A; Kaya, MG; Oguzhan, A; Saglam, H; Sahin, O; Sarli, B; Urkmez, S | 1 |
| Cao, J; Hou, M; Liu, N; Ren, W; Wu, H; Zhou, W | 1 |
| Cao, Z; Du, X; Hu, S; Wang, D; Wang, K; Zhang, C; Zheng, L; Zuo, G | 1 |
| Agostoni, P; Stella, PR; Timmers, L | 1 |
| Francis, PK; Gupta, PN; Shylaja, SV; Thomas, J | 1 |
| Adiyaman, A; Giannitsis, E; Hamm, C; Hoorntje, JC; Schellings, DA; Suryapranata, H; Ten Berg, JM; Van't Hof, AW | 1 |
| Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L | 1 |
| Chen, J; Feng, L; Liu, J; Lv, CF | 1 |
| Alüzüm, H; Ede, H; Erbay, AR; Erkoç, MF; Özdemir, ZT | 1 |
| Liu, CM; Xu, HP; Zhang, WW | 1 |
| Dong, PS; Han, YH; Lai, LH; Wang, HL; Xing, SY; Zhao, JF; Zhu, JH | 1 |
| Natarajan, D | 1 |
| Adnet, F; Assez, N; Benamer, H; Beruben, A; Boccara, A; Cattan, S; Hennequin, B; Javaud, N; Jullien, T; Lapostolle, F; Montely, JM; Raphael, V; Reuter, PG; Rouchy, C; Soulat, L | 1 |
| Ding, FH; Du, R; Hu, J; Liao, ML; Shen, WF; Wang, XL; Yang, ZK; Zhang, JS; Zhang, Q; Zhang, RY; Zhu, TQ | 1 |
| Adiyaman, A; Beukema, R; Elvan, A; Gal, P; Parlak, E; Schellings, DA; ten Berg, J; van 't Hof, AW | 1 |
| Heemskerk, JW; Lancé, MD; Lionikiene, AS; Mastenbroek, TG; Mutch, NJ; Swieringa, F; van der Meijden, PE; Whyte, CS | 1 |
| Cavender, MA; Faxon, DP | 1 |
| Chen, J; Chen, S; Guo, J; Han, Y; Jiang, D; Jiang, T; Jing, Q; Li, J; Li, Y; Liang, Z; Liu, H; Stone, GW; Su, X; Wang, Y; Xu, B; Yang, P; Zang, H; Zhao, X; Zheng, Y | 1 |
| Barbieri, L; De Luca, G; Marino, P; Schaffer, A; Verdoia, M | 1 |
| Can, MM; Demircan, HC; Esen, AM; İzgi, İA; Kaymaz, C; Keleş, N; Kırma, C; Koca, F; Özdemir, N; Özkan, A; Tanboğa, İH; Türkmen, M | 1 |
| Chang, ST; Chu, CM; Chung, CM; Hsiao, JF; Hsu, JT; Pan, KL; Yang, TY | 1 |
| Barry, DM; Dai, XR; Fan, ML; Hou, SX; Jin, H; Kong, F; Lau, LF; Li, TT; Li, XY; Luo, SY; Zhang, GH; Zhou, LL | 1 |
| Herter, JM; Kraft, F; Meersch, M; Rossaint, J; Van Aken, H; Zarbock, A | 1 |
| Eric Wang, W; Guan, W; Han, Y; Liu, Y; Ren, H; Wang, Z; Yang, J; Zeng, C; Zhou, L | 1 |
| He, Y; Huang, WG; Li, B; Luo, JY; Wang, LX; Wang, SX; Wu, TG; Xu, YJ; Zhao, Q | 1 |
| Jing, Q; Li, R; Liu, P; Liu, Y; Tang, X | 1 |
| Bruder, M; El-Fiki, A; Güresir, E; Konczalla, J; Lescher, S; Schuss, P; Seifert, V; Vatter, H | 1 |
| Harmon, C; King, S; Short, M | 1 |
| He, Y; Jin, J; Li, J; Qian, D; Yu, S | 1 |
| Aparci, M; Balta, S; Celik, T; Demir, M; Demirkol, S; Iyisoy, A; Kaya, MG; Kilic, S; Ozturk, C; Unlu, M; Yildirim, OA | 1 |
| Cha, JK; Choi, JH; Huh, JT; Kang, M; Kim, S | 1 |
| Chalouhi, N; Daou, B; Hasan, DM; Jabbour, P; Shields, B; Starke, RM | 1 |
| Djorgoski, I; Janevik-Ivanovska, E; Serafimovska, MD; Ugresic, M | 1 |
| Choi, JH; Chon, MK; Chun, KJ; Han, DC; Han, J; Hwang, J; Hwang, KW; Jeong, YH; Kim, CH; Kim, IS; Kim, JH; Kim, JS; Lee, SH; Lee, SM; Lee, SY; Noh, M; Park, DW; Park, YH; Sohn, CB | 1 |
| Bai, WX; He, YK; Li, TX; Liang, XD; Wang, YY; Wang, ZL; Zhou, GY | 1 |
| Coscioni, E; D'Angelillo, A; Giordano, A; Messina, S; Musumeci, G; Romano, MF; Romano, S; Rossini, R; Zoccai, GB | 1 |
| Boschetti, E; D'Urbano, M; De Servi, S; Klugmann, S; La Vecchia, C; Lazzari, L; Martina, P; Morici, N; Musumeci, G; Rossini, R; Savonitto, S; Senni, M | 1 |
| Avellino, R; Biondi-Zoccai, G; Corcione, N; D'Angelillo, A; Ferraro, P; Giordano, A; Messina, S; Romano, MF; Romano, S | 1 |
| Dondurmacı, E; Sağ Ertürk, F; Şarlı, B; Tok, A; Uğurlu, M | 1 |
| Bandello, F; Cappelletti, A; Cicinelli, MV; Corvi, F; La Spina, C; Pierro, L; Scomazzoni, F | 1 |
| Han, Y; Li, Y; Liang, Z; Liu, H; Ma, L; Stone, GW; Wang, D; Wang, J; Wang, S; Yang, L | 1 |
| Huang, H; Ouyang, F; Peng, H; Yin, Y; Zeng, J; Zhou, X | 1 |
| Avakian, SD; Caribé, PM; Mansur, Ade P; Roggerio, A; Strunz, CM; Takada, JY | 1 |
| Huang, H; Sun, Z; Zeng, J | 1 |
| Chen, SL; Chen, YD; Chen, YG; Cheng, XS; Ge, JB; Han, YL; Jiang, TM; Li, JL; Li, Y; Liang, ZY; Liu, HW; Liu, ML; Ma, LK; Ma, YT; Wang, G; Wang, HY; Xie, Q; Yang, BS; Zhao, X; Zheng, XQ | 1 |
| Chen, C; Fu, J; Guan, W; Han, Y; Wang, WE; Xia, T; Zeng, C; Zhou, L; Zou, X | 1 |
| Chalouhi, N; Daou, B; Hasan, DM; Jabbour, P; Starke, RM | 1 |
| Li, WM; Liu, Y; Ni, ZH; Wang, HS; Wang, LF; Xia, K; Xu, L; Yang, XC; Zhang, DP | 1 |
| Bongetta, D; Gaetani, P; Lafe, E; Melazzini, F; Zappoli Thyrion, F; Zoia, C | 1 |
| Ahn, JH; Chang, IB; Jun, HS; Kim, JH; Oh, JK; Song, JH | 1 |
| Fu, Q; Huang, YJ; Qiu, CR; Tao, ZQ; Wei, P; Yang, XJ; Zhang, Q; Zhang, YG; Zuo, XH | 1 |
| Hwang, YH; Kang, DH; Kim, YS; Kim, YW; Liebeskind, DS | 1 |
| Dai, SP; Geng, T; Luo, Y; Song, ZY; Xu, ZS; Zhang, JG | 1 |
| Dash, S; Kar, D; Ray, M; Sahrawat, TR; Shahbazi, S; Singh, S | 1 |
| Changjiang, H; Jian, Q; Liang, Y; Puqing, L; Xiaolong, G; Yuan, Z | 1 |
| Dreysse, S; Falk, V; Kaufmann, F; Krabatsch, T; Kretzschmar, A; Müller, M; Pergantis, P; Pieri, M; Potapov, EV; Scandroglio, AM | 1 |
| Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD | 1 |
| French, JK; Gupta, R; Holmes, LE; Juergens, CP; Luu, J; Rajendran, S | 1 |
| Borklu, EB; Cinier, G; Eren, M; Hayiroglu, MI; Kaya, A; Keskin, M; Tatlisu, MA; Uzman, O | 1 |
| Chen, YH; Ding, DD; Kong, Y; Li, Y; Long, CL; Luo, JF; Mei, RQ; Wang, YH; Yang, J | 1 |
| Cao, Z; Gao, L; Zhang, H | 1 |
| Allmendinger, S; Johnston, CP; MacMillan, DW; Smith, RT | 1 |
| Adamo, M; Ariotti, S; Costa, F; Curello, S; de Vries, T; Moschovitis, A; Valgimigli, M; White, HD; Windecker, S | 1 |
| Ahn, JH; Chang, IB; Cho, BM; Hyun, DK; Jun, HS; Kim, BC; Lee, HK; Song, JH | 1 |
| Döring, Y; Drechsler, M; Gombert, A; Grommes, J; Jacobs, MJ; Soehnlein, O; Tilgner, J; von Trotha, KT | 1 |
| Chen, J; Feng, W; Huang, S; Li, W; Li, X; Liang, C; Lin, L; Liu, C; Wang, Y; Wu, Y; Zhang, M | 1 |
| Bao, D; Chen, Y; Cong, H; Ding, S; Han, Y; Jia, S; Jing, Q; Li, J; Li, L; Li, Y; Liang, Z; Liu, B; Liu, H; Wang, H; Zhao, X | 1 |
| Dai, K; Nie, Y; Wang, Q; Yan, R; Zhou, B; Zhu, J | 1 |
| Chaudhary, HT | 1 |
| Badran, AV; Barbosa, R; Figueiredo, GL; Haddad, JL; Lago, IM; Lima, MO; Marin, JA; Novaes, GC; Pavão, RB; Schmidt, A | 1 |
| El-Bagary, RI; Elkady, EF; Farid, NA; Youssef, NF | 1 |
| Cao, Y; Ding, X; Gamariel, RR; Kong, Y; Li, ZY; Liu, TD; Liu, XD; Ming, X; Wang, CH; Xie, ZL; Zhao, Q | 1 |
| Bahia, A; Fry, J; Naqvi, A; Seto, A | 1 |
| Cios, TJ; Guvakov, D; Salamanca-Padilla, Y | 1 |
| Ballotta, E; Baracchini, C; Causin, F; Cester, G; Farina, F; Favaretto, S; Kulyk, C; Nico, L; Palmieri, A; Soso, M; Viaro, F | 1 |
| Baik, SK; Kim, YS; Lee, HW; Lee, SW; Roh, J; Yeom, JA; Yoon, CH | 1 |
| Çavuşoğlu, Y; Iskenderov, K; Mutlu, F; Şenol, U; Tahmazov, S; Ulus, T | 1 |
| Li, J; Sun, H; Wu, X; Zhou, X | 1 |
| Adina, Q; Bildirici, U; Celikyurt, U; Dervis, E; Ural, D; Yavuz, S | 1 |
| Dager, WE; Walker, EA | 1 |
| Choudhary, MI; Moin, SF; Waheed, H | 1 |
| Chen, Q; Geng, G; Han, W; Hao, Y; Hao, Z; Jia, K; Liu, H; Liu, L; Liu, Y; Wang, D; Zhou, Y | 1 |
| Fabris, E; Giannitsis, E; Hamm, C; Kennedy, MW; Kilic, S; Kolkman, E; Ottervanger, JP; Schellings, DAAM; Ten Berg, JM; van Houwelingen, KG; Van't Hof, AWJ | 1 |
| Bernit, E; Christen, JR; Cuisset, T; Darmon, O; Ebbo, M; Grados, A; Harlé, JR; Martinez, E; Picou, L; Roumieu, V; Scandaliaris, S; Schleinitz, N; Soubrier, C | 1 |
| Gang-Qin, X; Guang, F; Jiang-Yu, X; Li, L; Liang-Fu, Z; Qiu-Ji, S; Tian-Xiao, L; Wei-Xing, B; Xiao-Dong, L; Ying-Kun, H; Zhao-Shuo, L; Zi-Liang, W | 1 |
| Gannon, M; Hoch, B; LeVine, DN; Sarkar, A; Wang, X; Wang, Y; Zhao, Y | 1 |
| Chen, T; Jiang, Z; Liu, Z; Sun, B; Wang, T; Yang, S; Yin, H | 1 |
| Chen, T; Cheng, L; Feng, Z; Li, H; Li, Z; Lin, D | 1 |
| Chen, KJ; Feng, X; Li, SW; Xu, H | 1 |
| Che, R; Chen, J; Duan, J; Feng, W; Ji, X; Li, C; Liebeskind, D; Ling, F; Shang, S; Song, H; Wang, Y; Wu, C; Wu, L; Zhang, H; Zhao, W | 1 |
| Ge, Z; Jiang, S; Kuang, J; Li, L; Ma, X; Zhang, D | 1 |
| Feng, W; Huang, SH; Li, W; Li, XS; Liang, CR; Lin, L; Liu, CC; Wang, H; Wang, YJ; Wu, Y; Xu, ZQ; Zhang, LL; Zhang, M | 1 |
| Chourdakis, E; Hahalis, G; Koniari, I; Kounis, NG; Patsouras, N; Roumeliotis, A; Soufras, G; Tsigkas, G | 1 |
| Chen, WH; Lin, DL; Lin, XH; Wu, YM; Yi, TY; Zhang, MF | 1 |
| Barbieri, L; De Luca, G; Nardin, M; Negro, F; Pergolini, P; Rolla, R; Suryapranata, H; Verdoia, M | 1 |
| Chang, ST; Chu, CM; Chung, CM; Hsiao, JF; Hsu, JT; Lin, YS; Pan, KL; Yang, YT | 1 |
| Gao, D; Hu, S; Li, H; Li, M; Wang, H; Zhang, H; Zhu, J | 1 |
| Davakhar, S; Hiremath, S; Krishna, K; Lakade, S | 1 |
| Chang, K; He, Y; Li, L; Li, T; Liang, X; Shao, Q; Wu, Q | 1 |
| Wang, W; Zeng, Q; Zhang, LD | 1 |
| Degrauwe, S; Iglesias, JF; Laurencet, ME; Noble, S; Tessitore, E | 1 |
| Huang, W; Lei, B; Li, F; Li, H; Liu, W; Nogueira, RG; Qiu, Z; Sang, H; Saver, JL; Yang, Q; Zhang, M; Zhou, P; Zhou, Z; Zi, W | 1 |
| Chang, J; Han, B; Luo, Y; Ma, K; Mao, M; Wu, F; Xiang, R; Zuo, Z | 1 |
| Esposito, G; Ettori, F; Ferlini, M; Lettieri, C; Marchese, A; Musumeci, G; Passamonti, E; Pierini, S; Rigattieri, S; Romano, M; Tarantini, G; Testa, L; Tiberti, G | 1 |
| Gurbel, PA; Heramvand, N; Jung, C; Karathanos, A; Kelm, M; Masyuk, M; Muessig, JM; Nia, AM; Polzin, A; Tantry, US; Valgimigli, M | 1 |
| Aguiar Bucsai, M; Idel, C; Mannhalter, C; Verschoor, A; Wollenberg, B | 1 |
| Li, R; Tang, X; Zhang, T | 1 |
| Hu, J; Huang, J; Kong, W; Li, F; Li, L; Liu, S; Luo, W; Nogueira, RG; Qiu, Z; Sang, H; Saver, JL; Song, J; Tian, Y; Yang, J; Yang, Q; Zi, W | 1 |
| Hao, M; Liu, R; Luo, Y; Yan, F | 1 |
| Altmann, S; Brockmann, C; Brockmann, MA; Dillinger, D; Kerz, T; Maus, V; Mpotsaris, A; Othman, AE; Ringel, F; Spreer, A; Waldeck, S | 1 |
| Gao, X; Huang, D; Ren, Y; Su, M; Wang, L; Zhao, D | 1 |
| Jiang, P; Li, C; Lin, F; Qiao, C; Su, N; Sun, P; Yuan, X | 1 |
| Batta, A; Bhogal, S; Gupta, H; Jaiswal, B; Mehrotra, S; Panda, P; Rambabu, E; Sharma, YP | 1 |
| Wang, J; Zou, D | 1 |
161 review(s) available for tyrosine and tirofiban
| Article | Year |
|---|---|
Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Atherectomy, Coronary; Constriction, Pathologic; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recurrence; Stents; Tirofiban; Treatment Outcome; Tyrosine | 1996 |
The anti-GPIIb-IIIa agents: fundamental and clinical aspects.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Drug Evaluation, Preclinical; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Mice; Multicenter Studies as Topic; Oligopeptides; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Fusion Proteins; Thrombosis; Tirofiban; Tyrosine | 1996 |
[Platelet membrane glycoproteins as site of pharmacological intervention in the treatment of coronary disease].
Topics: Abciximab; Acetates; Alkynes; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Binding Sites; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Coronary Disease; Double-Blind Method; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Platelet Membrane Glycoproteins; Randomized Controlled Trials as Topic; Receptors, Antigen, B-Cell; Receptors, Cell Surface; Time Factors; Tirofiban; Tyrosine | 1997 |
Glycoprotein IIb/IIIa receptor antagonists for the treatment of unstable angina.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clinical Trials as Topic; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Tirofiban; Treatment Outcome; Tyrosine | 1997 |
An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Eptifibatide; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
New antiplatelet agents for acute coronary syndromes.
Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Blood Platelets; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine | 1998 |
An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Atherectomy, Coronary; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Survival Analysis; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Research Design; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
Glycoprotein IIb-IIIa antagonists in percutaneous coronary interventions and acute coronary syndromes.
Topics: Abciximab; Angina, Unstable; Angioplasty; Antibodies, Monoclonal; Coronary Artery Bypass; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Myocardial Ischemia; Myocardial Revascularization; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Tyrosine | 1998 |
Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Disease Progression; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Survival Analysis; Thrombolytic Therapy; Tirofiban; Tyrosine | 1998 |
Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tirofiban; Tyrosine | 1998 |
Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
Topics: Acetates; Acute Disease; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Eptifibatide; Heparin; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 1998 |
Tirofiban. A review of its use in acute coronary syndromes.
Topics: Acute Disease; Coronary Disease; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Tirofiban; Tissue Distribution; Tyrosine | 1998 |
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Cardiology; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Embolism; Eptifibatide; Female; Fibrinolytic Agents; Follow-Up Studies; Forecasting; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk; Stents; Structure-Activity Relationship; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Antiplatelet therapy for treatment of acute coronary syndromes.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine; Vascular Patency | 1999 |
Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Thrombosis; Eptifibatide; Forecasting; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Tyrosine | 1999 |
Economic issues in glycoprotein IIb/IIIa receptor therapy.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Drug Costs; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Tyrosine | 1999 |
Use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Angina, Unstable; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
Clinical trials of IIb/IIIa receptor blockers in patients undergoing angioplasty.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Safety; Tirofiban; Tyrosine | 1999 |
Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes.
Topics: Acute Disease; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Catheterization, Peripheral; Coronary Disease; Coronary Thrombosis; Eptifibatide; Femoral Artery; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Revascularization; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Blood Platelets; Coronary Artery Bypass; Coronary Disease; Coronary Thrombosis; Eptifibatide; Fibrinolytic Agents; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Incidence; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Safety; Tirofiban; Tyrosine | 1999 |
Inhibitors of the platelet receptor glycoprotein IIb-IIIa and complications during percutaneous coronary revascularization. Management strategies for the cardiac surgeon.
Topics: Cardiopulmonary Bypass; Coronary Artery Bypass; Coronary Thrombosis; Dose-Response Relationship, Drug; Emergencies; Eptifibatide; Hemostasis, Surgical; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 1999 |
Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Electrocardiography; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 1999 |
Analysis of number needed to treat and cost of platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions and acute coronary syndromes.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Tirofiban; Tyrosine; Vascular Surgical Procedures | 1999 |
Efficacy of low-molecular-weight heparin in acute coronary syndromes.
Topics: Angina, Unstable; Anticoagulants; Biomarkers; Drug Therapy, Combination; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Secondary Prevention; Survival Rate; Tirofiban; Treatment Outcome; Troponin T; Tyrosine | 2000 |
Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment.
Topics: Eptifibatide; Hemorrhage; Humans; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Risk Factors; Survival Rate; Thrombocytopenia; Tirofiban; Tyrosine | 2000 |
Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use model for expediting care in acute coronary syndromes.
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Coronary Disease; Drug Therapy, Combination; Electrocardiography; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Drug Therapy, Combination; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2000 |
[The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
Topics: Acute Disease; Clinical Trials as Topic; Coronary Disease; Electrocardiography; Eptifibatide; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Syndrome; Tirofiban; Tyrosine | 2000 |
Treatment of unstable angina: the role of platelet inhibitors and anticoagulants.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Coronary Thrombosis; Endothelium, Vascular; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Tyrosine | 1999 |
Glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes.
Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine | 1999 |
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
Topics: Abciximab; Acetates; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Combined Modality Therapy; Coronary Disease; Drug Monitoring; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Myocardial Infarction; Patient Selection; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Recurrence; Risk Factors; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
[GPIIb/IIIa inhibitor].
Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Thrombosis; Drug Design; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2000 |
Prognostic value of cardiac troponins in patients with acute coronary disease.
Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials as Topic; Dalteparin; Female; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Male; Multicenter Studies as Topic; Myocardial Infarction; Prognosis; Prospective Studies; Tirofiban; Troponin I; Tyrosine | 2000 |
Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis.
Topics: Abciximab; Antibodies, Monoclonal; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombocytopenia; Tirofiban; Tyrosine | 2000 |
Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials.
Topics: Abciximab; Acetates; Acute Disease; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Incidence; Infusions, Intravenous; Intracranial Hemorrhages; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Syndrome; Tirofiban; Tyrosine | 2000 |
The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Alanine; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Tirofiban; Tyrosine | 2000 |
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes.
Topics: Acetates; Acute Disease; Eptifibatide; Hemorrhage; Humans; Myocardial Infarction; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Tirofiban; Tyrosine | 1999 |
Platelet glycoprotein receptor site blockade in coronary artery disease.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Stents; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Acute Disease; Alanine; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Drug Therapy, Combination; Eptifibatide; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Tirofiban; Tyrosine | 2000 |
Redefining medical treatment in the management of unstable angina.
Topics: Abciximab; Administration, Oral; Angina, Unstable; Antibodies, Monoclonal; C-Reactive Protein; Diagnosis, Differential; Enoxaparin; Eptifibatide; Government Agencies; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Myocardial Infarction; National Institutes of Health (U.S.); Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Risk; Time Factors; Tirofiban; Troponin I; Troponin T; Tyrosine; United States | 2000 |
Pharmacology: antiplatelet and antithrombin therapy in acute coronary syndromes.
Topics: Abciximab; Antibodies, Monoclonal; Antithrombins; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2000 |
Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease.
Topics: Arteriosclerosis; Clopidogrel; Eptifibatide; Humans; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Stroke; Ticlopidine; Tirofiban; Tyrosine | 2000 |
[Platelet-leukocyte interactions in coronary heart disease: pathophysiology, clinical relevance, pharmacological modulation].
Topics: Abciximab; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood Platelets; CD18 Antigens; Chemotaxis, Leukocyte; Coronary Artery Bypass; Coronary Disease; Cytokines; Fibrinogen; Heparin; Humans; Immunoglobulin Fab Fragments; Leukocytes; Ligands; Macrophage-1 Antigen; Membrane Glycoproteins; Models, Biological; Myocardial Infarction; Neutrophils; P-Selectin; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombospondins; Tirofiban; Tyrosine | 2000 |
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina.
Topics: Acetates; Angina, Unstable; Biphenyl Compounds; Cost-Benefit Analysis; Eptifibatide; Female; Humans; Male; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Pyrrolidines; Tirofiban; Tyrosine | 2000 |
Platelet glycoprotein IIb/IIIa receptor antagonists and coronary artery disease.
Topics: Abciximab; Administration, Oral; Aged; Angioplasty; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Disease; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Sensitivity and Specificity; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Coronary Artery Bypass; Coronary Disease; Drug Approval; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Mice; Multicenter Studies as Topic; Myocardial Ischemia; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Recurrence; Safety; Single-Blind Method; Stents; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine; United States; United States Food and Drug Administration | 2000 |
[Investigational new drugs among glycoprotein IIb/IIIa-receptor antagonists].
Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials as Topic; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2000 |
[Tirofiban (Aggrastat). A non-peptide glycoprotein IIb/IIIa receptor inhibitor].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Fibrinolytic Agents; Humans; Injections, Intravenous; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2001 |
Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Survival Rate; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
New approaches to diagnosis and management of unstable angina and non-ST-segment elevation myocardial infarction.
Topics: Algorithms; Angina, Unstable; Antithrombins; Biomarkers; Diagnosis, Differential; Electrocardiography; Eptifibatide; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Tirofiban; Tyrosine | 2001 |
Low-molecular-weight heparin and other antithrombotic agents in the setting of a fast-track revascularization in unstable coronary artery disease.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clinical Trials as Topic; Combined Modality Therapy; Diabetes Complications; Drug Therapy, Combination; Eptifibatide; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Hirudin Therapy; Hirudins; Humans; Immunoglobulin Fab Fragments; Myocardial Revascularization; Oligosaccharides; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Randomized Controlled Trials as Topic; Recombinant Proteins; Risk Factors; Thrombocytopenia; Thrombosis; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
[Update on the treatment with platelet antiaggregation agents].
Topics: Abciximab; Adenosine Diphosphate; Antibodies, Monoclonal; Arachidonic Acid; Cell Membrane; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prostaglandin-Endoperoxide Synthases; Thromboxane A2; Tirofiban; Tyrosine | 2001 |
[Acute coronary syndromes: an update. I. Pathogenesis and drug therapy].
Topics: Acute Disease; Administration, Oral; Adrenergic beta-Antagonists; Angina, Unstable; Anticoagulants; Aspirin; Calcium Channel Blockers; Clinical Trials as Topic; Clopidogrel; Electrocardiography; Fibrinolytic Agents; Humans; Multicenter Studies as Topic; Myocardial Infarction; Nitrates; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Syndrome; Terminology as Topic; Ticlopidine; Tirofiban; Tyrosine | 2001 |
[GPIIb-IIIa inhibitors].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
Topics: Abciximab; Adenosine Diphosphate; Amino Acid Chloromethyl Ketones; Antibodies, Monoclonal; Anticoagulants; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Interactions; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Oligopeptides; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Proteins; Receptors, Thrombin; Thrombin; Tirofiban; Tyrosine | 2001 |
Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Artery Bypass; Dalteparin; Enoxaparin; Eptifibatide; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Nadroparin; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Thrombosis; Tirofiban; Transaminases; Tyrosine | 2001 |
Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs.
Topics: Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Combinations; Drug Stability; Drug Storage; Platelet Aggregation Inhibitors; Solutions; Tirofiban; Tyrosine | 2001 |
Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass.
Topics: Abciximab; Ancrod; Antibodies, Monoclonal; Anticoagulants; Arginine; Cardiopulmonary Bypass; Chondroitin Sulfates; Cross Reactions; Dermatan Sulfate; Drug Combinations; Drug Hypersensitivity; Factor Xa Inhibitors; Hemodilution; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Heparitin Sulfate; Hirudin Therapy; Humans; Immunoglobulin Fab Fragments; Perfusion; Pipecolic Acids; Platelet Aggregation Inhibitors; Protamines; Sulfonamides; Thrombocytopenia; Thrombophilia; Thrombosis; Tirofiban; Tyrosine | 2001 |
ReoPro rules: results from the 'Do Tirofiban and ReoPro Give Similar Efficacy Trial' (TARGET).
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Stenosis; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Aggregation Inhibitors; Stents; Tirofiban; Tyrosine | 2001 |
ESPRIT in context: pharmacology matters!
Topics: Abciximab; Angioplasty; Antibodies, Monoclonal; Eptifibatide; Half-Life; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Use of coronary revascularization in patients with unstable and non-ST-segment elevation acute myocardial infarction.
Topics: Angina, Unstable; Humans; Myocardial Infarction; Myocardial Revascularization; Randomized Controlled Trials as Topic; Risk Assessment; Syndrome; Thrombolytic Therapy; Tirofiban; Tyrosine | 2001 |
Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials.
Topics: Acetates; Clinical Trials as Topic; Electrocardiography; Eptifibatide; Heart Conduction System; Humans; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
Acute coronary syndrome without ST elevation: implementation of new guidelines.
Topics: Abciximab; Algorithms; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Disease; Electrocardiography; Europe; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Factors; Tirofiban; Troponin; Tyrosine; United States | 2001 |
GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us.
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Atherectomy; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Syndrome; Time Factors; Tirofiban; Treatment Outcome; Troponin T; Tyrosine | 2001 |
The role of alpha(v)beta3 integrins in vascular healing.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Cell Adhesion; Chemotaxis, Leukocyte; Clinical Trials as Topic; Coronary Restenosis; Coronary Stenosis; Drug Evaluation, Preclinical; Endothelium, Vascular; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Models, Animal; Papio; Peptides; Platelet Adhesiveness; Rabbits; Rats; Receptors, Vitronectin; Signal Transduction; Swine; Tirofiban; Tyrosine; Vasculitis; Wound Healing | 2002 |
Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab.
Topics: Abciximab; Antibodies, Monoclonal; Coronary Disease; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2002 |
Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Integrins; Peptides; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2002 |
The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2002 |
Antithrombotic agents: implications in dentistry.
Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Dental Care; Drug Interactions; Embolism; Fibrinolytic Agents; Hemostasis; Heparin; Heparin, Low-Molecular-Weight; Humans; Oral Hemorrhage; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Ticlopidine; Tirofiban; Tyrosine; Venous Thrombosis; Warfarin | 2002 |
Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: IIb or Not IIb, what is the question?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Intraoperative Care; Male; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials.
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Dose-Response Relationship, Drug; Drug Administration Schedule; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Syndrome; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
TARGET versus GUSTO-IV: appropriate use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and percutaneous coronary intervention.
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2002 |
Defining optimal therapy for the thrombolysis-ineligible patient.
Topics: Acute Disease; Coronary Disease; Enoxaparin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Male; Myocardial Reperfusion; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombolytic Therapy; Tirofiban; Tyrosine | 2002 |
Platelets: is aspirin sufficient or must we know how to pronounce abciximab?
Topics: Abciximab; Antibodies, Monoclonal; Arteriosclerosis; Aspirin; Blood Platelets; Clopidogrel; Endarterectomy, Carotid; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Ticlopidine; Tirofiban; Tyrosine | 2002 |
Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Drug Therapy, Combination; Eptifibatide; Female; Fibrinolytic Agents; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Thrombocytopenia; Tirofiban; Tyrosine | 2003 |
Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Atherectomy, Coronary; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Randomized Controlled Trials as Topic; Risk; Stents; Survival Analysis; Tirofiban; Tyrosine | 2003 |
[Stratification of cardiac risk in unstable angina: value of troponin measurements].
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Angiography; Electrocardiography; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Risk Factors; Time Factors; Tirofiban; Troponin; Troponin I; Troponin T; Tyrosine | 2002 |
The thrombolysis in myocardial infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Drug Therapy, Combination; Heparin; Humans; Logistic Models; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Recurrence; Risk Assessment; Thrombolytic Therapy; Tirofiban; Troponin; Tyrosine | 2003 |
Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Clinical Trials as Topic; Eptifibatide; Fibrinolytic Agents; Forecasting; Humans; Immunoglobulin Fab Fragments; Infusions, Parenteral; Myocardial Infarction; Peptides; Placebos; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Time Factors; Tirofiban; Tyrosine | 2003 |
The complementary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Stents; Tirofiban; Tyrosine | 2002 |
[GP IIb/IIIa receptor prevention medicine].
Topics: Abciximab; Animals; Antibodies, Monoclonal; Aspirin; Clinical Trials as Topic; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombolytic Therapy; Tirofiban; Tyrosine | 2003 |
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Anticholesteremic Agents; Arrhythmias, Cardiac; Aspirin; Atorvastatin; Clopidogrel; Defibrillators, Implantable; Double-Blind Method; Fibrinolytic Agents; Heart Failure; Heart Septal Defects, Atrial; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Myocardial Infarction; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Regeneration; Risk Factors; Syndrome; Ticlopidine; Time Factors; Tirofiban; Tyrosine | 2003 |
Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Coronary Disease; Drug Evaluation; Eptifibatide; Guidelines as Topic; Humans; Immunoglobulin Fab Fragments; Incidence; Injections, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
[Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
Topics: Abciximab; Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Controlled Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Electrocardiography; Emergencies; Eptifibatide; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Time Factors; Tirofiban; Tyrosine | 2003 |
Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention.
Topics: Abciximab; Acute Disease; Aged; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Syndrome; Tirofiban; Tyrosine | 2003 |
[Role of GP IIb/IIIa blockers in clinical cardiology].
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2003 |
Current management of unstable angina: lessons from the TACTICS-TIMI 18 trial.
Topics: Angina, Unstable; Angioplasty, Balloon; Aspirin; Dalteparin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Myocardial Ischemia; Randomized Controlled Trials as Topic; Risk Assessment; Thrombolytic Therapy; Tirofiban; Tyrosine | 2002 |
Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention.
Topics: Abciximab; Angioplasty; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Restenosis; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombosis; Tirofiban; Tyrosine | 2003 |
Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Animals; Antibodies, Monoclonal; Antibody Specificity; Clinical Trials as Topic; Epitopes; Eptifibatide; Fibrinogen; Humans; Immunoglobulin Fab Fragments; Mice; Myocardial Infarction; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Fusion Proteins; Thrombocytopenia; Tirofiban; Tyrosine | 2004 |
Glycoprotein IIb-IIIa antagonists in non-ST elevation acute coronary syndromes and percutaneous interventions: from pharmacology to individual patient's therapy: part 1: the evidence of benefit.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Comorbidity; Coronary Disease; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Stents; Tirofiban; Tyrosine | 2004 |
Intravenous glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: lessons from recently conducted randomized clinical trials.
Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2004 |
Use of the early invasive approach in the management of acute coronary syndromes.
Topics: Angina, Unstable; Cardiac Catheterization; Humans; Myocardial Infarction; Myocardial Revascularization; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Assessment; Syndrome; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Comorbidity; Coronary Restenosis; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Peptide Fragments; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Stents; Thrombophilia; Ticlopidine; Tirofiban; Tyrosine | 2004 |
Practical approach to the diagnosis and management of thrombocytopenia associated with tirofiban treatment.
Topics: Aged; Disease Management; Female; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 2004 |
Thrombocytopenia resulting from sensitivity to GPIIb-IIIa inhibitors.
Topics: Abciximab; Antibodies, Monoclonal; Diagnosis, Differential; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Immunoglobulin G; Ligands; Models, Chemical; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Thrombocytopenia; Tirofiban; Tyrosine | 2004 |
Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2004 |
Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Contraindications; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Patient Selection; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Tirofiban; Tyrosine | 2005 |
Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 2005 |
Tirofiban in acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine | 2005 |
Tirofiban and emergency coronary surgery.
Topics: Acute Disease; Administration, Oral; Blood Platelets; Coronary Artery Bypass; Coronary Disease; Emergencies; Humans; Infusions, Intravenous; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Thrombocytopenia; Tirofiban; Tyrosine | 2005 |
Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clinical Trials as Topic; Clopidogrel; Eptifibatide; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Recombinant Proteins; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Tirofiban for the treatment of ischaemic stroke.
Topics: Animals; Brain Ischemia; Humans; Platelet Glycoprotein GPIIb-IIIa Complex; Stroke; Tirofiban; Tyrosine | 2006 |
Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists.
Topics: Abciximab; Adrenal Cortex Hormones; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Immunoglobulins, Intravenous; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prevalence; Thrombocytopenia; Tirofiban; Tyrosine | 2006 |
Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.
Topics: Abciximab; Antibodies, Monoclonal; Autoantibodies; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 2006 |
Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2005 |
[Antithrombotic treatment of acute coronary syndromes without ST-segment elevation].
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Syndrome; Ticlopidine; Tirofiban; Tyrosine | 2006 |
[Pathogenesis and therapy of the acute coronary syndrome: differentiated advantage of glycoprotein IIb/IIIa receptor antagonists for high-risk patients].
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Thrombosis; Diabetes Complications; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Renal Insufficiency; Risk Factors; Syndrome; Ticlopidine; Tirofiban; Troponin; Tyrosine | 2006 |
[Update on antithrombotic treatments in arterial diseases].
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Arteriosclerosis; Aspirin; Dipyridamole; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Pyridines; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Current strategies with high-dose tirofiban.
Topics: Dose-Response Relationship, Drug; Humans; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Emergency coronary artery bypass grafting in patients with acute myocardial infarction treated with glycoprotein IIb/IIIa receptor inhibitors.
Topics: Abciximab; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Emergency Treatment; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Male; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Bleeding Time; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Reoperation; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Electrocardiography; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Ticlopidine; Tirofiban; Tyrosine | 2008 |
Glycoprotein IIb/IIIa antagonists in acute ischaemic stroke: current status and future directions.
Topics: Abciximab; Acute Disease; Animals; Antibodies, Monoclonal; Brain Ischemia; Clinical Trials as Topic; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stroke; Tirofiban; Tyrosine | 2008 |
The role of tirofiban in the management of coronary artery disease.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Coronary Artery Disease; Cost-Benefit Analysis; Drug Design; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2008 |
Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Time Factors; Tirofiban; Tyrosine | 2009 |
Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis.
Topics: Abciximab; Angioplasty, Balloon; Antibodies, Monoclonal; Anticoagulants; Confidence Intervals; Coronary Angiography; Eptifibatide; Fibrinolytic Agents; Hematologic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2009 |
[The MULTISTRATEGY study].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Drug Therapy, Combination; Drug-Eluting Stents; Electrocardiography; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Sirolimus; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
[The FATA study].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Electrocardiography; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Randomized Controlled Trials as Topic; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Chemotherapy, Adjuvant; Hemorrhage; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptide Fragments; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Regression Analysis; Tirofiban; Tyrosine | 2010 |
Year in review 2008: Critical Care--nephrology.
Topics: Acute Kidney Injury; Anti-Infective Agents; Anticoagulants; Critical Care; Humans; Intensive Care Units; Nephrology; Platelet Aggregation Inhibitors; Protein C; Recombinant Proteins; Renal Replacement Therapy; Thrombocytopenia; Tirofiban; Tyrosine; Water-Electrolyte Balance | 2009 |
Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Thrombosis; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Tirofiban for myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Dose-Response Relationship, Drug; Electrocardiography; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 2010 |
Early administration of small-molecule glycoprotein IIb/IIIa inhibitors before primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from randomized clinical trials.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2010 |
Comparison by meta-analysis of eptifibatide and tirofiban to abciximab in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Electrocardiography; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
Safety evaluation of tirofiban.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Double-Blind Method; Drug Resistance; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Incidence; Multicenter Studies as Topic; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombocytopenia; Ticlopidine; Tirofiban; Tyrosine | 2010 |
Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Electrocardiography; Eptifibatide; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2012 |
Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and S
Topics: Abciximab; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiovascular Agents; Coronary Angiography; Coronary Circulation; Drug-Eluting Stents; Evidence-Based Medicine; Female; Humans; Immunoglobulin Fab Fragments; Kaplan-Meier Estimate; Male; Metals; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; No-Reflow Phenomenon; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sirolimus; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2011 |
Update on glycoprotein IIb/IIIa: role in primary coronary intervention.
Topics: Abciximab; Angioplasty; Animals; Antibodies, Monoclonal; Blood Platelets; Coronary Artery Disease; Coronary Vessels; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2011 |
Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
Topics: Acetates; Acute Coronary Syndrome; Administration, Cutaneous; Angioplasty; Electrocardiography; Eptifibatide; Hemorrhage; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Randomized Controlled Trials as Topic; Risk; Survival Analysis; Tirofiban; Tyrosine | 2011 |
Current issues with glycoprotein IIb-IIIa antagonists.
Topics: Abciximab; Acute Coronary Syndrome; Antibodies, Monoclonal; Anticoagulants; Eptifibatide; Hemostasis; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tirofiban; Tyrosine | 2011 |
Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab.
Topics: Abciximab; Antibodies, Monoclonal; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Immunoglobulin Fab Fragments; Meta-Analysis as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2011 |
Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Circulation; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2011 |
Contemporary use of glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty; Animals; Antibodies, Monoclonal; Clinical Trials as Topic; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Thrombosis; Tirofiban; Tyrosine | 2012 |
Treatment with tirofiban for acute coronary syndrome (ACS): a systematic review and network analysis.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Dose-Response Relationship, Drug; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2012 |
GP IIb/IIIa inhibitors for STEMI: still the gold standard or an old survivor?
Topics: Abciximab; Animals; Antibodies, Monoclonal; Arrhythmias, Cardiac; Eptifibatide; Evidence-Based Medicine; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2012 |
Tirofiban-induced diffuse alveolar hemorrhage: after primary angioplasty.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Fatal Outcome; Female; Hemorrhage; Humans; Lung Diseases; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Tirofiban; Tyrosine | 2012 |
Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review.
Topics: Acute Coronary Syndrome; Aged; Hemorrhage; Humans; Male; Middle Aged; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Pulmonary Alveoli; Thrombocytopenia; Tirofiban; Tyrosine | 2012 |
Glycoprotein IIb/IIIa antagonists.
Topics: Abciximab; Animals; Antibodies, Monoclonal; Blood Platelets; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2012 |
Ancillary approaches to plasminogen activators.
Topics: Anticoagulants; Arginine; Brain Ischemia; Cerebral Hemorrhage; Clinical Trials as Topic; Collateral Circulation; Drug Synergism; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Hypothermia, Induced; Low-Level Light Therapy; Pipecolic Acids; Plasminogen Activators; Platelet Aggregation Inhibitors; Prospective Studies; Recombinant Proteins; Sulfonamides; Thrombolytic Therapy; Tirofiban; Tyrosine; Ultrasonic Therapy; Vasodilator Agents | 2012 |
Acute myocardial infarction associated with thinner abuse: case report and literature review.
Topics: Adolescent; Adult; Biomarkers; Blood Coagulation Tests; Coronary Angiography; Creatine Kinase, MB Form; Electrocardiography; Fibrinolytic Agents; Humans; Infusions, Intravenous; Inhalation Exposure; Male; Middle Aged; Myocardial Infarction; Platelet Function Tests; Predictive Value of Tests; Solvents; Substance-Related Disorders; Time Factors; Tirofiban; Treatment Outcome; Troponin I; Tyrosine; Up-Regulation; Young Adult | 2013 |
Meta-analysis of randomized controlled trials on the efficacy and safety of intracoronary administration of tirofiban for no-reflow phenomenon.
Topics: Coronary Vessels; Humans; Injections, Intra-Arterial; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Brain Ischemia; Humans; Immunoglobulin Fab Fragments; Intracranial Hemorrhages; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Stroke; Tirofiban; Tyrosine | 2014 |
Safety and efficacy of early administration of tirofiban in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis.
Topics: Fibrinolytic Agents; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Thrombolytic Therapy; Tirofiban; Tyrosine | 2014 |
Pharmacologic therapy for reducing myocardial infarct size in clinical trials: failed and promising approaches.
Topics: Clinical Trials as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Myocardial Infarction; Stroke Volume; Tirofiban; Tyrosine | 2015 |
Rescue treatment of thromboembolic complications during endovascular treatment of cerebral aneurysms: a meta-analysis.
Topics: Abciximab; Antibodies, Monoclonal; Endovascular Procedures; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Intracranial Aneurysm; Intraoperative Complications; Male; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thromboembolism; Thrombolytic Therapy; Tirofiban; Tyrosine | 2015 |
+Ophitoxaemia and myocardial infarction--the issues during primary angioplasty: a review.
Topics: Angioplasty; Animals; Antivenins; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Snake Bites; Snake Venoms; Snakes; Tirofiban; Tyrosine | 2014 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin | 2014 |
Efficacy and Safety of Intracoronary versus Intravenous Administration of Tirofiban during Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
Topics: Acute Coronary Syndrome; Administration, Intravenous; Humans; Infusions, Intralesional; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tirofiban; Treatment Outcome; Tyrosine | 2015 |
Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban.
Topics: Abciximab; Acute Coronary Syndrome; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Thrombosis; Tirofiban; Tyrosine | 2016 |
Bivalirudin Anticoagulant Therapy With or Without Platelet Glycoprotein IIb/IIIa Inhibitors During Transcatheter Coronary Interventional Procedures: A Meta-Analysis.
Topics: Antithrombins; Cardiac Catheterization; Eptifibatide; Hirudins; Humans; Integrin alpha2; Myocardial Infarction; Peptide Fragments; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Tirofiban; Treatment Outcome; Tyrosine | 2015 |
Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
Topics: Abciximab; Animals; Antibodies, Monoclonal; Blood Platelets; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2016 |
Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Eptifibatide; Humans; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
Snake Venom: From Deadly Toxins to Life-saving Therapeutics.
Topics: Animals; Anticoagulants; Batroxobin; Blood Coagulation; Captopril; Peptides; Snake Venoms; Snakes; Thrombosis; Tirofiban; Toxins, Biological; Tyrosine | 2017 |
Intralesional versus intracoronary administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndromes: A meta-analysis of randomized controlled trials.
Topics: Abciximab; Acute Coronary Syndrome; Antibodies, Monoclonal; Coronary Vessels; Heart Conduction System; Humans; Immunoglobulin Fab Fragments; Injections, Intra-Arterial; Injections, Intralesional; Myocardial Reperfusion; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2017 |
Efficacy and safety of a bridging strategy that uses intravenous platelet glycoprotein receptor inhibitors for patients undergoing surgery after coronary stent implantation: a meta-analysis.
Topics: Eptifibatide; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2022 |
Safety and Efficacy of Tirofiban Combined with Statins in the Perioperative Period of Intracranial Aneurysms: Systematic Review and Meta-Analysis.
Topics: Aneurysm, Ruptured; Embolization, Therapeutic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Aneurysm; Perioperative Period; Postoperative Complications; Retrospective Studies; Tirofiban; Treatment Outcome; Tyrosine | 2022 |
Tirofiban-induced thrombocytopenia.
Topics: Acute Coronary Syndrome; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 2023 |
275 trial(s) available for tyrosine and tirofiban
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men.
Topics: Analysis of Variance; Blood Platelets; Double-Blind Method; Humans; Male; Platelet Membrane Glycoproteins; Reference Values; Tirofiban; Tyrosine | 1994 |
MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man.
Topics: Bleeding Time; Dose-Response Relationship, Drug; Double-Blind Method; Humans; In Vitro Techniques; Infusions, Intravenous; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Tirofiban; Tyrosine | 1993 |
Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Tyrosine | 1996 |
Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Coronary Artery Bypass; Coronary Thrombosis; Double-Blind Method; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIb-IX Complex; Postoperative Complications; Retreatment; Time Factors; Tirofiban; Tyrosine | 1997 |
The glycoprotein IIb/IIIa platelet receptor blocker tirofiban, but not heparin, counteracts platelet aggregation in unstable angina pectoris.
Topics: Aged; Angina, Unstable; Double-Blind Method; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1997 |
Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Tirofiban; Tyrosine | 1998 |
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heparin; Humans; Incidence; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Tirofiban; Tyrosine | 1998 |
Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Atherectomy, Coronary; Combined Modality Therapy; Coronary Angiography; Coronary Artery Bypass; Coronary Circulation; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Recurrence; Reoperation; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients.
Topics: Angina, Unstable; Heparin; Humans; Injections, Intravenous; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombin; Tirofiban; Tyrosine | 1998 |
Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Th
Topics: Adolescent; Angina, Unstable; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Bypass; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Research Design; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GPIIb/IIIa receptor.
Topics: Aged; Amino Acid Sequence; Angina, Unstable; Blood Platelets; Cell Aggregation; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Female; Fibrinogen; Flow Cytometry; Heparin; Humans; Male; Middle Aged; Molecular Sequence Data; Myocardial Infarction; Neutrophils; P-Selectin; Partial Thromboplastin Time; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Receptors, Thrombin; Tirofiban; Tyrosine | 1999 |
Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban]] and Determine Cost of Therapy with Invasive or Conservative Strategy)-TIMI 18 trial.
Topics: Angina Pectoris; Cost-Benefit Analysis; Drug Costs; Economics, Medical; Fibrinolytic Agents; Hospital Costs; Humans; Quality of Life; Relative Value Scales; Surveys and Questionnaires; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Cardiology; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Embolism; Eptifibatide; Female; Fibrinolytic Agents; Follow-Up Studies; Forecasting; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk; Stents; Structure-Activity Relationship; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects.
Topics: Adenosine Diphosphate; Adult; Dose-Response Relationship, Drug; Eptifibatide; Female; Fibrinogen; Flow Cytometry; Humans; Male; Middle Aged; P-Selectin; Peptides; Platelet Aggregation Inhibitors; Protein Binding; Tirofiban; Tyrosine | 1999 |
[Inhibitors of GPIIb/IIIa platelet receptors].
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Cerebrovascular Disorders; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 1999 |
Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Platelets; Eptifibatide; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Male; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome managemen
Topics: Aged; Angina, Unstable; Anticoagulants; Arteriosclerosis; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Coronary Thrombosis; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Economic impact of GPIIB/IIIA blockade after high-risk angioplasty: results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Cohort Studies; Combined Modality Therapy; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Retreatment; Risk Factors; Tirofiban; Tyrosine; United States | 1999 |
Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management.
Topics: Aged; Biomarkers; Coronary Disease; Creatine Kinase; Female; Fibrinolytic Agents; Heparin; Humans; Infusions, Intravenous; Isoenzymes; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Tirofiban; Troponin I; Troponin T; Tyrosine | 1999 |
High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Confounding Factors, Epidemiologic; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2000 |
Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
Topics: Angina, Unstable; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Injections, Intravenous; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Safety; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Uns
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Diabetes Complications; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heparin; Humans; Infusions, Intravenous; Likelihood Functions; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Global impairment of coronary blood flow in the setting of acute coronary syndromes (a RESTORE substudy). Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atherectomy, Coronary; Collateral Circulation; Confidence Intervals; Coronary Circulation; Coronary Disease; Coronary Vessels; Double-Blind Method; Fibrinolytic Agents; Humans; Multivariate Analysis; Myocardial Infarction; Placebos; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design.
Topics: Adult; Aged; Clinical Protocols; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Injections, Subcutaneous; Male; Middle Aged; Myocardial Infarction; Placebos; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Survival Rate; Tirofiban; Tyrosine | 2000 |
Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Topics: Angina, Unstable; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Humans; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Safety; Tirofiban; Tyrosine | 2000 |
Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: the NICE 3 story. National Investigators Collaborating on Enoxaparin.
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Feasibility Studies; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; North America; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Safety; Tirofiban; Tyrosine | 2000 |
Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. PRISM-PLUS Investigators.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Canada; Cardiac Catheterization; Double-Blind Method; Female; Heparin; Hospitals; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Survival Analysis; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Male; Middle Aged; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Stents; Tirofiban; Tyrosine | 2001 |
Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Platelets; Cohort Studies; Eptifibatide; Female; Heart Diseases; Humans; Immunoglobulin Fab Fragments; Logistic Models; Male; Multivariate Analysis; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk Factors; Time Factors; Tirofiban; Tyrosine | 2001 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Thrombocytopenia; Tirofiban; Tyrosine | 2001 |
Use of ICHOR-platelet works to assess platelet function in patients treated with GP IIb/IIIa inhibitors.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Feasibility Studies; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.
Topics: Abciximab; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Coronary Thrombosis; Eptifibatide; Exanthema; Female; Gastrointestinal Diseases; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Neutropenia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Thrombocytopenia; Ticlopidine; Tirofiban; Tyrosine | 2001 |
The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy.
Topics: Anticoagulants; Drug Therapy, Combination; Enoxaparin; Humans; Hypolipidemic Agents; Myocardial Infarction; Patient Selection; Platelet Glycoprotein GPIIb-IIIa Complex; Research Design; Simvastatin; Tirofiban; Tyrosine | 2001 |
Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects.
Topics: Abciximab; Adolescent; Adult; Antibodies, Monoclonal; Anticoagulants; Binding, Competitive; Bleeding Time; Blood Platelets; Drug Interactions; Factor Xa Inhibitors; Fibrinogen; Flow Cytometry; Heparin; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Male; Partial Thromboplastin Time; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Selectins; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
Elevation in serum troponin I predicts the benefit of tirofiban.
Topics: Acute Disease; Aged; Biomarkers; Coronary Disease; Drug Therapy, Combination; Female; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk Factors; Survival Rate; Tirofiban; Troponin I; Tyrosine | 2001 |
Safety and efficacy of thrombolysis with alteplase (50 mg) plus tirofiban versus alteplase (100 mg) alone in acute myocardial infarction: preliminary findings.
Topics: Creatine Kinase; Drug Therapy, Combination; Feasibility Studies; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombolytic Therapy; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 2001 |
Should patients with unstable coronary syndromes routinely undergo cardiac catheterization and appropriate revascularization?
Topics: Angina, Unstable; Cardiac Catheterization; Coronary Angiography; Humans; Myocardial Revascularization; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Bleeding risk of tirofiban, a nonpeptide GPIIb/IIIa platelet receptor antagonist in progressive stroke: an open pilot study.
Topics: Adult; Aged; Aged, 80 and over; Cerebral Hemorrhage; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Pilot Projects; Platelet Glycoprotein GPIIb-IIIa Complex; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Coronary Angiography; Drug Therapy, Combination; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Peptides; Pilot Projects; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Research Design; Risk Factors; Single-Blind Method; Thrombolytic Therapy; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 2001 |
An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Biomarkers; Coronary Disease; Creatine Kinase; Creatine Kinase, MB Form; Electrocardiography; Endpoint Determination; Follow-Up Studies; Heparin; Humans; Isoenzymes; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Risk Assessment; Survival Analysis; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Ischemic brain tissue salvaged from infarction by the GP IIb/IIIa platelet antagonist tirofiban.
Topics: Adult; Aged; Aged, 80 and over; Brain Infarction; Brain Ischemia; Cerebrovascular Circulation; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Tirofiban; Tyrosine | 2002 |
Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
Topics: Abciximab; Acute Disease; Aged; Antibodies, Monoclonal; Blood Vessel Prosthesis Implantation; Coronary Artery Disease; Disease-Free Survival; Double-Blind Method; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Postoperative Hemorrhage; Prospective Studies; Severity of Illness Index; Stents; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS
Topics: Acute Disease; Aged; Coronary Artery Disease; Creatinine; Double-Blind Method; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Injections, Intravenous; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Renal Insufficiency; Risk Assessment; Risk Factors; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention.
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Tyrosine | 2002 |
Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Circulation; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Insulin; Integrins; Kinetics; Male; Middle Aged; Neovascularization, Pathologic; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atherectomy; Blood Flow Velocity; Collateral Circulation; Coronary Circulation; Double-Blind Method; Fibrinolytic Agents; Humans; Myocardial Infarction; Prognosis; Tirofiban; Tyrosine | 2002 |
Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Elective Surgical Procedures; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Premedication; Stents; Ticlopidine; Tirofiban; Troponin T; Tyrosine | 2002 |
Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study).
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiac Catheterization; Cardiomyopathies; Combined Modality Therapy; Creatine Kinase; Creatine Kinase, MB Form; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Incidence; Isoenzymes; Male; Middle Aged; Myocardial Infarction; Necrosis; Peptides; Pilot Projects; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Stroke Volume; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2002 |
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Infusions, Intravenous; Male; Middle Aged; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Cohort Studies; Coronary Disease; Coronary Vessels; Female; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Severity of Illness Index; Survival Analysis; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, an
Topics: Abciximab; Acute Disease; Aged; Amino Acid Chloromethyl Ketones; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Citric Acid; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Kinetics; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine | 2002 |
A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement.
Topics: Angioplasty, Balloon, Coronary; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Tyrosine | 2002 |
Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study.
Topics: Abciximab; Antibodies, Monoclonal; Endpoint Determination; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Male; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction.
Topics: Aged; Angina, Unstable; Cost-Benefit Analysis; Female; Follow-Up Studies; Health Care Costs; Hospital Costs; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Outcome and Process Assessment, Health Care; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Quality-Adjusted Life Years; Tirofiban; Tyrosine; United States | 2002 |
Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservati
Topics: Acute Disease; Aged; Angina Pectoris; Biomarkers; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; Fees, Pharmaceutical; Female; Fibrinolytic Agents; Humans; Leukocyte Count; Male; Middle Aged; Multivariate Analysis; Severity of Illness Index; Smoking; Statistics as Topic; Stroke Volume; Survival Analysis; Syndrome; Tirofiban; Tyrosine | 2002 |
Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial).
Topics: Acute Disease; Aged; Angina, Unstable; Cardiac Catheterization; Coronary Disease; Creatinine; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Renal Insufficiency; Risk Factors; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Benefit of an early invasive management strategy in women with acute coronary syndromes.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Female; Follow-Up Studies; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Randomized Controlled Trials as Topic; Risk Assessment; Sex Factors; Stents; Survival Analysis; Tirofiban; Treatment Outcome; Troponin T; Tyrosine | 2002 |
Effects of tirofiban on hemostatic activation and inflammatory response during cardiopulmonary bypass.
Topics: Aged; Cardiopulmonary Bypass; Coronary Artery Bypass; Female; Hemostatic Techniques; Humans; Integrin alphaXbeta2; Male; Middle Aged; Platelet Aggregation; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2003 |
Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial.
Topics: Angioplasty, Balloon, Coronary; Chemotherapy, Adjuvant; Coronary Angiography; Coronary Thrombosis; Emergency Medical Services; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Dose-Response Relationship, Drug; Humans; Italy; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; C-Reactive Protein; Coronary Disease; Cytokines; Double-Blind Method; Humans; Inflammation; Interleukin-1; Interleukin-6; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Tirofiban; Troponin; Tumor Necrosis Factor-alpha; Tyrosine | 2003 |
Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation.
Topics: Aged; Anticoagulants; Antithrombins; Blood Coagulation Factors; Cardiopulmonary Bypass; Drug Resistance; Female; Fibrinolytic Agents; Hemostasis; Heparin; Hirudin Therapy; Humans; Male; Middle Aged; Platelet Count; Prospective Studies; Tirofiban; Tyrosine | 2003 |
Cerebral microembolism is blocked by tirofiban, a selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Carotid Artery Diseases; Clopidogrel; Female; Humans; Infusions, Intravenous; Intracranial Embolism; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine; Ultrasonography, Doppler, Transcranial | 2003 |
Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Coagulation; Blood Coagulation Tests; Clinical Trials as Topic; Coronary Artery Disease; Double-Blind Method; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Preoperative Care; Prospective Studies; Time Factors; Tirofiban; Tyrosine | 2003 |
Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease.
Topics: Acetylcholine; Biological Availability; Blood Flow Velocity; Blood Platelets; Coronary Artery Disease; Endothelium, Vascular; Enzyme Inhibitors; Eptifibatide; Forearm; Humans; Male; Middle Aged; Nitric Oxide; Nitric Oxide Donors; omega-N-Methylarginine; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Plethysmography; Tirofiban; Tyrosine; Vasodilation; Vasodilator Agents; Vasomotor System | 2003 |
A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes: results of the Early or Late Intervention in unStable Angina (ELISA) pilot study. 2b/3a upstream therapy and acute coronary syndromes.
Topics: Angina, Unstable; Coronary Angiography; Death, Sudden, Cardiac; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin.
Topics: Abciximab; Adenosine Diphosphate; Adult; Antibodies, Monoclonal; Aspirin; Collagen; Cross-Over Studies; Deamino Arginine Vasopressin; Dose-Response Relationship, Drug; Double-Blind Method; Epinephrine; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2003 |
Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Female; Fibrinolytic Agents; Heart Conduction System; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Research Design; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Impact of tirofiban on angiographic morphologic features of high-burden thrombus formation during direct percutaneous coronary intervention and short-term outcomes.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIb-IX Complex; Premedication; Recurrence; Stents; Survival Rate; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Angiography; Double-Blind Method; Female; Humans; Immunoglobulin Fab Fragments; Ischemia; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Risk Assessment; Stents; Tirofiban; Tyrosine | 2003 |
Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial.
Topics: Aged; Angina Pectoris; Aspirin; Catheterization; Clopidogrel; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Revascularization; Platelet Aggregation Inhibitors; Preoperative Care; Risk; Stents; Ticlopidine; Tirofiban; Treatment Outcome; Troponin T; Tyrosine | 2003 |
Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunoglobulin Fab Fragments; Louisiana; Male; Middle Aged; Minnesota; Myocardial Infarction; New York City; Ohio; Pennsylvania; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Premedication; Severity of Illness Index; Stents; Survival Analysis; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Coronary Angiography; Electrocardiography; Emergency Treatment; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Preoperative Care; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom.
Topics: Aged; Angina, Unstable; Anticoagulants; Cardiac Catheterization; Coronary Angiography; Coronary Disease; Electrocardiography; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Patient Admission; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Prospective Studies; Risk Factors; Sensitivity and Specificity; Syndrome; Tirofiban; Treatment Outcome; Tyrosine; United Kingdom | 2003 |
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial
Topics: Administration, Oral; Aspirin; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Incidence; Injections, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Time Factors; Tirofiban; Tyrosine | 2003 |
Optimizing outcomes in ST-segment elevation myocardial infarction.
Topics: Drug Therapy, Combination; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Female; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
Topics: Aged; Angina, Unstable; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sex Factors; Syndrome; Tirofiban; Tyrosine | 2003 |
Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Endothelium, Vascular; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Stents; Ticlopidine; Tirofiban; Tyrosine | 2003 |
Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial.
Topics: Age Factors; Aged; Anticoagulants; Bundle-Branch Block; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Survival Rate; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia.
Topics: Abciximab; Angioplasty, Balloon; Antibodies, Monoclonal; Anticoagulants; Drug Therapy, Combination; Eptifibatide; Female; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Recombinant Proteins; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Blockade of GPIIb/IIIa by eptifibatide and tirofiban does not alter tissue factor induced thrombin generation in human endotoxemia.
Topics: Adult; Biomarkers; Blood Coagulation; Double-Blind Method; Endotoxemia; Enzyme-Linked Immunosorbent Assay; Eptifibatide; Humans; Male; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; RNA, Messenger; Thrombin; Thromboplastin; Tirofiban; Tyrosine | 2003 |
Effect of tirofiban on C-reactive protein in non-ST-elevation myocardial infarction.
Topics: Analysis of Variance; C-Reactive Protein; Female; Heparin; Humans; Inflammation; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Tirofiban; Tyrosine | 2004 |
Effects of enoxaparin and nadroparin on major cardiac events in high-risk unstable angina treated with a glycoprotein IIb/IIIa inhibitor.
Topics: Aged; Angina, Unstable; Anticoagulants; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Nadroparin; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Diffusion Magnetic Resonance Imaging; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Infarction, Middle Cerebral Artery; Magnetic Resonance Angiography; Male; Middle Aged; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Thrombolytic Therapy; Tirofiban; Tissue Plasminogen Activator; Treatment Outcome; Tyrosine | 2004 |
Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Angiography; Coronary Circulation; Electrocardiography; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Stents; Thrombolytic Therapy; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 2004 |
Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombo
Topics: Acute Disease; Aged; Angina, Unstable; Biomarkers; C-Reactive Protein; Combined Modality Therapy; Creatine Kinase; Creatine Kinase, MB Form; Female; Fibrinolytic Agents; Humans; Isoenzymes; Male; Middle Aged; Myocardial Infarction; Myocardium; Natriuretic Peptide, Brain; Sex Factors; Syndrome; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Troponin; Tyrosine | 2004 |
Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes.
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Arachidonic Acid; Aspirin; Blood Platelets; C-Reactive Protein; Cell Aggregation; Drug Resistance; Eptifibatide; Female; Heparin; Humans; Leukocytes; Male; Middle Aged; Monocytes; Multivariate Analysis; Myocardial Infarction; Myocardial Ischemia; Neutrophils; Patient Selection; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Receptors, Thrombin; Recurrence; ROC Curve; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2004 |
Effects of glycoprotein IIb/IIIa receptor inhibition with tirofiban on minor myocardial damage in angiographically successful percutaneous coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Creatine Kinase; Female; Heart Injuries; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Tirofiban; Troponin I; Troponin T; Tyrosine | 2004 |
Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial.
Topics: Acute Disease; Angina Pectoris; Coronary Artery Bypass; Fibrinolytic Agents; Follow-Up Studies; Heparin; Humans; Myocardial Infarction; Myocardial Ischemia; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Effectiveness of tirofiban for failed thrombolysis during acute myocardial infarction.
Topics: Aged; Feasibility Studies; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Retreatment; Thrombolytic Therapy; Tirofiban; Tissue Plasminogen Activator; Treatment Failure; Tyrosine | 2004 |
Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial.
Topics: Adolescent; Adult; Calcium; Double-Blind Method; Eptifibatide; Hemorheology; Humans; Male; Peptides; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine; von Willebrand Factor | 2004 |
The effect of glycoprotein IIb/IIIa receptor inhibitor on the microcirculation in patients undergoing high-risk coronary stenting; a prospective, randomized study.
Topics: Aged; Blood Flow Velocity; Coronary Circulation; Coronary Disease; Embolism; Female; Humans; Male; Microcirculation; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Time Factors; Tirofiban; Tyrosine | 2003 |
Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
Topics: Abciximab; Adult; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Transfusion; Combined Modality Therapy; Coronary Stenosis; Double-Blind Method; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk Factors; Stents; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study).
Topics: Angioplasty, Balloon, Coronary; Arkansas; Coronary Artery Disease; Eptifibatide; Female; Humans; Infusions, Intravenous; Male; Mississippi; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tennessee; Tirofiban; Tyrosine; United States | 2004 |
Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Double-Blind Method; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Time Factors; Tirofiban; Transportation of Patients; Treatment Outcome; Tyrosine | 2004 |
The effect of combined thrombolysis with rtPA and tirofiban on ischemic brain lesions.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Brain; Brain Ischemia; Drug Synergism; Drug Therapy, Combination; Female; Follow-Up Studies; Heparin; Humans; Image Processing, Computer-Assisted; Infarction, Middle Cerebral Artery; Magnesium; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Thrombolytic Therapy; Tirofiban; Tissue Plasminogen Activator; Treatment Outcome; Tyrosine | 2004 |
[Pharmacologic therapy in failed thrombolysis: sequential infusion of tirofiban. Pilot study with 47 patients].
Topics: Aged; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Pilot Projects; Thrombolytic Therapy; Tirofiban; Treatment Failure; Tyrosine | 2004 |
Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Angiography; Echocardiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine; Ventricular Dysfunction, Left | 2004 |
High-dose bolus tirofiban and sirolimus eluting stent versus abiciximab and bare metal stent in acute myocardial infarction (STRATEGY) study--protocol design and demography of the first 100 patients.
Topics: Abciximab; Antibodies, Monoclonal; Clinical Protocols; Coronary Restenosis; Drug Implants; Drug Therapy, Combination; Electrocardiography; Female; Forecasting; Humans; Immunoglobulin Fab Fragments; Injections; Italy; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Sirolimus; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Coronary Stenosis; Creatine Kinase; Creatine Kinase, MB Form; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heparin; Humans; Intraoperative Complications; Isoenzymes; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prevalence; Risk Factors; Syndrome; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2004 |
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Topics: Aged; Angina Pectoris; Aspirin; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy).
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Coronary Angiography; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Microcirculation; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Platelet Aggregation Inhibitors; Premedication; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Survival Analysis; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS).
Topics: Acute Disease; Angina Pectoris; Female; Fibrinolytic Agents; Heparin; Humans; Male; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial.
Topics: Aspirin; Coronary Disease; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes.
Topics: Acute Disease; Anticoagulants; Aspirin; Biomarkers; C-Reactive Protein; Drug Therapy, Combination; Follow-Up Studies; Heparin; Humans; Incidence; Myocardial Infarction; Myocardial Ischemia; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptide Fragments; Predictive Value of Tests; Risk; Risk Assessment; Syndrome; Tirofiban; Troponin T; Tyrosine | 2004 |
Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease.
Topics: Aged; Brachial Artery; Coronary Artery Disease; Endothelium, Vascular; Female; Humans; Male; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2005 |
Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; C-Reactive Protein; CD40 Ligand; Coronary Artery Disease; Coronary Restenosis; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infusions, Intravenous; Interleukin-6; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
The effect of tirofiban on ST segment resolution in patients with non-ST elevated myocardial infarction.
Topics: Electrocardiography; Female; Fibrinolytic Agents; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Prognosis; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome.
Topics: Acute Disease; Aged; Coronary Disease; Dalteparin; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
The effect of tirofiban and clopidogrel pretreatment on outcome of old saphenous vein graft stenting in patients with acute coronary syndromes.
Topics: Acute Disease; Clopidogrel; Coronary Disease; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Saphenous Vein; Stents; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteers.
Topics: Adult; Biomarkers; Blood Coagulation; Cyclic N-Oxides; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Male; Partial Thromboplastin Time; Platelet Aggregation; Pyridines; Tirofiban; Tyrosine | 2005 |
Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pharmacokinetics; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Electrocardiography; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Pilot Projects; Platelet Glycoprotein GPIIb-IIIa Complex; Premedication; Prospective Studies; Stents; Tirofiban; Tyrosine | 2005 |
Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Drug Delivery Systems; Female; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Single-Blind Method; Sirolimus; Stents; Tirofiban; Tyrosine | 2005 |
The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Stenosis; Creatinine; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Logistic Models; Male; Middle Aged; Myocardial Ischemia; Platelet Glycoprotein GPIIb-IIIa Complex; Renal Insufficiency; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial).
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Drug Therapy, Combination; Elective Surgical Procedures; Enoxaparin; Eptifibatide; Female; Fibrinolytic Agents; Heparin; Humans; Integrin alpha2; Integrin beta3; Male; Membrane Glycoproteins; Middle Aged; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients.
Topics: Abciximab; Acute Disease; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Angiography; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial.
Topics: Adolescent; Adult; Aged; Drug Therapy, Combination; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Tenecteplase; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 2005 |
Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy).
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Coated Materials, Biocompatible; Coronary Angiography; Coronary Restenosis; Creatine Kinase; Creatine Kinase, MB Form; Double-Blind Method; Drug Interactions; Eptifibatide; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Isoenzymes; Male; Middle Aged; Myocardial Ischemia; Myocardial Revascularization; Paclitaxel; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Stents; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Effect of adjunctive treatment with tirofiban on troponin T elevation during stenting of critically stenosed aortocoronary saphenous vein grafts.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Bypass; Coronary Restenosis; Female; Fibrinolytic Agents; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Male; Pilot Projects; Saphenous Vein; Stents; Tirofiban; Treatment Outcome; Troponin T; Tyrosine; Ultrasonography, Doppler; Ultrasonography, Interventional | 2005 |
Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstrea
Topics: Abciximab; Acute Disease; Aged; Angina, Unstable; Antibodies, Monoclonal; Clopidogrel; Creatine Kinase, MB Form; Electrocardiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Myocardial Infarction; Necrosis; Prospective Studies; Syndrome; Ticlopidine; Time Factors; Tirofiban; Troponin I; Tyrosine | 2005 |
Early discharge is feasible following primary percutaneous coronary intervention with transradial stent implantation under platelet glycoprotein IIb/IIIa receptor blockade. Results of the AGGRASTENT Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Feasibility Studies; Female; Femoral Artery; Follow-Up Studies; Humans; Length of Stay; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Premedication; Prospective Studies; Stents; Tirofiban; Tyrosine | 2005 |
Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Circulation; Coronary Disease; Echocardiography; Electrocardiography; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Tirofiban; Troponin I; Tyrosine | 2006 |
The effects of tirofiban on peripheral markers of oxidative stress and endothelial dysfunction in patients with acute coronary syndromes.
Topics: Acute Disease; Aged; Biomarkers; Coronary Disease; Endothelium; Female; Humans; Male; Middle Aged; Neutrophils; Oxidative Stress; Time Factors; Tirofiban; Tyrosine | 2007 |
Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Angiographic and clinical outcome in ST-segment elevation myocardial infarction patients receiving an adjunctive double bolus regimen of tirofiban for primary percutaneous coronary intervention.
Topics: Aged; Angiography; Angioplasty, Balloon, Coronary; Female; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Recurrence; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Platelet microaggregation inhibition in patients with acute myocardial infarction pretreated with tirofiban and relationship with angiographic and clinical outcome.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome: results of the ELISA-2 trial.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Drug Combinations; Enzymes; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Impact of early tirofiban administration on myocardial salvage in patients with acute myocardial infarction undergoing infarct-related artery stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Radionuclide Imaging; Radiopharmaceuticals; Salvage Therapy; Stents; Technetium Tc 99m Sestamibi; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Vessel Prosthesis Implantation; Coated Materials, Biocompatible; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Survival Rate; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients with acute coronary syndromes scheduled for coronary intervention.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Drug Monitoring; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Prospective Studies; Syndrome; Tirofiban; Tyrosine | 2006 |
Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial.
Topics: Acute Disease; Aged; C-Reactive Protein; Coronary Disease; Female; Follow-Up Studies; Humans; Lipoproteins, LDL; Male; Middle Aged; Prognosis; Risk Factors; Simvastatin; Survival Analysis; Tirofiban; Tyrosine | 2006 |
Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?).
Topics: Abciximab; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Angiography; Coronary Disease; Double-Blind Method; Female; Graft Occlusion, Vascular; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Reoperation; Research Design; Risk Factors; Saphenous Vein; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine; Venous Thrombosis | 2007 |
[Effect of pre-angiography use of tirofiban in patients with acute ST-elevation myocardial infarction treated by primary percutaneous coronary intervention].
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2006 |
Routine upstream versus selective down stream use of tirofiban in non-ST elevation myocardial infarction patients scheduled for early invasive therapy; a randomized comparison.
Topics: Aged; Coronary Angiography; Creatine Kinase; Drug Administration Routes; Electrocardiography; Female; Fibrinolytic Agents; Humans; L-Lactate Dehydrogenase; Male; Middle Aged; Myocardial Infarction; Tirofiban; Tyrosine | 2007 |
Evaluation on the safety and efficacy of tirofiban in the treatment of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Angina, Unstable; Double-Blind Method; Female; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
[Absence of benefit with triple antiaggregation in acute non persistent ST segment elevation myocardial infarction in patients not subjected to early interventionism].
Topics: Aged; Aspirin; Clopidogrel; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; Tirofiban; Tyrosine | 2007 |
Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEG
Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Metals; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Research Design; Sirolimus; Stents; Tirofiban; Tyrosine | 2007 |
Association of interleukin-10 level with increased 30-day mortality in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention.
Topics: Aged; Angioplasty, Balloon; Clopidogrel; Cohort Studies; Electrocardiography; Female; Humans; Interleukin-10; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prognosis; Prospective Studies; Risk Factors; Stents; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Restenosis; Disease-Free Survival; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Prosthesis Design; Risk; Sirolimus; Stents; Tirofiban; Tyrosine | 2007 |
Optimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Eptifibatide; Humans; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Registries; Ticlopidine; Tirofiban; Tyrosine | 2007 |
A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Cost Control; Cost-Benefit Analysis; Drug-Eluting Stents; Female; Hospital Costs; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Sirolimus; Statistics, Nonparametric; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
[Effects of intracoronary or intravenous tirofiban administration in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention].
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Electrocardiography; Emergency Treatment; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intra-Arterial; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals.
Topics: Aged; Angioplasty, Balloon, Coronary; Female; Fibrinolytic Agents; Hospitals, Community; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Poland; Risk Factors; Survival Rate; Thrombolytic Therapy; Tirofiban; Tyrosine | 2007 |
Comparison of the effects of pretreatment with tirofiban, clopidogrel or both on the inhibition of platelet aggregation and activation in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Animals; Clopidogrel; Drug Administration Schedule; Drug Synergism; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Tyrosine | 2009 |
Facilitated PCI by combination fibrinolysis or upstream tirofiban in acute ST-segment elevation myocardial infarction: results of the Alteplase and Tirofiban in Acute Myocardial Infarction (ATAMI) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Drug Therapy, Combination; Female; Fibrinolysis; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 2008 |
Change of white blood cell count more prognostic important than baseline values after primary percutaneous coronary intervention for ST elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Double-Blind Method; Female; Humans; Leukocytes; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Prognosis; Prospective Studies; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents; Atorvastatin; Atrial Fibrillation; Dose-Response Relationship, Drug; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Pravastatin; Pyrroles; Thrombolytic Therapy; Tirofiban; Tyrosine | 2008 |
[Clinical outcomes and safety of primary percutaneous coronary intervention combined with tirofiban therapy in patients with acute ST-segment elevation myocardial infarction].
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Chemotherapy, Adjuvant; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Safety; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Effects of coronary prestenting platelet inhibition on coronary poststenting inflammation.
Topics: Aged; alpha 1-Antitrypsin; Clopidogrel; Drug Administration Schedule; Female; Humans; Inflammation; Infusions, Intravenous; Male; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Ticlopidine; Time Factors; Tirofiban; Tyrosine | 2008 |
Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Tyrosine; Vasodilation | 2008 |
Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Drug-Eluting Stents; Female; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Tyrosine | 2008 |
Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Prospective Studies; Tirofiban; Tyrosine | 2008 |
Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Drug Resistance; Europe; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Research Design; Ticlopidine; Tirofiban; Treatment Outcome; Troponin I; Troponin T; Tyrosine | 2008 |
Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial.
Topics: Angioplasty, Balloon, Coronary; Double-Blind Method; Electrocardiography; Emergency Medical Services; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
Topics: Atorvastatin; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Syndrome; Thrombolytic Therapy; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Vessels; Drug Administration Routes; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Tirofiban; Tyrosine | 2008 |
Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Blood Platelets; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Count; Prospective Studies; Renal Replacement Therapy; Shock, Cardiogenic; Tirofiban; Tyrosine | 2008 |
[Tirofiban or abciximab and sirolimus-eluting or bare metal uncoated stents in primary percutaneous coronary intervention for acute myocardial infarction: results of MULTISTRATEGY trial].
Topics: Abciximab; Antibodies, Monoclonal; Blood Vessel Prosthesis Implantation; Coated Materials, Biocompatible; Coronary Angiography; Electrocardiography; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Metals; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Sirolimus; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Necrosis; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Angiography; Dose-Response Relationship, Drug; Drug-Eluting Stents; Electrocardiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Prospective Studies; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
[Safety and efficacy of firebird drug-eluting stent combination tirofiban in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Iron-induced platelet aggregation measurement: a novel method to measure platelet function in stenting for ST segment elevation myocardial infarction.
Topics: Aged; Aspirin; Clopidogrel; Feasibility Studies; Female; Humans; Iron; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Reproducibility of Results; Stainless Steel; Stents; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.
Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Cardiovascular Diseases; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Diabetes Complications; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardium; Necrosis; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Stents; Time Factors; Tirofiban; Treatment Outcome; Troponin T; Tyrosine | 2009 |
Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial).
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Electrocardiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Tyrosine; Ventricular Function, Left | 2009 |
Benefit of standard versus low-dose tirofiban for percutaneous coronary intervention in very elderly patients with high-risk acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Angiography; Female; Hemorrhage; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug Resistance; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2009 |
Upstream high-dose tirofiban does not reduce myocardial infarct size in patients undergoing primary percutaneous coronary intervention: a magnetic resonance imaging pilot study.
Topics: Aged; Angioplasty, Balloon, Coronary; Contrast Media; Coronary Angiography; Coronary Circulation; Echocardiography; Female; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Myocardium; Pilot Projects; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prospective Studies; Stents; Stroke Volume; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Ventricular Function, Left | 2009 |
Efficacy and safety of tirofiban in high-risk patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Biomarkers; Creatine Kinase, MB Form; Double-Blind Method; Electrocardiography; Female; Heart Diseases; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Risk Assessment; Thrombocytopenia; Time Factors; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2009 |
[Safety and efficacy of the use of glycoprotein IIb/IIIa inhibitors in the invasive treatment of patients with ST-elevation acute coronary syndrome].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Thrombolytic Therapy; Time Factors; Tirofiban; Tyrosine | 2009 |
[The use of tirofiban in invasive treatment of patients with non-ST-elevation acute coronary syndrome].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Dose-Response Relationship, Drug; Electrocardiography; Exercise Test; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Stroke Volume; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Ventricular Function, Left | 2009 |
[Effects of upstream tirofiban versus downstream tirofiban on platelet aggregation and clinical outcomes in patients with high-risk acute coronary syndromes undergoing percutaneous coronary interventions].
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Risk Factors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Emergency Medical Services; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stents; Thrombolytic Therapy; Ticlopidine; Tirofiban; Tyrosine | 2009 |
Treatment of progressive stroke with tirofiban--experience in 35 patients.
Topics: Aged; Arterial Occlusive Diseases; Disease Progression; Female; Humans; Injections, Intravenous; Male; Microcirculation; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Safety and efficacy of transradial vs transfemoral arterial primary coronary angioplasty for acute myocardial infarction: single-center experience.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Circulation; Female; Femoral Artery; Humans; Intra-Aortic Balloon Pumping; Male; Middle Aged; Myocardial Infarction; Radial Artery; Safety; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Effect of high bolus dose tirofiban on the inflammatory response following percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Biomarkers; C-Reactive Protein; CD40 Antigens; Clopidogrel; Creatine Kinase, MB Form; Female; Humans; Inflammation; Interleukin-6; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Time Factors; Tirofiban; Tyrosine | 2010 |
Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Prospective Studies; Recombinant Proteins; Retreatment; Thrombocytopenia; Tirofiban; Tyrosine | 2009 |
Safety of downstream high-dose tirofiban bolus among 1578 patients undergoing percutaneous coronary intervention: the Sant'ANna TIrofiban Safety study.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2010 |
[Effect of tirofiban in acute anterior myocardial infarction patients without ST segment resolution after primary percutaneous coronary intervention].
Topics: Aged; Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon; Anticoagulants; Biomarkers; Blood Coagulation Factors; Blood Platelets; CD40 Ligand; Enoxaparin; Female; Flow Cytometry; Heparin; Humans; Inflammation; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Tirofiban; Tyrosine | 2010 |
Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Administration Schedule; Drug-Eluting Stents; Emergencies; Female; Hemostasis, Surgical; Humans; Male; Middle Aged; Perioperative Care; Pilot Projects; Platelet Aggregation Inhibitors; Prospective Studies; Substance Withdrawal Syndrome; Ticlopidine; Tirofiban; Tyrosine | 2010 |
The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Platelets; C-Reactive Protein; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Heparin; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Stents; Time Factors; Tirofiban; Tyrosine | 2010 |
Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Disability Evaluation; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Fibrinolytic Agents; Hospital Mortality; Humans; Intracranial Hemorrhages; Italy; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recovery of Function; Stroke; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Drug Resistance; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Tyrosine | 2010 |
Thrombus aspiration plus intra-infarct-related artery administration of tirofiban improves myocardial perfusion during primary angioplasty for acute myocardial infarction.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Thrombosis; Electrocardiography; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Suction; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Tirofiban; Tyrosine | 2010 |
Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Emergency Medical Services; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Probability; Prognosis; Prospective Studies; Pulse Therapy, Drug; Reference Values; Risk Assessment; Single-Blind Method; Survival Analysis; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
Prehospital high-dose tirofiban in patients undergoing primary percutaneous intervention. The AGIR-2 study.
Topics: Ambulances; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Coronary Angiography; Coronary Circulation; Creatine Kinase; Drug Administration Schedule; Drug Therapy, Combination; Emergency Medical Services; Female; France; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2010 |
Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty; Eptifibatide; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Tyrosine | 2011 |
Role of the paclitaxel-eluting stent and tirofiban in patients with ST-elevation myocardial infarction undergoing postfibrinolysis angioplasty: the GRACIA-3 randomized clinical trial.
Topics: Angioplasty; Drug-Eluting Stents; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Emergency Service, Hospital; Enoxaparin; Female; Follow-Up Studies; Humans; India; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Reference Values; Severity of Illness Index; Survival Rate; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
Pre-hospital administration of tirofiban in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: a sub-analysis of the On-Time 2 trial.
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Diabetes Mellitus; Double-Blind Method; Electrocardiography; Emergency Medical Services; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) tr
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Elective Surgical Procedures; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Prospective Studies; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
High-dose tirofiban pretreatment reduces the need for bail-out study medication in patients with ST-segment elevation myocardial infarction: results of a subgroup analysis of the On-TIME 2 trial.
Topics: Angioplasty, Balloon, Coronary; Double-Blind Method; Emergency Medical Services; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Preoperative Care; Tirofiban; Treatment Outcome; Tyrosine | 2011 |
Upstream tirofiban reduces reperfusion cardiac arrhythmias in patients of acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Arrhythmias, Cardiac; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Tirofiban; Tyrosine; Young Adult | 2011 |
Additive benefit of glycoprotein IIb/IIIa inhibition and adjunctive thrombus aspiration during primary coronary intervention: results of the Initial Thrombosuction and Tirofiban Infusion (ITTI) trial.
Topics: Adult; Aged; Combined Modality Therapy; Coronary Thrombosis; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Suction; Tirofiban; Treatment Outcome; Tyrosine | 2012 |
The golden hour of prehospital reperfusion with triple antiplatelet therapy: a sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emergency Medical Services; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Young Adult | 2010 |
Risk of bleeding after prehospital administration of high dose tirofiban for ST elevation myocardial infarction.
Topics: Aged; Emergency Medical Services; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Risk Factors; Single-Blind Method; Tirofiban; Tyrosine | 2012 |
Long-term reduction of mortality in the 4-year follow up of tirofiban therapy in elective percutaneous coronary interventions (TOPSTAR) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Survival Rate; Ticlopidine; Tirofiban; Treatment Outcome; Troponin; Tyrosine | 2011 |
Failed recovery from thrombolysis is predicted by the initial diffusion weighted imaging lesion.
Topics: Aged; Brain Ischemia; Diffusion Magnetic Resonance Imaging; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Recovery of Function; Severity of Illness Index; Stroke; Thrombolytic Therapy; Tirofiban; Tissue Plasminogen Activator; Treatment Failure; Tyrosine | 2011 |
Intracoronary bolus-only compared with intravenous bolus plus infusion of tirofiban application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Coronary Angiography; Coronary Circulation; Echocardiography; Female; Hemodynamics; Humans; Infusions, Intravenous; Injections, Intra-Arterial; Injections, Intravenous; Male; Microcirculation; Middle Aged; Myocardial Infarction; Pilot Projects; Platelet Aggregation Inhibitors; Predictive Value of Tests; Time Factors; Tirofiban; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Turkey; Tyrosine | 2012 |
A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab wi
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; United States | 2011 |
The impact of age on effects of pre-hospital initiation of high bolus dose of tirofiban before primary angioplasty for ST-elevation myocardial infarction.
Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Double-Blind Method; Electrocardiography; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2011 |
Higher efficacy of pre-hospital tirofiban with longer pre-treatment time to primary PCI: protection for the negative impact of time delay.
Topics: Aged; Ambulances; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Emergency Medical Services; Female; Fibrinolytic Agents; Health Services Accessibility; Heparin; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Netherlands; Outcome and Process Assessment, Health Care; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2011 |
Safety of Tirofiban in acute Ischemic Stroke: the SaTIS trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Ischemia; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Radiography; Stroke; Time Factors; Tirofiban; Tyrosine | 2011 |
Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY).
Topics: Abciximab; Aged; Antibodies, Monoclonal; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Male; Metals; Middle Aged; Myocardial Infarction; Prospective Studies; Sirolimus; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Beneficial effects of intracoronary tirofiban bolus administration following upstream intravenous treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the ICT-AMI study.
Topics: Aged; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intra-Arterial; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Comparison of tirofiban combined with dalteparin or unfractionated heparin in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction patients.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Dalteparin; Female; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Tirofiban; Treatment Outcome; Tyrosine | 2011 |
[Tirofiban improved the prognosis of senior acute coronary syndrome patients received percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Ticlopidine; Tirofiban; Tyrosine | 2011 |
The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Emergency Medical Services; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Prospective Studies; Severity of Illness Index; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Vascular Patency | 2012 |
Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Arrhythmias, Cardiac; Drug-Eluting Stents; Female; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Italy; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Sex Factors; Sirolimus; Tirofiban; Tyrosine | 2012 |
Intracoronary versus intravenous high-dose bolus plus maintenance administration of tirofiban in patients undergoing primary percutaneous coronary intervention for acute ST elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Flow Velocity; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Necrosis; Pilot Projects; Platelet Aggregation Inhibitors; Time Factors; Tirofiban; Tyrosine | 2012 |
Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Electrocardiography; Emergency Medical Services; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prevalence; Retrospective Studies; Risk Factors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2012 |
Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOppin
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Italy; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2012 |
[Effect of early high-loading-dose tirofiban on platelet activity in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention].
Topics: Aged; Blood Platelets; Emergency Treatment; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Tyrosine | 2012 |
Safety and efficacy of tirofiban in stent-assisted coil embolization of intracranial aneurysms.
Topics: Adult; Aged; Cerebral Hemorrhage; Embolization, Therapeutic; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Intracranial Aneurysm; Male; Middle Aged; Platelet Aggregation Inhibitors; Stents; Thromboembolism; Tirofiban; Tyrosine | 2012 |
Intra-arterial tirofiban infusion for thromboembolic complication during coil embolization of ruptured intracranial aneurysms.
Topics: Adult; Aged; Aged, 80 and over; Aneurysm, Ruptured; Comorbidity; Embolization, Therapeutic; Female; Fibrinolytic Agents; Humans; Infusions, Intra-Arterial; Intracranial Aneurysm; Intracranial Embolism; Male; Middle Aged; Postoperative Complications; Prevalence; Radiography; Republic of Korea; Tirofiban; Treatment Outcome; Tyrosine | 2012 |
[High-dose tirofiban in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention].
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Tirofiban; Tyrosine; Young Adult | 2012 |
Efficacy and safety of standard-dose versus half-dose tirofiban in patients with non-ST elevation acute coronary syndromes undergoing early percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Administration, Intravenous; Aged; Chi-Square Distribution; China; Coronary Angiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?
Topics: Abciximab; Acute Coronary Syndrome; Aged; Antibodies, Monoclonal; Early Termination of Clinical Trials; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stents; Survival Rate; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Routine early versus deferred provisional tirofiban treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Drug Administration Schedule; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Postoperative Complications; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Intra-arterial infusion of a glycoprotein IIb/IIIa antagonist for the treatment of thromboembolism during coil embolization of intracranial aneurysm: a comparison of abciximab and tirofiban.
Topics: Abciximab; Adult; Antibodies, Monoclonal; Anticoagulants; Female; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Infusions, Intra-Arterial; Intracranial Aneurysm; Intracranial Thrombosis; Male; Mechanical Thrombolysis; Middle Aged; Platelet Glycoprotein GPIIb-IIIa Complex; Radiography; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
[Prevention of non-acute stent thrombosis after drug-eluting stent implantation].
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine; Tirofiban; Tyrosine; Warfarin | 2013 |
Short-term follow-up of tirofiban as alternative therapy for urgent surgery patients with an implanted coronary drug-eluting stent after ST-elevation myocardial infarction.
Topics: Aged; Aspirin; China; Clopidogrel; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prospective Studies; Risk Factors; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Impact of selective infarct-related artery infusion of tirofiban on myocardial reperfusion and bleeding complications in patients with acute myocardial infarction: the SUIT-AMI trial.
Topics: Aged; Cardiac Catheterization; Electrocardiography; Female; Follow-Up Studies; Hemorrhage; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prevalence; Prospective Studies; Risk Factors; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Clinical evaluation of thrombus aspiration combined with tirofiban in patients with acute myocardial infarction with elective percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Thrombosis; Echocardiography; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Radiography; Suction; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Randomized comparison of intracoronary tirofiban versus urokinase as an adjunct to primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: results of the ICTUS-AMI trial.
Topics: Adult; Aged; Electrocardiography; Female; Fibrinolytic Agents; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Tirofiban; Tyrosine; Urokinase-Type Plasminogen Activator; Ventricular Function, Left | 2013 |
Effects of tirofiban maintenance duration on myocardial perfusion defect severity in anterior myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Combined Modality Therapy; Coronary Angiography; Female; Heart; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Radiopharmaceuticals; Single-Blind Method; Technetium Tc 99m Sestamibi; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
[Efficacy and safety of tirofiban use after successful percutaneous coronary intervention for patients with moderate to high risk non-ST segment elevation acute coronary syndromes].
Topics: Acute Coronary Syndrome; Aged; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: an Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy.
Topics: Acute Coronary Syndrome; Aged; Comparative Effectiveness Research; Coronary Angiography; Eptifibatide; Female; Humans; Male; Middle Aged; Multivariate Analysis; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Propensity Score; Tirofiban; Treatment Outcome; Tyrosine | 2014 |
[Efficacy comparison of combined intracoronary administration of high-dose adenosine and tirofiban versus intracoronary tirofiban during primary percutaneous coronary intervention in patients with acute myocardial infarction].
Topics: Adenosine; Aged; Angioplasty, Balloon, Coronary; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2013 |
[The clinical efficacy and safety of fondaparinux combined with tirofiban hydrochloride in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention].
Topics: Adult; Aged; Angina, Unstable; Anticoagulants; Female; Fondaparinux; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polysaccharides; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Efficacy and safety of tirofiban-supported primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: results of propensity analysis using the Clinical Center of Serbia STEMI Register.
Topics: Aged; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Preoperative Care; Propensity Score; Registries; Retrospective Studies; Serbia; Survival Rate; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2014 |
[Effect of intracoronary tirofiban combined with nitroprusside injection through thrombus aspiration catheter during primary percutaneous coronary intervention on acute anterior myocardial infarction patients with heavy thrombosis burden].
Topics: Aged; Cardiac Catheters; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Myocardial Infarction; Nitroprusside; Percutaneous Coronary Intervention; Prognosis; Suction; Tirofiban; Tyrosine | 2014 |
Effects of verapamil and adenosine in an adjunct to tirofiban on resolution and prognosis of noreflow phenomenon in patients with acute myocardial infarction.
Topics: Adenosine; Aged; Female; Fibrinolytic Agents; Follow-Up Studies; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Prognosis; Prospective Studies; Survival Rate; Tirofiban; Tyrosine; Vasodilator Agents; Verapamil | 2014 |
[The effects of tirofiban on acute non-ST segment elevation myocardial infarction patients not receiving early reperfusion intervention].
Topics: Aged; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Tyrosine | 2014 |
[Short- or long-outcome of early tirofiban in ST-segment elevated acute myocardial infarction undergoing elective percutaneous coronary intervention].
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Tyrosine | 2014 |
Acute Effects of Intracoronary Tirofiban on No-Reflow Phenomena in Patients With ST-Segment Elevated Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Topics: Aged; Coronary Circulation; Coronary Thrombosis; Female; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recurrence; Risk Factors; Stents; Time Factors; Tirofiban; Treatment Outcome; Turkey; Tyrosine | 2015 |
Effects of tirofiban on platelet activation and endothelial function in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Electrocardiography; Endothelium, Vascular; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pilot Projects; Platelet Activation; Tirofiban; Treatment Outcome; Tyrosine | 2015 |
Early discharge after primary percutaneous coronary intervention: the added value of N-terminal pro-brain natriuretic peptide to the Zwolle Risk Score.
Topics: Aged; Area Under Curve; Biomarkers; Decision Support Techniques; Female; Hemorrhage; Humans; Length of Stay; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Natriuretic Peptide, Brain; Patient Discharge; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; ROC Curve; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2014 |
Effect of intracoronary tirofiban on platelet alpha-granule membrane protein and myocardial perfusion level during emergency percutaneous coronary intervention.
Topics: Aged; Emergencies; Female; Humans; Male; Middle Aged; Myocardium; Natriuretic Peptide, Brain; P-Selectin; Peptide Fragments; Percutaneous Coronary Intervention; Perfusion; Tirofiban; Troponin I; Tyrosine | 2014 |
Safety and efficacy of intracoronary tirofiban administration in patients with serious thrombus burden and ST-elevation myocardial infarction undergoing percutaneous coronary intervention.
Topics: Coronary Thrombosis; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Tirofiban; Tyrosine | 2014 |
Early invasive strategy in high-risk acute coronary syndrome without ST-segment elevation. The Sisca randomized trial.
Topics: Acute Coronary Syndrome; Aged; Coronary Angiography; Electrocardiography; Female; Follow-Up Studies; France; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Revascularization; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Retrospective Studies; Survival Rate; Tirofiban; Tyrosine | 2015 |
Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.
Topics: Aged; Biomarkers; Chi-Square Distribution; China; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Creatine Kinase, MB Form; Drug-Eluting Stents; Female; Hemorrhage; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Prosthesis Design; Risk Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Up-Regulation | 2015 |
Association of serial high sensitivity troponin T with onset of atrial fibrillation in ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.
Topics: Aged; Atrial Fibrillation; Biomarkers; Female; Fibrinolytic Agents; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Sensitivity and Specificity; Tirofiban; Troponin T; Tyrosine | 2016 |
Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
Topics: Aged; Antithrombins; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Recombinant Proteins; Tirofiban; Tyrosine | 2015 |
Effect of Intracoronary Plus Low-Dose Intravenous Tirofiban in Elderly Patients with Acute Myocardial Infarction.
Topics: Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Stroke Volume; Tirofiban; Troponin T; Tyrosine | 2015 |
Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Republic of Korea; Ticagrelor; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial.
Topics: Aged; Anticoagulants; Antithrombins; Chi-Square Distribution; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Emergency Treatment; Female; Hemorrhage; Heparin; Hirudins; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Protective Factors; Recombinant Proteins; Risk Assessment; Risk Factors; Sex Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Intracoronary injection of tirofiban prevents microcirculation dysfunction during delayed percutaneous coronary intervention in patients with acute myocardial infarction.
Topics: Aged; Coronary Vessels; Female; Fibrinolytic Agents; Humans; Injections, Intra-Arterial; Male; Microcirculation; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; Tirofiban; Tyrosine | 2016 |
[The effect and safety of tirofiban on acute ST segment elevation myocardial infarction patients receiving no early reperfusion therapy].
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Safety; Secondary Prevention; ST Elevation Myocardial Infarction; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Clinical effects of treatment with Tirofiban on patients with high-risk NSTE-ACS after PCI.
Topics: Acute Coronary Syndrome; Adult; Aged; Creatine Kinase, MB Form; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2016 |
Aspiration thrombectomy and intracoronary tirofiban in ST-segment elevation myocardial infarction : Combination treatment for patients undergoing primary percutaneous coronary intervention.
Topics: China; Combined Modality Therapy; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prevalence; Risk Factors; ST Elevation Myocardial Infarction; Survival Rate; Thrombectomy; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Tirofiban Combined with Fondaparinux for Post-PCI Treatment of Patients with Acute Coronary Syndrome and Mild Renal Insufficiency.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Drug Combinations; Female; Fondaparinux; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Polysaccharides; Postoperative Complications; Renal Insufficiency; Tirofiban; Tyrosine | 2015 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Tirofiban; Tyrosine | 2016 |
A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; New South Wales; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Efficacy and Safety of Thrombectomy Combined with Intracoronary Administration of Tirofiban in ST-segment Elevation Myocardial Infarction (STEMI).
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Combined Modality Therapy; Coronary Angiography; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Thrombectomy; Thrombosis; Tirofiban; Tyrosine | 2016 |
Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the PRISM Trial.
Topics: Acute Coronary Syndrome; Aged; Buffers; Chi-Square Distribution; Citrates; Double-Blind Method; Drug Compounding; Drug Stability; Drugs, Generic; Female; Heparin; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Odds Ratio; Phosphates; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; Thrombocytopenia; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Cardiac Catheterization; China; Emergencies; Female; Hemorrhage; Hirudins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Radial Artery; Recombinant Proteins; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Warfarin; Young Adult | 2017 |
In-Lab Upfront Use of Tirofiban May Reduce the Occurrence of No-Reflow During Primary Percutaneous Coronary Intervention. A Pilot Randomized Study.
Topics: Aged; Brazil; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Pilot Projects; Placebos; Platelet Aggregation Inhibitors; Postoperative Complications; Predictive Value of Tests; Stents; Time Factors; Tirofiban; Tyrosine | 2016 |
Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
Long-term mortality and prehospital tirofiban treatment in patients with ST elevation myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Emergency Medical Services; Europe; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Survival Rate; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Young Adult | 2017 |
Another Endovascular Therapy Strategy for Acute Tandem Occlusion: Protect-Expand-Aspiration-Revascularization-Stent (PEARS) Technique.
Topics: Acute Disease; Aged; Aspirin; Carotid Artery Thrombosis; Carotid Artery, Internal; Cerebral Revascularization; Clopidogrel; Endovascular Procedures; Feasibility Studies; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Severity of Illness Index; Stents; Thrombectomy; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2018 |
Endovascular treatment with versus without tirofiban for stroke patients with large vessel occlusion: The multicenter, randomized, placebo-controlled, double-blind RESCUE BT study protocol.
Topics: Arterial Occlusive Diseases; Double-Blind Method; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2022 |
Comparison of intracoronary versus intravenous tirofiban in acute ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.
Topics: Anterior Wall Myocardial Infarction; Arrhythmias, Cardiac; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Tirofiban; Treatment Outcome; Tyrosine | 2022 |
RESCUE BT 2, a multicenter, randomized, double-blind, double-dummy trial of intravenous tirofiban in acute ischemic stroke: Study rationale and design.
Topics: Aspirin; Double-Blind Method; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Prospective Studies; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2023 |
[Efficacité du tirofiban intracoronaire avant pose d'un stent suivi d'une perfusion dans une charge de thrombus importante prouvée par angiographie : une étude randomisée].
Topics: Angiography; Angioplasty, Balloon, Coronary; Coronary Thrombosis; Humans; Percutaneous Coronary Intervention; Perfusion; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2023 |
525 other study(ies) available for tyrosine and tirofiban
| Article | Year |
|---|---|
Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.
Topics: Adenosine Diphosphate; Amino Acid Sequence; Binding Sites; Endothelium, Vascular; Fibrinogen; Humans; Molecular Sequence Data; Molecular Structure; Oligopeptides; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Tirofiban; Tyrosine; Umbilical Veins | 1992 |
Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.
Topics: Adenosine Diphosphate; Animals; Coronary Circulation; Dogs; Female; Hemostasis; In Vitro Techniques; Male; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Streptokinase; Thrombosis; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 1995 |
Determination of MK-383, a non-peptide fibrinogen receptor antagonist, in human plasma and urine by radioimmunoassay.
Topics: Animals; Antibody Specificity; Female; Fibrinolytic Agents; Heparin; Humans; Iodine Radioisotopes; Isotope Labeling; Platelet Membrane Glycoproteins; Rabbits; Radioimmunoassay; Tirofiban; Tyrosine | 1994 |
Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.
Topics: Adenosine Diphosphate; Amino Acid Sequence; Animals; Dogs; Endothelium, Vascular; Humans; Kinetics; Models, Molecular; Molecular Sequence Data; Molecular Structure; Oligopeptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Structure-Activity Relationship; Templates, Genetic; Tirofiban; Tyrosine; Umbilical Veins | 1994 |
The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active.
Topics: Acetates; Adenosine Diphosphate; Administration, Oral; Animals; Benzamides; Bleeding Time; Dogs; Drug Administration Routes; Duodenum; Female; Fibrinolytic Agents; Guinea Pigs; Injections, Intravenous; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Reproducibility of Results; Species Specificity; Tirofiban; Tyrosine | 1993 |
Tirofiban provides "platelet anesthesia" during cardiopulmonary bypass in baboons.
Topics: Animals; Bleeding Time; Cardiopulmonary Bypass; Hemodynamics; Hemorrhage; Heparin; Papio; Platelet Aggregation Inhibitors; Platelet Count; Postoperative Complications; Tirofiban; Tyrosine | 1997 |
Use of LC-MS/MS to cross-validate a radioimmunoassay for the fibrinogen receptor antagonist, Aggrastat (tirofiban hydrochloride) in human plasma.
Topics: Calibration; Chromatography, Liquid; Fibrinolytic Agents; Humans; Mass Spectrometry; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Radioimmunoassay; Reproducibility of Results; Sensitivity and Specificity; Tirofiban; Tyrosine | 1997 |
In search of a superaspirin for the heart.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 1997 |
Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Adult; Bleeding Time; Cross-Over Studies; Drug Therapy, Combination; Humans; Infusions, Intravenous; Injections, Intravenous; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Tyrosine | 1997 |
Survival analysis with uncertain endpoints.
Topics: Angioplasty, Balloon; Biometry; Clinical Trials as Topic; Computer Simulation; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Tirofiban; Tyrosine | 1998 |
Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1998 |
Nature's agents help heal humans--some now take steps to reciprocate.
Topics: Analgesics, Non-Narcotic; Animals; Azetidines; Biological Factors; Biological Products; Bridged Bicyclo Compounds, Heterocyclic; Chemistry, Pharmaceutical; Conservation of Natural Resources; Drug Industry; Humans; Intercellular Signaling Peptides and Proteins; Neuroprotective Agents; Nicotinic Agonists; omega-Conotoxins; Peptides; Platelet Aggregation Inhibitors; Pyridines; Tirofiban; Tyrosine | 1998 |
Difference of (Ca2+)i movements in platelets stimulated by thrombin and TRAP: the involvement of alpha(IIb)beta3-mediated TXA2 synthesis.
Topics: Adenosine Diphosphate; Antibodies, Monoclonal; Apyrase; Aspirin; Blood Platelets; Calcium; Cyclooxygenase Inhibitors; Dipeptides; Fibrinogen; Humans; Ion Transport; Peptide Fragments; Phenylacetates; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Thrombin; Signal Transduction; Sulfonamides; Thrombin; Thromboxane A2; Thromboxane B2; Tirofiban; Tyrosine | 1998 |
Advances in antiplatelet therapy for acute coronary syndromes.
Topics: Abciximab; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1998 |
Two i.v. antiplatelet agents marketed for coronary disease.
Topics: Coronary Disease; Drug Approval; Eptifibatide; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine; United States; United States Food and Drug Administration | 1998 |
Two new antiplatelet drugs for angioplasty and acute coronary syndromes.
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Premedication; Syndrome; Tirofiban; Tyrosine | 1998 |
Tirofiban in unstable coronary disease.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Research Design; Tirofiban; Tyrosine | 1998 |
Safety and effectiveness of inhaled nitric oxide and tirofiban for acute coronary syndromes: a report from the cardiovascular and renal advisory panel of the food and drug administration.
Topics: Acute Disease; Administration, Inhalation; Coronary Disease; Humans; Nitric Oxide; Platelet Aggregation Inhibitors; Syndrome; Tirofiban; Tyrosine; United States; United States Food and Drug Administration; Vasodilator Agents | 1998 |
Association between ligand-induced conformational changes of integrin IIbbeta3 and IIbbeta3-mediated intracellular Ca2+ signaling.
Topics: Acetates; Antibodies, Monoclonal; Benzamidines; Calcium Signaling; Dipeptides; Humans; Intracellular Fluid; Molecular Structure; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Conformation; Structure-Activity Relationship; Tirofiban; Tyrosine; Valerates | 1998 |
Super-aspirins in severe angina.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 1998 |
Correlation between the in vivo efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) and ex vivo platelet inhibition.
Topics: Adenosine Diphosphate; Animals; Antibodies, Monoclonal; Arachidonic Acid; Bleeding Time; Blood Flow Velocity; Blood Platelets; Carotid Arteries; Carotid Artery Thrombosis; Citrates; Dogs; Dose-Response Relationship, Drug; Female; Heparin; Immunoglobulin Fab Fragments; Male; Mesylates; Mice; Peptides, Cyclic; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
New drugs blast budgets. Patients benefit; hospital pharmacies weigh options.
Topics: Abciximab; Angina Pectoris; Antibodies, Monoclonal; Anticoagulants; Drug Approval; Drug Costs; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Pharmacy Service, Hospital; Tirofiban; Tyrosine; United States; United States Food and Drug Administration | 1998 |
GP IIb/IIIa inhibitors: an evidence-based approach to their use.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Cost-Benefit Analysis; Disease Management; Drug Costs; Eptifibatide; Evidence-Based Medicine; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine; United States | 1999 |
[Plaque inhibition with the GPIIb/IIIa antagonist Tirofiban].
Topics: Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 1999 |
Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Arginine; Blood Platelets; Drug Therapy, Combination; Female; Heparin; Hirudin Therapy; Humans; Immunoglobulin Fab Fragments; Male; Pipecolic Acids; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sulfonamides; Thrombocytopenia; Tirofiban; Tyrosine | 1999 |
Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.
Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration.
Topics: Chromatography, High Pressure Liquid; Dopamine; Drug Incompatibility; Drug Stability; Famotidine; Heparin; Hydrogen-Ion Concentration; Injections, Intravenous; Lidocaine; Platelet Aggregation Inhibitors; Potassium Chloride; Time Factors; Tirofiban; Tyrosine | 1999 |
Comparative study of antiplatelet drugs in vitro: distinct effects of cAMP-elevating drugs and GPIIb/IIIa antagonists on thrombin-induced platelet responses.
Topics: Abciximab; Alprostadil; Antibodies, Monoclonal; Blood Platelets; Cells, Cultured; Cilostazol; Cyclic AMP; Drug Evaluation, Preclinical; Hemostatics; Humans; Immunoglobulin Fab Fragments; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tetrazoles; Thrombin; Tirofiban; Tyrosine | 1999 |
Platelet glycoprotein IIb/IIIa blockade with tirofiban: effect on aggregation caused by P256, an antibody to human IIb/IIIa receptors.
Topics: Abciximab; Antibodies, Blocking; Antibodies, Monoclonal; Arachidonic Acid; Female; Humans; Immunoglobulin Fab Fragments; In Vitro Techniques; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
Cost-effective treatment of acute coronary syndromes-IIB or not IIB?
Topics: Angina, Unstable; Cost-Benefit Analysis; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Switzerland; Tirofiban; Tyrosine | 1999 |
Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial.
Topics: Angina, Unstable; Cost of Illness; Cost-Benefit Analysis; Fibrinolytic Agents; Heparin; Hospitalization; Humans; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Switzerland; Tirofiban; Tyrosine | 1999 |
Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons.
Topics: Animals; Cardiopulmonary Bypass; Fibrinolytic Agents; Intraoperative Complications; Papio; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombin; Thrombosis; Tirofiban; Tyrosine | 1999 |
Stability of tirofiban hydrochloride in three commonly used i.v. solutions and polyvinyl chloride administration sets.
Topics: Drug Stability; Fibrinolytic Agents; Glucose; Hydrogen-Ion Concentration; Infusions, Intravenous; Polyvinyl Chloride; Sodium Chloride; Tirofiban; Tyrosine | 1999 |
Preoperative use of enoxaparin and tirofiban: possible association with increased bleeding postbypass.
Topics: Aged; Anticoagulants; Antifibrinolytic Agents; Coronary Artery Bypass; Enoxaparin; Humans; Male; Postoperative Hemorrhage; Tirofiban; Tyrosine | 1999 |
Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Infusions, Parenteral; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tirofiban; Tyrosine | 1999 |
A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes.
Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Safety; Tirofiban; Tyrosine | 1999 |
The newest critical care drugs. Part 2.
Topics: Critical Care; Drug Interactions; Drug Monitoring; Eptifibatide; Humans; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 1999 |
In vitro and in vivo studies on the metabolism of tirofiban.
Topics: Animals; Bile; Dogs; Feces; Female; Fibrinolytic Agents; Half-Life; Humans; Male; Protein Binding; Rats; Rats, Sprague-Dawley; Tirofiban; Tissue Distribution; Tyrosine | 1999 |
Tirofiban for cocaine-induced coronary artery thrombosis: a novel therapeutic approach.
Topics: Adult; Cocaine; Coronary Thrombosis; Fibrinolytic Agents; Humans; Male; Tirofiban; Tyrosine; Vasoconstrictor Agents | 1999 |
[GP-IIb/IIIa antagonists expand the anti thrombotic therapy of acute coronary syndromes. Satellite symposium during the 21st Congress of the European Society of Cardiology. Barcelona, August 1999].
Topics: Acute Disease; Coronary Disease; Drug Combinations; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Thrombolytic Therapy; Tirofiban; Tyrosine | 1999 |
Ultrasound has synergistic effects in vitro with tirofiban and heparin for thrombus dissolution.
Topics: Albumins; Blood Coagulation; Contrast Media; Fibrin; Fibrinolytic Agents; Fluorocarbons; Heparin; Humans; In Vitro Techniques; Sodium Chloride; Solubility; Sonication; Stents; Thrombosis; Time Factors; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 1999 |
Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: a nemesis of platelet glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Fatal Outcome; Female; Hemoptysis; Humans; Immunoglobulin Fab Fragments; Male; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pulmonary Alveoli; Thrombosis; Tirofiban; Tyrosine | 2000 |
A coumarin-based prodrug strategy to improve the oral absorption of RGD peptidomimetics.
Topics: Animals; Anticoagulants; Biotransformation; Cell Line; Chemical Phenomena; Chemistry, Physical; Coumarins; Dogs; Half-Life; Humans; Mouth Mucosa; Oligopeptides; Platelet Aggregation Inhibitors; Prodrugs; Receptors, Immunologic; Tirofiban; Tyrosine | 2000 |
Effects of abciximab and tirofiban on vitronectin receptors in human endothelial and smooth muscle cells.
Topics: Abciximab; Antibodies, Monoclonal; Cell Adhesion; Endothelium, Vascular; Fibrinolytic Agents; Flow Cytometry; Humans; Iliac Artery; Immunoglobulin Fab Fragments; Immunohistochemistry; Integrins; Muscle, Smooth, Vascular; Oligopeptides; Receptors, Vitronectin; Reverse Transcriptase Polymerase Chain Reaction; Tirofiban; Tyrosine; Umbilical Veins; Vitronectin | 2000 |
Uneventful use of tirofiban as an adjunct to coronary stenting in a patient with a history of abciximab-associated thrombocytopenia 10 months earlier.
Topics: Abciximab; Antibodies, Monoclonal; Coronary Vessels; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation Inhibitors; Stents; Thrombocytopenia; Tirofiban; Tyrosine | 2000 |
An in-vitro model to study device-induced thrombosis and embolism: evaluation of the efficacy of tirofiban, aspirin, and dipyridamole.
Topics: Animals; Anticoagulants; Aspirin; Blood Flow Velocity; Cattle; Dipyridamole; Dose-Response Relationship, Drug; Edetic Acid; Embolism; Equipment and Supplies; Equipment Design; Evaluation Studies as Topic; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Scattering, Radiation; Stents; Thrombosis; Tirofiban; Tyrosine | 2000 |
Tirofiban and intracoronary stenting: evaluation of a new pharmacologic regimen.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Stents; Tirofiban; Tyrosine | 1999 |
Tirofiban-induced coronary thrombolysis.
Topics: Angioplasty, Balloon, Coronary; Coronary Stenosis; Humans; Male; Middle Aged; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Tirofiban--an overview of the phase III trials.
Topics: Tirofiban; Tyrosine | 1999 |
Therapeutic efficiency of tirofiban in acute coronary syndromes.
Topics: Aged; Coronary Disease; Fibrinolytic Agents; Humans; Predictive Value of Tests; Tirofiban; Treatment Outcome; Troponin I; Troponin T; Tyrosine | 2000 |
Therapeutic efficiency of tirofiban in acute coronary syndromes.
Topics: Coronary Disease; Fibrinolytic Agents; Humans; Risk Factors; Tirofiban; Treatment Outcome; Troponin I; Troponin T; Tyrosine | 2000 |
Does perioperative antithrombotic therapy increase the likelihood of a postoperative coagulopathy after cardiac surgery?
Topics: Cardiac Surgical Procedures; Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Humans; Intraoperative Period; Postoperative Hemorrhage; Tirofiban; Tyrosine | 2000 |
IIb's are not IIb's.
Topics: Abciximab; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine; Vitronectin | 2000 |
Beyond aspirin: how glycoprotein inhibitors ease acute coronary syndromes.
Topics: Abciximab; Acute Disease; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Disease; Drug Monitoring; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Middle Aged; Nursing Assessment; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
The role of tirofiban in acute coronary syndromes.
Topics: Angina, Unstable; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Thrombosis; Tirofiban; Tyrosine | 2000 |
Glycoprotein IIb/IIIa receptor inhibitor attenuates platelet aggregation induced by thromboxane A2 during in vitro nonpulsatile ventricular assist circulation.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Analysis of Variance; Anti-Bacterial Agents; Blood Platelets; Cell Degranulation; Collagen; Heart-Assist Devices; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Ristocetin; Thromboxane A2; Tirofiban; Tyrosine | 2000 |
What have We learned from ESPRIT? What will we learn from TARGET?
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Cohort Studies; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Stents; Ticlopidine; Tirofiban; Tyrosine | 2000 |
[The use of BP IIb/IIIa inhibitors].
Topics: Fibrinolytic Agents; Humans; Myocardial Ischemia; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2000 |
Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Anticoagulants; Blood Platelets; Coronary Disease; Dose-Response Relationship, Drug; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Kinetics; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombin; Thromboplastin; Tirofiban; Tyrosine | 2000 |
Drip and ship: a new strategy for the treatment of acute coronary syndromes.
Topics: Abciximab; Acute Disease; Adult; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clinical Protocols; Coronary Angiography; Coronary Disease; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Hospitalization; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Nitrates; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
[Different inhibiting effects of abciximab and tirofiban on platelet thrombus formation on a collagen surface under flow conditions].
Topics: Abciximab; Adult; Antibodies, Monoclonal; Anticoagulants; Collagen; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; In Vitro Techniques; Microscopy, Fluorescence; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tirofiban; Tyrosine | 2000 |
Healing of spontaneous coronary dissection in the context of glycoprotein IIB/IIIA inhibitor therapy: a case report.
Topics: Adult; Coronary Angiography; Electrocardiography; Female; Heart Aneurysm; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Timing of coronary stent thrombosis in patients treated with prophylactic tirofiban.
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prosthesis Failure; Retrospective Studies; Stents; Time Factors; Tirofiban; Tyrosine | 2000 |
Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
Topics: Abciximab; Alanine; Amidines; Analysis of Variance; Antibodies, Monoclonal; Anticoagulants; Blood Platelets; Calcium; Citric Acid; Eptifibatide; Fibrinogen; Heparin; Humans; Immunoglobulin Fab Fragments; Iodine Radioisotopes; Isoxazoles; Peptides; Platelet Activation; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Pyrrolidines; Tirofiban; Tyrosine | 2000 |
Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes.
Topics: Angina, Unstable; Anticoagulants; Coronary Disease; Creatine Kinase; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heart Failure; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Regression Analysis; Risk Factors; Statistics, Nonparametric; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2000 |
GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood.
Topics: Abciximab; Antibodies, Monoclonal; Blood Platelets; Collagen; Dose-Response Relationship, Drug; Eptifibatide; Factor V; Flow Cytometry; Humans; Immunoglobulin Fab Fragments; Infant, Newborn; Membrane Proteins; Peptides; Phosphatidylserines; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Thrombasthenia; Thrombin; Tirofiban; Tyrosine | 2000 |
Platelets and coronary intervention: some practical precautions.
Topics: Abciximab; Antibodies, Monoclonal; Coronary Disease; Drug Monitoring; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Peptides; Platelet Aggregation Inhibitors; Prognosis; Risk Assessment; Thrombocytopenia; Tirofiban; Tyrosine | 2000 |
[New antiplatelet agents].
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Dipyridamole; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2000 |
A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Double-Blind Method; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Multicenter Studies as Topic; Patient Selection; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Research Design; Sample Size; Stents; Tirofiban; Tyrosine | 2000 |
Tirofiban counteracts pending myocardial infarction.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Drug Monitoring; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2000 |
[Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Atherectomy; Clinical Trials as Topic; Combined Modality Therapy; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Syndrome; Tirofiban; Tyrosine; United States; United States Food and Drug Administration | 2000 |
Fast, aggressive treatment for myocardial infarction urged.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Artery Bypass; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Stents; Tirofiban; Tyrosine | 2000 |
[New thrombocyte aggregation inhibitor in therapy of unstable angina].
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2000 |
Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb/IIIa inhibitor tirofiban as anticoagulant.
Topics: Cardiopulmonary Bypass; Drug Therapy, Combination; Female; Heart Valve Prosthesis Implantation; Heparin; Hirudins; Humans; Kidney Function Tests; Middle Aged; Mitral Valve; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Prosthesis Failure; Recombinant Proteins; Reoperation; Thrombocytopenia; Tirofiban; Tyrosine | 2000 |
Complicated acute myocardial infarction.
Topics: Electrocardiography; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Retrobulbar Hemorrhage; Tirofiban; Tomography, X-Ray Computed; Tyrosine | 2001 |
Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban.
Topics: Adult; Aged; Anticoagulants; Blood Platelets; Cardiopulmonary Bypass; Female; Fibrin Fibrinogen Degradation Products; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Renal Insufficiency; Thrombocytopenia; Tirofiban; Tyrosine | 2001 |
Role of tirofiban in the medical treatment of the intermediate-risk patient with an acute coronary syndrome cannot be denied.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Confidence Intervals; Coronary Angiography; Double-Blind Method; Fibrinolytic Agents; Heparin; Humans; Incidence; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
[Update on tirofiban].
Topics: Coronary Disease; France; Humans; Patient Selection; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
Impact of abciximab versus tirofiban on hospital length of stay for PCI patients.
Topics: Abciximab; Adult; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cost-Benefit Analysis; Female; Humans; Immunoglobulin Fab Fragments; Length of Stay; Male; Middle Aged; Multivariate Analysis; Pennsylvania; Platelet Aggregation Inhibitors; Retrospective Studies; Tirofiban; Tyrosine | 2001 |
A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban.
Topics: Abciximab; Aged; Angioplasty, Balloon; Antibodies, Monoclonal; Blood Platelets; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Light; Male; Middle Aged; Peptides; Physiology; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Point-of-Care Systems; Tirofiban; Tyrosine | 2001 |
Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Calcium; Chelating Agents; Citric Acid; Dose-Response Relationship, Drug; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Kinetics; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Unexpected flow cytometric results with two small GPIIb/IIIa blockers: eptifibatide and tirofiban.
Topics: Antibodies, Monoclonal; Drug Monitoring; Eptifibatide; Flow Cytometry; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist.
Topics: Blood Platelets; Dose-Response Relationship, Drug; Drug Interactions; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thromboplastin; Tirofiban; Tyrosine | 2001 |
[Risk stratification in acute coronary syndrome].
Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Biomarkers; Clinical Trials as Topic; Coronary Disease; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Nadroparin; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Retrospective Studies; Risk Factors; Syndrome; Terminology as Topic; Tirofiban; Troponin I; Troponin T; Tyrosine | 2001 |
[Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa inhibitors].
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Platelets; Clopidogrel; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2001 |
Quantification by flow cytometry of the efficacy of and interindividual variation of platelet inhibition induced by treatment with tirofiban and abciximab.
Topics: Abciximab; Adult; Aged; Antibodies, Monoclonal; Coronary Disease; Female; Fibrinogen; Flow Cytometry; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2001 |
Effects on thrombin generation of the platelet glycoprotein IIb/IIIa inhibitors abciximab versus tirofiban during coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Atherectomy, Coronary; Coronary Disease; Female; Heparin; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptide Fragments; Platelet Glycoprotein GPIIb-IIIa Complex; Prothrombin; Stents; Thrombin; Tirofiban; Tyrosine; Whole Blood Coagulation Time | 2001 |
Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.
Topics: Abciximab; Antibodies, Monoclonal; Eptifibatide; Heart Diseases; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Exit of platelet glycoprotein-IIb/IIIa-receptor inhibitors?
Topics: Aged; Angina, Unstable; Drug Administration Schedule; Drug Therapy, Combination; Female; Hematoma; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Streptokinase; Thrombolytic Therapy; Tirofiban; Tyrosine | 2001 |
Future trials of antiplatelet agents in cardiac ischemia.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Disease; Immunoglobulin Fab Fragments; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Research Design; Stents; Tirofiban; Tyrosine | 2001 |
Optimal treatment of acute coronary syndromes--an evolving strategy.
Topics: Abciximab; Acute Disease; Algorithms; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Disease; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Tyrosine | 2001 |
[Lysis of an extensive thrombus in the internal carotid artery using a glycoprotein IIb/IIIa receptor antagonist].
Topics: Aphasia, Broca; Carotid Artery, Internal; Carotid Stenosis; Cerebral Angiography; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Male; Middle Aged; Paralysis; Platelet Glycoprotein GPIIb-IIIa Complex; Smoking; Thrombosis; Tirofiban; Tomography, X-Ray Computed; Tyrosine | 2001 |
Glycoprotein IIb/IIIa inhibitors: more different than alike?
Topics: Abciximab; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin.
Topics: Abciximab; Antibodies, Monoclonal; Binding, Competitive; Cell Adhesion; Cell Division; Cell Line; Cells, Cultured; Dimerization; Dose-Response Relationship, Drug; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Muscle, Smooth, Vascular; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prothrombin; Receptors, Vitronectin; Thrombospondin 1; Thrombospondins; Tirofiban; Tyrosine; Vitronectin | 2001 |
Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (alphaIIb/beta3) receptor-directed platelet inhibition.
Topics: Adult; Cells, Cultured; Dose-Response Relationship, Drug; Eptifibatide; Fibrinogen; Humans; Middle Aged; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Transfusion; Reference Values; Tirofiban; Tyrosine | 2001 |
Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method.
Topics: Adenosine Diphosphate; Amino Acid Chloromethyl Ketones; Aspirin; Blood Coagulation; Blood Platelets; Cilostazol; Collagen; Dipyridamole; Filtration; Heparin; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Pressure; Tetrazoles; Time Factors; Tirofiban; Tyrosine | 2001 |
Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics.
Topics: Abciximab; Adenosine Diphosphate; Antibodies, Monoclonal; Biotinylation; Depression, Chemical; Dose-Response Relationship, Drug; Eptifibatide; Fibrinogen; Humans; Immunoglobulin Fab Fragments; Kinetics; Peptides; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Proteins; Receptors, Thrombin; Tirofiban; Tyrosine | 2001 |
A risk score system for predicting adverse outcomes and magnitude of benefit with glycoprotein IIb/IIIa inhibitor therapy in patients with unstable angina pectoris.
Topics: Adult; Age Distribution; Aged; Angina, Unstable; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heparin; Humans; Male; Middle Aged; Myocardial Ischemia; Odds Ratio; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Probability; Proportional Hazards Models; Recurrence; Risk Assessment; Risk Factors; Sensitivity and Specificity; Severity of Illness Index; Sex Distribution; Survival Rate; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
Adjunctive therapies in the cath lab. Combination of tirofiban and alteplase in acute myocardial infarction.
Topics: Adult; Angioplasty, Balloon; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 2001 |
Adjunctive therapies in the cath lab. Intracoronary tirofiban infusion in a case with massive intracoronary thrombus.
Topics: Adult; Coronary Thrombosis; Humans; Male; Platelet Aggregation Inhibitors; Radiography; Tirofiban; Tyrosine | 2001 |
Adjunctive therapies in the cath lab. Use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia.
Topics: Aged; Aged, 80 and over; Anticoagulants; Combined Modality Therapy; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heparin; Hirudin Therapy; Hirudins; Humans; Platelet Aggregation Inhibitors; Recombinant Proteins; Renal Insufficiency; Stents; Thrombocytopenia; Tirofiban; Tyrosine | 2001 |
Tirofiban therapy does not increase the risk of hemorrhage after emergency coronary surgery.
Topics: Blood Coagulation; Blood Transfusion; Coronary Disease; Drug Administration Schedule; Drug Monitoring; Emergencies; Hemorrhage; Humans; Infusions, Intravenous; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
[Antithrombotic therapy of unstable angina pectoris].
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Ticlopidine; Tirofiban; Tyrosine | 1998 |
Resolution of a spontaneous coronary artery thrombus with a new antiplatelet agent.
Topics: Coronary Angiography; Coronary Thrombosis; Female; Humans; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Creatine Kinase; Drug Therapy, Combination; Eptifibatide; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Immunoglobulin Fab Fragments; Length of Stay; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Recurrence; Retrospective Studies; Survival Rate; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
A comparison of total hospital costs for percutaneous coronary intervention patients receiving abciximab versus tirofiban.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Female; Health Status; Hospital Costs; Humans; Immunoglobulin Fab Fragments; Insurance, Health; Length of Stay; Male; Middle Aged; Models, Econometric; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2001 |
Stability of tirofiban hydrochloride in 0.9% sodium chloride injection for 30 days.
Topics: Drug Stability; Humans; Injections; Pharmaceutical Solutions; Platelet Aggregation Inhibitors; Sodium Chloride; Tirofiban; Tyrosine | 2001 |
Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban).
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function.
Topics: Abciximab; Antibodies, Monoclonal; Blood Platelets; Drug Therapy, Combination; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Standardized ultrasound as a new method to induce platelet aggregation: evaluation, influence of lipoproteins and of glycoprotein IIb/IIIa antagonist tirofiban.
Topics: Blood Platelets; Cholesterol, LDL; Humans; In Vitro Techniques; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Statistics, Nonparametric; Stimulation, Chemical; Tirofiban; Triglycerides; Tyrosine; Ultrasonography | 2001 |
Treatment of acute basilar artery thrombosis with a combination of systemic alteplase and tirofiban, a nonpeptide platelet glycoprotein IIb/IIIa inhibitor: report of four cases.
Topics: Aged; Basilar Artery; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 2001 |
[Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban].
Topics: Coronary Disease; Humans; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Syndrome; Time Factors; Tirofiban; Tyrosine | 2001 |
[Comparison of 2 platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2001 |
Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting.
Topics: Blood Transfusion; Case-Control Studies; Coronary Artery Bypass; Emergencies; Female; Heparin; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Postoperative Hemorrhage; Time Factors; Tirofiban; Tyrosine | 2001 |
One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II.
Topics: Anticoagulants; Cardiopulmonary Bypass; Cardiovascular Diseases; Heparin; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 2001 |
A risk stratification scheme for selection of a glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention based on clinical and angiographic criteria.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Angiography; Creatine Kinase; Creatine Kinase, MB Form; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Isoenzymes; Myocardial Infarction; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk Factors; Tirofiban; Tyrosine | 2001 |
Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban.
Topics: Abciximab; Amino Acid Chloromethyl Ketones; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Blood Specimen Collection; Calcium; Chelating Agents; Citric Acid; Drug Interactions; Drug Monitoring; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Tirofiban; Tyrosine | 2001 |
Cost effectiveness of invasive strategy in unstable coronary disease--what are we waiting for?
Topics: Coronary Artery Bypass; Coronary Artery Disease; Coronary Disease; Cost-Benefit Analysis; Europe; Fibrinolytic Agents; Health Care Costs; Humans; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2002 |
Cost implications of routine tirofiban use in the management of acute coronary syndromes.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Coronary Disease; Eligibility Determination; Female; Health Care Costs; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Random Allocation; Syndrome; Tirofiban; Tyrosine | 2001 |
Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes.
Topics: Abciximab; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Survival Analysis; Tirofiban; Treatment Outcome; Troponin T; Tyrosine | 2001 |
Platelet inhibition after glycoprotein IIb/IIIa inhibitor therapy.
Topics: Abciximab; Antibodies, Monoclonal; Blood Platelets; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tirofiban; Tyrosine | 2001 |
[Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes.
Topics: Angioplasty, Balloon, Coronary; Bias; Combined Modality Therapy; Creatine Kinase; Creatine Kinase, MB Form; Humans; Isoenzymes; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Hypothermia-induced platelet aggregation in heparinized flowing human blood: identification of a high responder subpopulation.
Topics: Alprostadil; Anemia, Hemolytic, Autoimmune; Aspirin; Blood Cell Count; Citric Acid; Cold Temperature; Edetic Acid; Filtration; Hemorheology; Heparin; Humans; Hypothermia; Light; Models, Biological; Platelet Aggregation; Platelet Aggregation Inhibitors; Pressure; Protamines; Scattering, Radiation; Tirofiban; Tyrosine | 2002 |
Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta3 integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin.
Topics: Antibodies, Monoclonal; Eptifibatide; Humans; Muscle, Smooth, Vascular; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Prothrombin; Receptors, Vitronectin; Thrombospondins; Tirofiban; Tyrosine | 2002 |
Synthesis of RGD analogs as potential vectors for targeted drug delivery.
Topics: Drug Delivery Systems; Humans; Inhibitory Concentration 50; Molecular Mimicry; Oligopeptides; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban.
Topics: Anticoagulants; Coronary Stenosis; Drug Therapy, Combination; Enoxaparin; Factor VII; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Stents; Tirofiban; Tyrosine; Vascular Patency | 2002 |
Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Coagulation Tests; Coronary Disease; Drug Therapy, Combination; Fibrinogen; Heparin; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2002 |
Duration of action of GpIIb-IIIa antagonists.
Topics: Abciximab; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Time Factors; Tirofiban; Tyrosine | 2000 |
Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition.
Topics: Adult; Blood Platelets; Eptifibatide; Fibrinogen; Fibrinolytic Agents; Humans; Linear Models; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2002 |
Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Cardiac Catheterization; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sex Factors; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis.
Topics: Animals; Arteriovenous Shunt, Surgical; Bleeding Time; Blood Coagulation; Blood Pressure; Dogs; Eptifibatide; Fibrinolytic Agents; Heart Rate; Heparin; Magnesium Sulfate; P-Selectin; Peptides; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Thrombosis; Time Factors; Tirofiban; Tyrosine | 2002 |
Images in cardiology. Glycoprotein IIb/IIIa induced coronary thrombolysis.
Topics: Adult; Anticoagulants; Coronary Thrombosis; Drug Therapy, Combination; Female; Heparin, Low-Molecular-Weight; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2002 |
[Pilot study of the effectiveness of combination therapy with reduced dose alteplase and the glycoprotein IIb/IIIa antagonist tirofiban in acute myocardial infarct].
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Angiography; Coronary Circulation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Pilot Projects; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Thrombolytic Therapy; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 2002 |
Glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2002 |
Tirofiban blocks platelet adhesion to fibrin with minimal perturbation of GpIIb/IIIa structure.
Topics: Adult; Circular Dichroism; Dose-Response Relationship, Drug; Fibrin; Humans; Microscopy, Electron; Nephelometry and Turbidimetry; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Conformation; Protein Interaction Mapping; Protein Structure, Secondary; Protein Structure, Tertiary; Protein Subunits; Receptor Aggregation; Tirofiban; Tyrosine | 2002 |
The TARGET trial: hit or miss?
Topics: Abciximab; Antibodies, Monoclonal; Coronary Disease; Humans; Immunoglobulin Fab Fragments; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Stents; Tirofiban; Tyrosine | 2002 |
Cost efficacy of platelet glycoprotein IIb/IIIa antagonists in clinical trials and clinical practice.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Thrombosis; Cost-Benefit Analysis; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Patterns, Physicians'; Tirofiban; Tyrosine | 2002 |
Vertebrobasilar thrombolysis with intravenous tirofiban: case report.
Topics: Aged; Arterial Occlusive Diseases; Fibrinolytic Agents; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stroke; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine; Vertebrobasilar Insufficiency | 2002 |
[Platelet antiaggregation treatment in the aftermath of GUSTO IV, TARGET, TACTICS, and CURE trials].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Coronary Artery Bypass; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Ticlopidine; Time Factors; Tirofiban; Tyrosine | 2002 |
Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited.
Topics: Cardiac Catheterization; Coronary Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Radiology, Interventional; Tirofiban; Tyrosine | 2002 |
Anti-platelet effects of GPIIb/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils.
Topics: Abciximab; Amidines; Analysis of Variance; Antibodies, Monoclonal; Cells, Cultured; Humans; Immunoglobulin Fab Fragments; Isoxazoles; Neutrophils; P-Selectin; Platelet Activation; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2002 |
Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Adenosine Diphosphate; Adult; Antibodies, Monoclonal; Antigens, Human Platelet; Case-Control Studies; Coronary Artery Disease; Eptifibatide; Female; Genotype; Humans; Immunoglobulin Fab Fragments; Incidence; Integrin beta3; Male; Middle Aged; P-Selectin; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Tirofiban; Tyrosine | 2002 |
MK-383 (tirofiban) induces a GPIIb/IIIa receptor conformation which differs from the resting and activated receptor.
Topics: Flow Cytometry; Fluorescence Resonance Energy Transfer; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Conformation; Tirofiban; Tyrosine | 2002 |
Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies.
Topics: Abciximab; Animals; Antibodies, Monoclonal; Antibody Specificity; Autoantibodies; Blood Platelets; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Macaca mulatta; Models, Animal; Peptides; Phylogeny; Plasmapheresis; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Factor 4; Platelet Glycoprotein GPIIb-IIIa Complex; Purpura, Thrombocytopenic, Idiopathic; Serotonin; Species Specificity; Tirofiban; Tyrosine | 2002 |
Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.
Topics: Acute Disease; Aged; Autoantibodies; Calcium; Case-Control Studies; Cross Reactions; Epitopes; Eptifibatide; Female; Humans; Ligands; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 2002 |
Human thrombocytes are able to induce a myocardial dysfunction in the ischemic and reperfused guinea pig heart mediated by free radicals-role of the GPIIb/IIIa-blocker tirofiban.
Topics: Animals; Blood Platelets; Cardiac Output; Disease Models, Animal; Fibrinolytic Agents; Guinea Pigs; Humans; In Vitro Techniques; Male; Myocardial Reperfusion Injury; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Transfusion; Superoxide Dismutase; Tirofiban; Tyrosine | 2002 |
Molecular mechanisms of platelet-mediated leukocyte recruitment during myocardial reperfusion.
Topics: Animals; Blood Platelets; Cell Adhesion; Chemotaxis, Leukocyte; Coronary Vessels; Endothelium, Vascular; Intercellular Adhesion Molecule-1; Ligation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Ischemia; Myocardial Reperfusion; P-Selectin; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine; Ventricular Function, Left | 2002 |
ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidel
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Biomarkers; Clopidogrel; Disease Management; Drug Therapy, Combination; Electrocardiography; Eptifibatide; Female; Health Behavior; Hemorrhage; Humans; Hypolipidemic Agents; Immunoglobulin Fab Fragments; Male; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2002 |
No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Adenosine Diphosphate; Antibodies, Monoclonal; Antigens, Human Platelet; Blood Platelets; Fibrinogen; Genotype; Humans; Immunoglobulin Fab Fragments; Integrin beta3; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Tirofiban; Tyrosine | 2002 |
Percutaneous femoral artery angioplasty with stent-in-stent technique and tirofiban administration.
Topics: Angioplasty, Balloon; Female; Femoral Artery; Fibrinolytic Agents; Humans; Middle Aged; Recurrence; Stents; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation.
Topics: Abciximab; Adult; Antibodies, Monoclonal; Blood Platelets; Cells, Cultured; Collagen; Drug Evaluation, Preclinical; Endothelium, Vascular; Eptifibatide; Extracellular Matrix; Factor VIIa; Factor X; Hemorheology; Humans; Immunoglobulin Fab Fragments; Oligopeptides; Peptides; Platelet Adhesiveness; Platelet Glycoprotein GPIIb-IIIa Complex; Prothrombin; Recombinant Proteins; Tetradecanoylphorbol Acetate; Thrombasthenia; Thrombin; Thromboplastin; Tirofiban; Tyrosine | 2003 |
Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.
Topics: Abciximab; Alanine; Amidines; Analysis of Variance; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cell Aggregation; Dose-Response Relationship, Drug; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Isoxazoles; Peptides; Platelet Activation; Platelet Adhesiveness; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Rheology; Shear Strength; Temperature; Tirofiban; Tyrosine | 2002 |
Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban.
Topics: Blood Coagulation Tests; Blood Platelets; Coronary Disease; Female; Fibrinolytic Agents; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Time Factors; Tirofiban; Tyrosine | 2002 |
Decrease of vascular smooth muscle cell locomotion by abciximab, but not tirofiban: a possible role of different affinity to alpha v beta 3 integrins.
Topics: Abciximab; Analysis of Variance; Antibodies, Monoclonal; Binding, Competitive; Cell Movement; Cells, Cultured; Chemotaxis; Coronary Vessels; Humans; Immunoglobulin Fab Fragments; Integrin alphaVbeta3; Muscle, Smooth, Vascular; Tirofiban; Tyrosine | 2002 |
Endothelin-1 induced proinflammatory markers in the myocardium and leukocytes of guinea-pigs: role of glycoprotein IIB/IIIA receptors.
Topics: Animals; Blood Platelets; Cells, Cultured; Cyclooxygenase 2; Endothelin-1; Guinea Pigs; Isoenzymes; Leukocytes, Mononuclear; Male; Myocardium; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Prostaglandin-Endoperoxide Synthases; Stimulation, Chemical; Thromboplastin; Tirofiban; Tyrosine | 2003 |
Outcome of access site in patients treated with platelet glycoprotein IIb/IIIa inhibitors in the era of closure devices.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Catheters, Indwelling; Cohort Studies; Dose-Response Relationship, Drug; Equipment Failure; Female; Femoral Artery; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Ischemia; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Retrospective Studies; Time Factors; Tirofiban; Tyrosine; Vascular Diseases | 2003 |
Thrombocytopenia following treatment with platelet glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Antibodies, Monoclonal; Autoantibodies; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 2003 |
Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban.
Topics: Coronary Disease; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Radioimmunoassay; Tirofiban; Tyrosine | 2003 |
Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban.
Topics: Abciximab; Adult; Antibodies, Monoclonal; Binding, Competitive; Dose-Response Relationship, Drug; Female; Fibrinogen; Fibrinolytic Agents; Genetic Variation; Humans; Immunoglobulin Fab Fragments; Kinetics; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Tirofiban; Tyrosine; von Willebrand Factor | 2003 |
Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Coronary Disease; Electrocardiography; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Linear Models; Logistic Models; Male; Middle Aged; Myocardial Infarction; Patient Selection; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Risk Factors; Safety; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Comparison of the i-STAT handheld activated clotting time with the Hemochron activated clotting time during and after percutaneous coronary intervention.
Topics: Abciximab; Analysis of Variance; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Monitoring; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Linear Models; Peptides; Platelet Aggregation Inhibitors; Point-of-Care Systems; Predictive Value of Tests; Tirofiban; Treatment Outcome; Tyrosine; Whole Blood Coagulation Time | 2003 |
Access to new cardiovascular therapies in Canadian hospitals: a national survey of the formulary process.
Topics: Abciximab; Antibodies, Monoclonal; Canada; Cardiovascular Agents; Clopidogrel; Dalteparin; Data Collection; Drug Utilization; Enoxaparin; Eptifibatide; Formularies, Hospital as Topic; Health Services Accessibility; Hematologic Agents; Humans; Immunoglobulin Fab Fragments; Peptides; Pharmacy and Therapeutics Committee; Ticlopidine; Tirofiban; Tyrosine | 2003 |
Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Platelets; CD40 Ligand; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Kinetics; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2003 |
[New antiaggregants and their importance for the practitioner].
Topics: Abciximab; Administration, Oral; Adult; Anesthesia, Spinal; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Contraindications; Drug Therapy, Combination; Eptifibatide; Female; Fibrinolytic Agents; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pregnancy; Ticlopidine; Tirofiban; Tyrosine | 2003 |
Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.
Topics: Abciximab; Animals; Antibodies, Monoclonal; Binding Sites, Antibody; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eptifibatide; Female; Immunoglobulin Fab Fragments; Macaca fascicularis; Male; Peptides; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Tirofiban; Tyrosine | 2002 |
Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.
Topics: Abciximab; Animals; Antibodies, Monoclonal; CHO Cells; Cricetinae; Dose-Response Relationship, Drug; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2003 |
Effects of GP IIb/IIIa receptor inhibitor tirofiban (aggrastat) in ex vivo canine arteriovenous shunt model of stent thrombosis.
Topics: Animals; Arteriovenous Shunt, Surgical; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrinolytic Agents; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tirofiban; Tyrosine | 2003 |
Preoperative platelet inhibition and bleeding after cardiopulmonary bypass.
Topics: Cardiopulmonary Bypass; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Postoperative Hemorrhage; Preoperative Care; Time Factors; Tirofiban; Tyrosine | 2003 |
Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Cohort Studies; Female; Fibrinolytic Agents; Heparin; Humans; Infusions, Intravenous; Male; Middle Aged; Multivariate Analysis; Nitrates; Observer Variation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Use of platelet glycoprotein IIb/IIIa inhibitors and spontaneous pulmonary hemorrhage.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Incidence; Lung Diseases; Male; Michigan; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pulmonary Wedge Pressure; Tirofiban; Treatment Failure; Tyrosine; Ventricular Pressure | 2003 |
A propensity analysis of the impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes after percutaneous coronary intervention.
Topics: Abciximab; Antibodies, Monoclonal; Coronary Disease; Coronary Thrombosis; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Multivariate Analysis; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Association of an activated clotting time < or =250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy).
Topics: Angioplasty, Balloon, Coronary; Blood Coagulation Tests; Coronary Disease; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Tirofiban; Tyrosine | 2003 |
Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment.
Topics: Abciximab; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Death, Sudden; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Tirofiban; Tyrosine | 2003 |
Dissolution of a huge spontaneous coronary artery thrombus with a new antiplatelet agent and coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Thrombosis; Fibrinolytic Agents; Humans; Male; Tirofiban; Tyrosine | 2003 |
Prolonged systemic delivery of tirofiban in a thrombus-laden saphenous vein graft.
Topics: Aged; Coronary Artery Bypass; Coronary Artery Disease; Fibrinolytic Agents; Graft Occlusion, Vascular; Humans; Infusions, Intravenous; Male; Platelet Glycoprotein GPIIb-IIIa Complex; Radiography; Saphenous Vein; Thromboembolism; Tirofiban; Tyrosine | 2003 |
Evaluation of glycoprotein IIb/IIIa inhibitors in carotid angioplasty and stenting.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angioplasty; Antibodies, Monoclonal; Carotid Stenosis; Case-Control Studies; Eptifibatide; Female; Heparin; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Retrospective Studies; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Adjunctive use of platelet glycoprotein IIb/IIIa inhibitors for carotid angioplasty and stent placement: time to say good bye?
Topics: Abciximab; Angioplasty; Antibodies, Monoclonal; Carotid Stenosis; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Value of thromboelastography in the assessment of platelet function.
Topics: Adenosine Diphosphate; Aspirin; Humans; Peripheral Vascular Diseases; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Sensitivity and Specificity; Thrombelastography; Tirofiban; Tyrosine | 2003 |
Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke: preliminary observations.
Topics: Acute Disease; Aged; Case-Control Studies; Drug Therapy, Combination; Feasibility Studies; Fibrinolytic Agents; Humans; Pilot Projects; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Retrospective Studies; Severity of Illness Index; Stroke; Thrombolytic Therapy; Time Factors; Tirofiban; Tissue Plasminogen Activator; Treatment Outcome; Tyrosine | 2003 |
Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Case-Control Studies; Drug Costs; Eptifibatide; Female; Hospital Costs; Hospital Mortality; Humans; Immunoglobulin Fab Fragments; Length of Stay; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine; United States | 2003 |
Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.
Topics: Abciximab; Analysis of Variance; Antibodies, Monoclonal; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Immunoglobulin Fab Fragments; Leukocytes; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombolytic Therapy; Tirofiban; Tyrosine | 2002 |
Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity.
Topics: Abciximab; Antibodies, Monoclonal; Coagulants; Eptifibatide; Humans; Immunoglobulin Fab Fragments; P-Selectin; Particle Size; Peptides; Perfusion; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Factor 3; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2003 |
Angiographic predictors of adverse outcomes in the modern interventional era.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Angiography; Humans; Immunoglobulin Fab Fragments; Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Risk Assessment; Stents; Tirofiban; Tyrosine | 2003 |
Isolation of a Zn-binding protein mediating cell adhesion from common carp.
Topics: Animals; Autoradiography; Carps; Carrier Proteins; Cell Adhesion; Chromatography, Affinity; Detergents; Electrophoresis, Polyacrylamide Gel; Liposomes; Oligopeptides; Tirofiban; Tyrosine | 2003 |
[Angiogram of the month].
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Disease; Fibrinolytic Agents; Humans; Male; Middle Aged; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Outcomes with changes in prescribing of glycoprotein IIb/IIIa inhibitors in PCI.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Evidence of platelet activation due to tirofiban-dependent platelet antibodies: double trouble.
Topics: Aged; Antibodies; Blood Platelets; Flow Cytometry; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Serotonin; Thrombocytopenia; Time Factors; Tirofiban; Tyrosine | 2003 |
Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Administration Schedule; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Tyrosine | 2003 |
Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation.
Topics: Abciximab; Adult; Antibodies, Monoclonal; Eptifibatide; Female; Humans; Hypothermia, Induced; Immunoglobulin Fab Fragments; In Vitro Techniques; Leukocytes; Male; Middle Aged; Peptides; Platelet Adhesiveness; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2003 |
Beta brachytherapy of an old degenerated saphenous vein graft with occlusive in-stent restenosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Beta Particles; Blood Vessel Prosthesis; Brachytherapy; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Female; Fibrinolytic Agents; Graft Occlusion, Vascular; Humans; Myocardial Infarction; Phosphorus Radioisotopes; Reoperation; Saphenous Vein; Stents; Ticlopidine; Tirofiban; Tyrosine | 2003 |
Effect of the PercuSurge GuardWire device on the integrity of microvasculature and clinical outcomes during primary transradial coronary intervention in acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Chi-Square Distribution; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Female; Fibrinolytic Agents; Humans; Male; Microcirculation; Middle Aged; Myocardial Infarction; Statistics, Nonparametric; Thrombectomy; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Retroperitoneal hematoma following tirofiban and enoxaparin coadministration in a patient with acute coronary syndrome.
Topics: Acute Disease; Aged; Anticoagulants; Coronary Disease; Enoxaparin; Hematoma; Humans; Male; Partial Thromboplastin Time; Platelet Aggregation Inhibitors; Retroperitoneal Space; Tirofiban; Tyrosine | 2003 |
Diffuse alveolar hemorrhage following administration of tirofiban in a patient with acute coronary syndrome: a fatal complication.
Topics: Coronary Stenosis; Fatal Outcome; Female; Hemorrhage; Humans; Lung Diseases; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2004 |
Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study.
Topics: Animals; Coronary Circulation; Dogs; Echocardiography; Microcirculation; Models, Animal; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Reperfusion Injury; Tirofiban; Tyrosine | 2004 |
Glycoprotein IIb/IIIa inhibitors and no-reflow.
Topics: Animals; Coronary Circulation; Fibrinolytic Agents; Humans; Microcirculation; Models, Animal; Myocardial Infarction; Myocardial Reperfusion; Platelet Glycoprotein GPIIb-IIIa Complex; Reperfusion Injury; Thrombosis; Tirofiban; Tyrosine; Vascular Patency | 2004 |
Synergism of aspirin and heparin with a low-frequency non-invasive ultrasound system for augmentation of in-vitro clot lysis.
Topics: Adult; Aspirin; Drug Synergism; Drug Therapy, Combination; Eptifibatide; Heparin; Humans; In Vitro Techniques; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombolytic Therapy; Tirofiban; Tyrosine; Ultrasonic Therapy | 2003 |
Safety of a high bolus dose of tirofiban in patients undergoing coronary stent placement.
Topics: Aged; Cardiac Catheterization; Chi-Square Distribution; Coronary Angiography; Coronary Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Complications; Retrospective Studies; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and th
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Comorbidity; Coronary Disease; Female; Hospitalization; Humans; Life Tables; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Risk Factors; Severity of Illness Index; Stents; Survival Analysis; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Massive pulmonary haemorrhage complicating the treatment of acute coronary syndrome.
Topics: Angina, Unstable; Diagnostic Errors; Fatal Outcome; Hemorrhage; Humans; Lung Diseases; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Pulmonary Edema; Radiography; Tirofiban; Tyrosine | 2004 |
Effect of adjunctive tirofiban therapy on angiographic and clinical outcomes in patients with ST-segment elevated acute myocardial infarction undergoing primary stenting.
Topics: Aged; Coronary Angiography; Coronary Circulation; Electrocardiography; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Acute myocardial infarction in a patient with essential thrombocythemia treated with glycoprotein IIb/IIIa inhibitor.
Topics: Female; Humans; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocythemia, Essential; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
[Efficacy and safety of treatment of acute ischemic stroke with glycoprotein IIb/IIIa receptor blocker in routine clinical practice].
Topics: Adult; Aged; Anticoagulants; Aspirin; Brain; Brain Ischemia; Carotid Arteries; Clopidogrel; Drug Therapy, Combination; Echocardiography, Transesophageal; Eptifibatide; Female; Heparin; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Stroke; Ticlopidine; Tirofiban; Tomography, X-Ray Computed; Tyrosine; Ultrasonography, Doppler | 2004 |
Tirofiban and eptifibatide treatment of patients presenting with acute coronary syndrome with non-ST segment elevation.
Topics: Acute Disease; Aged; Aged, 80 and over; Biomarkers; Coronary Disease; Drug Utilization Review; Electrocardiography; Eptifibatide; Female; Formularies, Hospital as Topic; Humans; Inpatients; Male; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Retrospective Studies; Tirofiban; Tyrosine | 2004 |
Transradial application of PercuSurge GuardWire device during primary percutaneous intervention of infarct-related artery with high-burden thrombus formation.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Circulation; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Equipment Design; Female; Fibrinolytic Agents; Humans; Incidence; Intraoperative Care; Male; Middle Aged; Myocardium; Postoperative Complications; Taiwan; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Characterization and metal affinity of Tirofiban, a pharmaceutical compound used in acute coronary syndromes.
Topics: Coronary Disease; Hydrogen Bonding; Hydrogen-Ion Concentration; Ligands; Magnetic Resonance Spectroscopy; Metals; Models, Molecular; Platelet Aggregation Inhibitors; Potentiometry; Spectrophotometry, Infrared; Tirofiban; Tyrosine | 2004 |
Treatment of intracoronary thrombus using tirofiban in a patient with normal coronary arteries.
Topics: Angina, Unstable; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Fibrinolytic Agents; Humans; Male; Middle Aged; Tirofiban; Tyrosine | 2004 |
Determination of Tirofiban in human serum by liquid chromatography-tandem mass spectrometry.
Topics: Chromatography, Liquid; Humans; Mass Spectrometry; Platelet Aggregation Inhibitors; Reproducibility of Results; Tirofiban; Tyrosine | 2004 |
Detection of acutely impaired microvascular reperfusion after infarct angioplasty with magnetic resonance imaging.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Circulation; Female; Heart Ventricles; Heparin; Humans; Immunoglobulin Fab Fragments; Magnetic Resonance Imaging; Male; Microcirculation; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Prospective Studies; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine; Ventricular Function, Left | 2004 |
Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro.
Topics: Antibodies, Monoclonal; Blood Platelets; Collagen; Eptifibatide; Fibrinogen; Humans; Isoxazoles; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sulfonamides; Thrombin; Tirofiban; Tyrosine | 2004 |
Tirofiban for catheter intervention in acute myocardial infarction?
Topics: Angioplasty, Balloon, Coronary; Fibrinolytic Agents; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2004 |
Successful recanalization of an occluded coronary artery by percutaneous coronary intervention, systemic administration of tirofiban, a glycoprotein IIb/IIIa inhibitor, and intracoronary thrombolysis with alteplase.
Topics: Angioplasty, Balloon, Coronary; Coronary Thrombosis; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recovery of Function; Thrombolytic Therapy; Tirofiban; Tissue Plasminogen Activator; Treatment Failure; Treatment Outcome; Tyrosine | 2004 |
Inhibition of streptokinase-induced, antibody-mediated platelet aggregation with tirofiban after exposure to streptokinase or streptococcal infection.
Topics: Adult; Antibody Formation; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Streptococcal Infections; Streptokinase; Tirofiban; Tyrosine | 2004 |
Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion.
Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials, Phase II as Topic; Cohort Studies; Coronary Angiography; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Platelet Glycoprotein GPIIb-IIIa Complex; Tenecteplase; Thrombolytic Therapy; Time Factors; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 2004 |
Effects of tirofiban on haemostatic activation in vitro.
Topics: Adenosine Diphosphate; Blood Coagulation; Dose-Response Relationship, Drug; Hemostasis; Heparin; Humans; In Vitro Techniques; Platelet Aggregation; Platelet Aggregation Inhibitors; Thrombin; Tirofiban; Tyrosine | 2004 |
Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Restenosis; Enoxaparin; Eptifibatide; Flow Cytometry; Hemostatics; Heparin; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Receptors, G-Protein-Coupled; Thrombin; Tirofiban; Tyrosine | 2004 |
Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions.
Topics: Abciximab; Adult; Antibodies, Monoclonal; Anticoagulants; Arginine; Blood Platelets; Collagen; Eptifibatide; Fibrinolytic Agents; Hemorheology; Humans; Immunoglobulin Fab Fragments; In Vitro Techniques; Peptides; Pipecolic Acids; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sulfonamides; Thrombosis; Tirofiban; Tyrosine | 2004 |
Continuous tenecteplase infusion combined with peri/postprocedural platelet glycoprotein IIb/IIIa inhibition in peripheral arterial thrombolysis: initial safety and feasibility experience.
Topics: Aged; Drug Therapy, Combination; Feasibility Studies; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Infusions, Intravenous; Ischemia; Leg; Male; Middle Aged; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Tenecteplase; Thrombolytic Therapy; Thrombosis; Tirofiban; Tissue Plasminogen Activator; Treatment Outcome; Tyrosine | 2004 |
Safety and feasibility of a novel dosing regimen of tirofiban administered in patients with acute myocardial infarction with ST elevation before primary coronary angioplasty: a pilot study.
Topics: Angioplasty, Balloon, Coronary; Chi-Square Distribution; Coronary Vessels; Drug Administration Schedule; Feasibility Studies; Heparin; Humans; Myocardial Infarction; Pilot Projects; Prospective Studies; Regional Blood Flow; Statistics, Nonparametric; Time Factors; Tirofiban; Tyrosine | 2004 |
Platelet function predicts myocardial damage in patients with acute myocardial infarction.
Topics: Abciximab; Adenosine Diphosphate; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cardiovascular Agents; Clopidogrel; Collagen; Comorbidity; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Leukocyte Count; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardium; Necrosis; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Ticlopidine; Tirofiban; Tyrosine; von Willebrand Factor | 2004 |
Impact of invasive strategy for the management of patients with cardiogenic shock after acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Chemotherapy, Adjuvant; Coronary Artery Bypass; Female; Fibrinolytic Agents; Hospital Mortality; Humans; Intra-Aortic Balloon Pumping; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Risk Factors; Shock, Cardiogenic; Survival Analysis; Thrombolytic Therapy; Tirofiban; Tyrosine | 2004 |
Elevations in troponin I after percutaneous coronary interventions are associated with abnormal tissue-level perfusion in high-risk patients with non-ST-segment-elevation acute coronary syndromes.
Topics: Abciximab; Acute Disease; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Biomarkers; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Coronary Circulation; Electrocardiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Ischemia; Myocardial Reperfusion Injury; Platelet Aggregation Inhibitors; Prospective Studies; Risk; Ticlopidine; Tirofiban; Troponin I; Tyrosine; Ultrasonography | 2004 |
An image of coronary thrombus mimicking dissection detected by intravascular ultrasound during functional evaluation of an intermediate lesion.
Topics: Aged; Anticoagulants; Aortic Dissection; Coronary Aneurysm; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Diagnosis, Differential; Fibrinolytic Agents; Heparin; Humans; Infusions, Intravenous; Male; Tirofiban; Tyrosine; Ultrasonography, Interventional; Whole Blood Coagulation Time | 2004 |
Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation.
Topics: Antibodies, Monoclonal; Aspirin; Blood Platelets; Calcium; Cell Separation; Cilostazol; Collagen; Cyclic AMP; Humans; Leukocytes; Male; P-Selectin; Platelet Activation; Platelet Adhesiveness; Platelet Glycoprotein GPIIb-IIIa Complex; Tetrazoles; Thrombin; Tirofiban; Tyrosine | 2004 |
Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Hemorrhage; Hospitals, Veterans; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Regression Analysis; Retrospective Studies; Risk Factors; Tirofiban; Tyrosine | 2004 |
Extracorporeal elimination of large concentrations of tirofiban by zero-balanced ultrafiltration during cardiopulmonary bypass: an in vitro investigation.
Topics: Cardiopulmonary Bypass; Extracorporeal Circulation; Gas Chromatography-Mass Spectrometry; Humans; In Vitro Techniques; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine; Ultrafiltration | 2004 |
Effects of tirofiban on acute systemic inflammatory response in elective percutaneous coronary interventions.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon; C-Reactive Protein; Coronary Angiography; Female; Fibrinogen; Follow-Up Studies; Humans; Interleukin-1; Interleukin-6; Interleukin-8; Leukocyte Count; Male; Middle Aged; Myocardium; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Troponin; Tumor Necrosis Factor-alpha; Tyrosine | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Safety; Tirofiban; Tyrosine | 2004 |
Intra-arterial thrombolysis for acute ischemic stroke: preliminary experience with platelet glycoprotein IIb/IIIa inhibitors as adjunctive therapy.
Topics: Abciximab; Acute Disease; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Brain Ischemia; Chemotherapy, Adjuvant; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Stroke; Thrombolytic Therapy; Tirofiban; Tyrosine | 2005 |
[Spleen rupture in myocardial infarction after administration of GP IIb-IIIa-antagonists].
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Echocardiography; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Splenectomy; Splenic Rupture; Stents; Ticlopidine; Tirofiban; Tomography, X-Ray Computed; Tyrosine | 2005 |
Safety of tirofiban therapy in very old patients with acute coronary syndrome or non-Q-wave myocardial infarction.
Topics: Aged; Aged, 80 and over; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Risk Factors; Tirofiban; Tyrosine | 2005 |
FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban.
Topics: Animals; Blood Platelets; Brain; Brain Ischemia; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Guinea Pigs; Infarction, Middle Cerebral Artery; Intracranial Thrombosis; Male; Microcirculation; Neutrophils; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Propionates; Recovery of Function; Reperfusion Injury; Tirofiban; Tyrosine | 2005 |
Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Vessel Prosthesis; Death, Sudden, Cardiac; Emergency Treatment; Female; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation Inhibitors; Secondary Prevention; Stents; Survival Analysis; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry study.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Clopidogrel; Drug Combinations; Drug Interactions; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Tyrosine | 2004 |
Von Willebrand factor can support platelet aggregation via interaction with activated GPIIb-IIIa and GPIb.
Topics: Antibodies, Monoclonal; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine; von Willebrand Factor | 2004 |
Repetitive profound thrombocytopenia after treatment with tirofiban: a case report.
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Administration Schedule; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Thrombocytopenia; Ticlopidine; Tirofiban; Tyrosine | 2004 |
Combination of a high bolus dose of tirofiban with half-dose thrombolytics for the treatment of subacute stent thrombosis.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrinolytic Agents; Follow-Up Studies; Humans; Male; Myocardial Infarction; Risk Assessment; Stents; Tirofiban; Tyrosine; Vascular Patency | 2005 |
Leukocyte-platelet aggregates in rat peripheral blood after ischemic stroke and reperfusion.
Topics: Analysis of Variance; Animals; Anticoagulants; Biomarkers; Blood Platelets; Brain Ischemia; Disease Models, Animal; Flow Cytometry; Inflammation; Leukocytes; Male; Myocardial Reperfusion Injury; Neutrophil Activation; Neutrophils; Platelet Aggregation; Platelet Aggregation Inhibitors; Polysaccharides; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Severity of Illness Index; Stroke; Time Factors; Tirofiban; Tyrosine | 2005 |
Is platelet function as measured by Thrombelastograph monitoring in whole blood affected by platelet inhibitors?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Platelets; Eptifibatide; Humans; Immunoglobulin Fab Fragments; In Vitro Techniques; Integrin beta3; Models, Theoretical; Peptides; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Membrane Glycoprotein IIb; Point-of-Care Systems; Thrombelastography; Tirofiban; Tyrosine | 2005 |
Hyperglycemia is an important predictor of impaired coronary flow before reperfusion therapy in ST-segment elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Blood Glucose; Case-Control Studies; Coronary Circulation; Female; Humans; Hyperglycemia; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Preoperative Care; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2005 |
Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study.
Topics: Aged; Angina, Unstable; Anticoagulants; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Syndrome; Tirofiban; Tyrosine | 2005 |
Restoration of normal coronary flow with tirofiban by intracoronary administration for no-reflow phenomenon after stent deployment.
Topics: Aged; Coronary Circulation; Coronary Disease; Humans; Infusions, Intravenous; Male; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Syndrome; Tirofiban; Tyrosine | 2005 |
Delayed tirofiban-induced thrombocytopenia: two case reports.
Topics: Aged; Aged, 80 and over; Antibodies; Anticoagulants; Blood Platelets; Echocardiography; Enzyme-Linked Immunosorbent Assay; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Count; Platelet Transfusion; Thrombocytopenia; Time Factors; Tirofiban; Tyrosine | 2005 |
Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
Topics: Abciximab; Adenosine Diphosphate; Antibodies, Monoclonal; C-Reactive Protein; Chromatography, Gel; Coagulants; Collagen; Dose-Response Relationship, Drug; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Models, Statistical; Peptides; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Tirofiban; Tyrosine | 2006 |
Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction.
Topics: Aged; Angiography; Angioplasty, Balloon, Coronary; Female; Fibrinolytic Agents; Follow-Up Studies; Heart; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Perfusion; Stroke; Time Factors; Tirofiban; Tyrosine | 2005 |
Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
Topics: Abciximab; Adenosine Diphosphate; Adult; Antibodies, Monoclonal; Anticoagulants; Binding Sites; Blood Platelets; Female; Flow Cytometry; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Models, Statistical; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Platelet Glycoprotein GPIb-IX Complex; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Thrombin; Time Factors; Tirofiban; Tyrosine; Up-Regulation | 2006 |
Simultaneous integrin alphavbeta3 and glycoprotein IIb/IIIa inhibition causes reduction in infarct size in a model of acute coronary thrombosis and primary angioplasty.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Animals; Coronary Thrombosis; Dogs; Integrin alphaVbeta3; Male; Models, Animal; Myocardial Infarction; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrimidines; Random Allocation; Tirofiban; Tyrosine | 2005 |
Safety of tirofiban therapy in korean patients with acute coronary syndrome.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Disease; Drug Evaluation; Female; Humans; Korea; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Syndrome; Tirofiban; Tyrosine | 2005 |
Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen.
Topics: Adenosine Diphosphate; Aged; Binding, Competitive; Blood Platelets; Clopidogrel; Coronary Artery Disease; Data Interpretation, Statistical; Eptifibatide; Fibrinogen; Flow Cytometry; Fluorescein-5-isothiocyanate; Humans; Iodine Radioisotopes; Male; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Thrombin; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration.
Topics: Abciximab; Antibodies, Monoclonal; Blood Platelets; Drug Contamination; Drug Incompatibility; Drug Stability; Drug Storage; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine; United States | 2005 |
The effect of tirofiban on microvascular thrombosis: crush model.
Topics: Anastomosis, Surgical; Animals; Disease Models, Animal; Femoral Artery; Isotonic Solutions; Microsurgery; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Random Allocation; Rats; Rats, Sprague-Dawley; Ringer's Lactate; Thrombosis; Tirofiban; Tyrosine; Vascular Patency | 2005 |
Choice of GPIIb/IIIa antagonist in percutaneous coronary intervention: how should economic criteria be factored in?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cost-Benefit Analysis; Diabetes Mellitus; Drug Costs; Eptifibatide; Hospital Costs; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Platelet glycoprotein IIb/IIIa inhibition as adjunctive therapy during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
Topics: Abciximab; Acute Disease; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Chemotherapy, Adjuvant; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2005 |
Delayed stenting of a thrombotic saphenous vein graft after intravenous tirofiban pretreatment.
Topics: Aged; Coronary Disease; Humans; Male; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Saphenous Vein; Stents; Thrombosis; Tirofiban; Tyrosine | 2006 |
Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Australia; Diabetic Angiopathies; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Syndrome; Tirofiban; Troponin; Tyrosine | 2006 |
A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome.
Topics: Acute Disease; Aged; Angioplasty, Balloon; Anticoagulants; Feasibility Studies; Female; Follow-Up Studies; Hirudins; Humans; Ischemia; Leg; Male; Myocardial Ischemia; Peptide Fragments; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Retrospective Studies; Thrombin; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Facilitated percutaneous coronary intervention (PCI) in patients with acute ST-elevation myocardial infarction: comparison of prehospital tirofiban versus fibrinolysis before direct PCI.
Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Coronary Angiography; Creatine Kinase; Female; Fibrinolytic Agents; Follow-Up Studies; Heart Conduction System; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Preoperative Care; Recombinant Proteins; Research Design; Streptokinase; Tenecteplase; Thrombolytic Therapy; Time Factors; Tirofiban; Tissue Plasminogen Activator; Treatment Outcome; Tyrosine | 2005 |
Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting.
Topics: Abciximab; Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Biomarkers; C-Reactive Protein; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Female; Heparin; Humans; Immunoglobulin Fab Fragments; Inflammation; Male; Middle Aged; Postoperative Period; Premedication; Stents; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Ability of different glycoprotein IIb-IIIa ligands to support platelet aggregation induced by activating antibody CRC54.
Topics: Antibodies, Monoclonal; Calcium; Fibrinogen; Humans; Immunoglobulin Fab Fragments; Ligands; Platelet Activation; Platelet Aggregation; Platelet Glycoprotein GPIb-IX Complex; Platelet Glycoprotein GPIIb-IIIa Complex; Serotonin; Time Factors; Tirofiban; Tyrosine; von Willebrand Factor | 2005 |
Intravenous tirofiban with intra-arterial urokinase and mechanical thrombolysis in stroke: preliminary experience in 11 cases.
Topics: Adult; Aged; Aged, 80 and over; Carotid Stenosis; Catheterization; Combined Modality Therapy; Female; Heparin; Humans; Infarction, Middle Cerebral Artery; Infusions, Intra-Arterial; Infusions, Intravenous; Intracranial Hemorrhages; Male; Middle Aged; Risk; Severity of Illness Index; Stroke; Thrombolytic Therapy; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Urokinase-Type Plasminogen Activator | 2005 |
Is platelet adhesion assay able to quantify drug-induced platelet dysfunction?
Topics: Abciximab; Aged; Antibodies, Monoclonal; Blood Platelet Disorders; Blood Platelets; Cell Separation; Clopidogrel; Dose-Response Relationship, Drug; Eptifibatide; Female; Fibrinogen; Flow Cytometry; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Adhesiveness; Platelet Aggregation; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Polymers; Pyridines; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Tirofiban plus sirolimus-eluting stent vs abciximab plus bare-metal stent.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Drug Delivery Systems; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sirolimus; Stents; Tirofiban; Tyrosine | 2005 |
Tirofiban plus sirolimus-eluting stent vs abciximab plus bare-metal stent.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Drug Delivery Systems; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sirolimus; Stents; Thrombectomy; Tirofiban; Tyrosine | 2005 |
Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
Topics: Abciximab; Adenosine Monophosphate; Antibodies, Monoclonal; Aspirin; Blood Platelets; CD40 Ligand; Coagulants; Humans; Immunoglobulin Fab Fragments; Membrane Proteins; Plasminogen Activator Inhibitor 1; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Receptors, Thrombin; Secretory Vesicles; Tirofiban; Tyrosine | 2005 |
Impact of ABO blood groups on tirofiban mediated inhibition of platelet function.
Topics: ABO Blood-Group System; Adult; Anti-Bacterial Agents; Blood Platelets; Factor VIII; Humans; Male; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Ristocetin; Tirofiban; Tyrosine; von Willebrand Factor | 2005 |
Iliac artery thrombosis after aortic balloon counterpulsation: treatment with intraarterial tirofiban, manual thrombectomy and stenting.
Topics: Aged; Coronary Angiography; Fibrinolytic Agents; Heparin; Humans; Iliac Artery; Infusions, Intra-Arterial; Intra-Aortic Balloon Pumping; Male; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Thrombectomy; Thrombosis; Tirofiban; Tyrosine | 2006 |
Treatment of acute central retinal artery occlusionwith the platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban.
Topics: Aged; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retinal Artery Occlusion; Tirofiban; Treatment Outcome; Tyrosine; Visual Acuity | 2005 |
Are tirofiban and abciximab identical in efficacy?
Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials as Topic; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Two distinct subgroups of tirofiban-induced thrombocytopenia exist due to drug dependent antibodies that cause platelet activation and increased ischaemic events.
Topics: Acute Disease; Aged; Aged, 80 and over; Autoantibodies; Coronary Disease; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purpura, Thrombocytopenic, Idiopathic; Tirofiban; Tyrosine | 2005 |
Pharmacodynamics of two different dosing regimens of tirofiban in citrate or PPACK anticoagulated blood.
Topics: Aged; Amino Acid Chloromethyl Ketones; Anticoagulants; Blood Platelets; Citric Acid; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Tirofiban; Tyrosine | 2005 |
[Effects of anti-platelet drugs on myocardial no-reflow after acute myocardial infarction and reperfusion: experiment with mini-swine model].
Topics: Animals; Clopidogrel; Coronary Circulation; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Platelet Aggregation Inhibitors; Random Allocation; Swine; Swine, Miniature; Thrombolytic Therapy; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Increased ability of tirofiban to maintain its inhibitory effects on the binding of fibrinogen to platelets in blood from patients with and without diabetes mellitus.
Topics: Aged; Diabetes Mellitus; Female; Fibrinogen; Flow Cytometry; Humans; In Vitro Techniques; Male; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2006 |
Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling.
Topics: Adenosine Monophosphate; Blood Platelets; Calcium Channel Blockers; Calcium Signaling; Collagen; Humans; In Vitro Techniques; Lanthanum; Platelet Adhesiveness; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Thrombosis; Tirofiban; Tyrosine | 2006 |
Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion.
Topics: Animals; Aspirin; Clopidogrel; Coronary Circulation; Drug Therapy, Combination; Myocardial Infarction; Myocardial Reperfusion; Nitric Oxide; Nitric Oxide Synthase; Platelet Aggregation Inhibitors; Random Allocation; Swine; Swine, Miniature; Ticlopidine; Tirofiban; Tyrosine | 2006 |
Downstream administration of a high-dose tirofiban bolus in high-risk patients with unstable angina undergoing early percutaneous coronary intervention.
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Biomarkers; Case-Control Studies; Confounding Factors, Epidemiologic; Coronary Angiography; Disease-Free Survival; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
A fibrin encapsulated liposomes-in-chitosan matrix (FLCM) for delivering water-soluble drugs. Influences of the surface properties of liposomes and the crosslinked fibrin network.
Topics: Amines; Chitosan; Cross-Linking Reagents; Delayed-Action Preparations; Drug Compounding; Fibrin; Glutaral; Liposomes; Organophosphates; Particle Size; Platelet Aggregation Inhibitors; Polyethylene Glycols; Porosity; Quinacrine; Solubility; Surface Properties; Time Factors; Tirofiban; Tyrosine; Water | 2006 |
The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Life Expectancy; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Quality-Adjusted Life Years; Risk Assessment; Risk Factors; Tirofiban; Tyrosine | 2006 |
Upstream/downstream glycoprotein IIb/IIIa in non-ST-segment elevation myocardial infarction.
Topics: Abciximab; Antibodies, Monoclonal; Cost-Benefit Analysis; Drug Costs; Electrocardiography; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2006 |
Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Platelet Aggregation; Platelet Glycoprotein GPIb-IX Complex; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Tirofiban; Tyrosine | 2006 |
Effect of tirofiban therapy on ST segment resolution and clinical outcomes in patients with ST segment elevated acute myocardial infarction undergoing primary angioplasty.
Topics: Adult; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Combined Modality Therapy; Coronary Angiography; Coronary Artery Disease; Echocardiography; Electrocardiography; Female; Fibrinolytic Agents; Heart Conduction System; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Reproducibility of Results; Research Design; Retrospective Studies; Stents; Stroke Volume; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters.
Topics: Aspirin; Blood Coagulation; Blood Platelets; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Eptifibatide; Factor Xa Inhibitors; Female; Heparin; Humans; Indoles; Male; Partial Thromboplastin Time; Peptides; Platelet Aggregation Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 2006 |
Collagen XVII promotes integrin-mediated squamous cell carcinoma transmigration--a novel role for alphaIIb integrin and tirofiban.
Topics: Adult; Antineoplastic Agents; Autoantigens; Carcinoma, Squamous Cell; Cell Adhesion; Cell Adhesion Molecules; Cell Line, Tumor; Cell Movement; Chemotaxis; Collagen Type XVII; Epithelium; Humans; Integrin alpha5beta1; Kalinin; Keratinocytes; Neoplasm Invasiveness; Non-Fibrillar Collagens; Platelet Aggregation Inhibitors; Platelet Membrane Glycoprotein IIb; Protein Structure, Tertiary; Tirofiban; Tyrosine; Wound Healing | 2006 |
Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Artery Disease; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 2006 |
Successful lysis of coronary thrombi by long term warfarin treatment after a failed course of tirofiban infusion.
Topics: Angina Pectoris; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Enoxaparin; Female; Humans; Infusion Pumps; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Tirofiban; Treatment Failure; Treatment Outcome; Tyrosine; Warfarin | 2006 |
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
Topics: Aged; Blood Platelets; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Cell Surface; Tirofiban; Tyrosine | 2007 |
Direct comparison of the A to Z and PROVE IT trials: a second chance to gain a first impression.
Topics: Africa; Angioplasty, Balloon, Coronary; Asia; Atorvastatin; Australia; Canada; Case Management; Cholesterol, LDL; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Europe; Heptanoic Acids; Humans; Multicenter Studies as Topic; Myocardial Ischemia; New Zealand; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Simvastatin; South America; Stents; Tirofiban; Treatment Outcome; Tyrosine; United States | 2006 |
Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model.
Topics: Aprotinin; Binding, Competitive; Biomarkers; Blood Platelets; Dipyridamole; Eptifibatide; Extracorporeal Circulation; Flow Cytometry; Granulocytes; Humans; Male; Milrinone; P-Selectin; Peptides; Phosphodiesterase Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Serine Proteinase Inhibitors; Tirofiban; Tyrosine | 2006 |
Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome.
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Angiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Registries; Stents; Syndrome; Tirofiban; Tyrosine | 2006 |
Platelet function monitoring with the Sonoclot analyzer after in vitro tirofiban and heparin administration.
Topics: Adult; Anticoagulants; Blood Coagulation Tests; Blood Platelets; Female; Heparin; Humans; Male; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2006 |
[Statistical notes. Which risks do the patient incur if his own cardiologist accepts to be involved in a clinical trial without deep consideration of the a priori available evidence?].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Confidence Intervals; Data Interpretation, Statistical; Evaluation Studies as Topic; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Physician-Patient Relations; Platelet Aggregation Inhibitors; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Role of tirofiban in treatment of stent thrombosis.
Topics: Aged; Coronary Angiography; Coronary Thrombosis; Female; Fibrinolytic Agents; Humans; Infusions, Intravenous; Male; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Tyrosine | 2006 |
Acute coronary embolism after mitral valve replacement in a patient presenting with non-ST-segment elevation myocardial infarction.
Topics: Adult; Angina Pectoris; Coronary Angiography; Coronary Thrombosis; Diagnosis, Differential; Electrocardiography; Fibrinolytic Agents; Heart Conduction System; Heart Valve Prosthesis Implantation; Humans; Male; Mitral Valve; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2006 |
Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets.
Topics: Amino Acid Motifs; Animals; Antibodies; Bleeding Time; Blood Platelets; Carotid Artery Diseases; Chlorides; Complementarity Determining Regions; Eptifibatide; Ferric Compounds; Fibrinogen; Fibrinolytic Agents; Humans; Mice; Mice, Inbred C57BL; Molecular Conformation; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tirofiban; Tyrosine | 2006 |
Use of heparin upon reoperation in a pediatric patient with heparin-induced thrombocytopenia after disappearance of antibodies.
Topics: Antibodies; Anticoagulants; Aprotinin; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Child; Drug Therapy, Combination; Heart Valve Prosthesis Implantation; Hemostatics; Heparin; Hirudins; Humans; Male; Mitral Valve; Phenprocoumon; Platelet Aggregation Inhibitors; Platelet Factor 4; Recombinant Proteins; Reoperation; Thrombocytopenia; Tirofiban; Tyrosine; Ventricular Outflow Obstruction | 2006 |
Differential diagnosis and management of acute profound thrombocytopenia by tirofiban: a case report.
Topics: Acute Disease; Diagnosis, Differential; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 2006 |
Complementary effects of sirolimus-eluting stents and glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention in diabetic patients: one-year follow up of a single-centre registry.
Topics: Coronary Restenosis; Diabetic Angiopathies; Disease-Free Survival; Drug Combinations; Drug Implants; Eptifibatide; Follow-Up Studies; Humans; Immunosuppressive Agents; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sirolimus; Stents; Tirofiban; Tyrosine | 2006 |
Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative.
Topics: Acute Disease; Adult; Angina, Unstable; Blood Transfusion; Cerebral Hemorrhage; Creatinine; Disease Susceptibility; Dose-Response Relationship, Drug; Eptifibatide; Glomerular Filtration Rate; Hemorrhage; Hemorrhagic Disorders; Humans; Kidney Diseases; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Registries; Sex Characteristics; Tirofiban; Tyrosine | 2006 |
Mitigation of device-associated thrombosis and thromboembolism using combinations of heparin and tirofiban.
Topics: Animals; Anticoagulants; Drug Therapy, Combination; Heparin; In Vitro Techniques; Male; Platelet Aggregation Inhibitors; Sheep; Stents; Thromboembolism; Thrombosis; Tirofiban; Tyrosine | 2006 |
[Platelet function after a high dose bolus of tirofiban immediately after coronary angioplasty].
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Syndrome; Time Factors; Tirofiban; Tyrosine | 2006 |
Tirofiban-associated acute thrombocytopenia.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Coronary Stenosis; Humans; Infusions, Intravenous; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Stents; Thrombocytopenia; Tirofiban; Tyrosine | 2006 |
Acute ischaemic stroke treated with combined intra-arterial thrombolysis and intravenous tirofiban despite oral anticoagulant therapy at an international normalised ratio > or = 2.0.
Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Brain Ischemia; Contraindications; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Injections, Intra-Arterial; Injections, Intravenous; Male; Middle Aged; Patient Selection; Stroke; Thrombolytic Therapy; Tirofiban; Tyrosine | 2006 |
Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba.
Topics: Abciximab; Annexin A5; Antibodies, Monoclonal; Binding Sites, Antibody; Blood Platelets; Dose-Response Relationship, Drug; Epitope Mapping; Eptifibatide; Flow Cytometry; Humans; Immunoglobulin Fab Fragments; In Vitro Techniques; Peptides; Phosphatidylserines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIb-IX Complex; Platelet Glycoprotein GPIIb-IIIa Complex; Stress, Mechanical; Thrombin; Tirofiban; Tyrosine; von Willebrand Factor | 2006 |
Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Platelets; Coronary Angiography; Creatine Kinase, MB Form; Electrocardiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Randomized Controlled Trials as Topic; Stents; Time Factors; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2006 |
AlphaIIbbeta3 priming and clustering by orally active and intravenous integrin antagonists.
Topics: Administration, Oral; Alanine; Amidines; Binding, Competitive; Blood Platelets; Dimerization; Dose-Response Relationship, Drug; Eptifibatide; Female; Fibrinogen; Humans; In Vitro Techniques; Injections, Intravenous; Intercellular Signaling Peptides and Proteins; Isoxazoles; Kinetics; Male; Models, Molecular; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Protein Conformation; Pyrrolidines; Reference Values; Structure-Activity Relationship; Tirofiban; Tyrosine | 2007 |
Bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in drug-eluting stent implantations in the absence of acute myocardial infarction: clinical and economic results.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Coronary Artery Disease; Costs and Cost Analysis; Drug Delivery Systems; Drug Therapy, Combination; Eptifibatide; Female; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Length of Stay; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Peptide Fragments; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Retrospective Studies; Sirolimus; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Transvenous pacing causing tamponade in patients receiving glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty; Antibodies, Monoclonal; Atherectomy, Coronary; Cardiac Catheterization; Cardiac Pacing, Artificial; Cardiac Tamponade; Female; Femoral Vein; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Pacemaker, Artificial; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Thrombectomy; Tirofiban; Tyrosine | 2007 |
Ischemic coronary syndromes and SVG Interventions--do 2b/3a inhibitors miss the target?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Disease; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine; Venous Thrombosis | 2007 |
A case of profound and prolonged tirofiban-induced thrombocytopenia and its correction by intravenous immunoglobulin G.
Topics: Enzyme-Linked Immunosorbent Assay; Humans; Immunoglobulins, Intravenous; Male; Middle Aged; Platelet Aggregation Inhibitors; Thrombocytopenia; Tirofiban; Tyrosine | 2007 |
CABG-procedures in patients with pretreatment with the GPIIb/IIIa-receptor antagonist tirofiban (Aggrastat): modification of perioperative management?
Topics: Antifibrinolytic Agents; Aprotinin; Coronary Artery Bypass; Fibrinolytic Agents; Hemostatics; Humans; Postoperative Hemorrhage; Preoperative Care; Retrospective Studies; Tirofiban; Tranexamic Acid; Tyrosine | 2008 |
Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Eptifibatide; Female; Hospital Mortality; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; United States | 2007 |
Thrombin formation in vitro in response to shear-induced activation of platelets.
Topics: Antithrombin III; Aspirin; Biomedical Engineering; Blood Platelets; Heart Valve Prosthesis; Hemorheology; Humans; In Vitro Techniques; Peptide Hydrolases; Platelet Activation; Platelet Aggregation Inhibitors; Stress, Mechanical; Thrombin; Thromboembolism; Tirofiban; Tyrosine; von Willebrand Factor | 2007 |
Glycoprotein IIb/IIIa antagonists during carotid artery stenting: results from the carotid artery stenting (CAS) registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK).
Topics: Abciximab; Aged; Antibodies, Monoclonal; Carotid Stenosis; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Logistic Models; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Registries; Stents; Tirofiban; Tyrosine | 2007 |
Beta2-integrins and acquired glycoprotein IIb/IIIa (GPIIb/IIIa) receptors cooperate in NF-kappaB activation of human neutrophils.
Topics: Abciximab; Antibodies, Monoclonal; Blood Platelets; CD18 Antigens; Eptifibatide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunoglobulin Fab Fragments; Integrin beta3; Neutrophils; NF-kappa B; Peptides; Phosphatidylinositol 3-Kinases; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoprotein IIb; Tirofiban; Tumor Necrosis Factor-alpha; Tyrosine | 2007 |
Treatment of acute myocardial infarction in pregnancy with coronary artery balloon angioplasty and stenting: use of tirofiban and clopidogrel.
Topics: Adult; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Myocardial Infarction; Pregnancy; Pregnancy Complications, Cardiovascular; Ticlopidine; Tirofiban; Tyrosine | 2008 |
Cerebellar hematoma complicating 600 mg loading dose of clopidogrel in combination with tirofiban.
Topics: Aged; Cerebellar Diseases; Clopidogrel; Drug Therapy, Combination; Hematoma; Humans; Male; Ticlopidine; Tirofiban; Tyrosine | 2008 |
Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Benzothiazoles; Blood Platelets; Coronary Disease; Crotalid Venoms; Flow Cytometry; Fluorescent Dyes; Hemostatics; Humans; Lectins, C-Type; Platelet Activating Factor; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Quinolines; Thrombin; Tirofiban; Tyrosine | 2007 |
Pulmonary hemorrhage in a patient with acute coronary syndrome.
Topics: Aged; Angina, Unstable; Hemorrhage; Humans; Lung Diseases; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Radiography; Tirofiban; Tyrosine | 2007 |
Perioperative thrombotic risk of coronary artery stents: possible role for intravenous platelet blockade.
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Injections, Intravenous; Perioperative Care; Platelet Aggregation Inhibitors; Postoperative Complications; Risk Factors; Stents; Ticlopidine; Tirofiban; Tyrosine | 2007 |
Prevention of microsurgical anastomotic thrombosis using aspirin, heparin, and the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Anastomosis, Surgical; Animals; Anticoagulants; Aspirin; Drug Therapy, Combination; Heparin; Male; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Random Allocation; Rats; Rats, Sprague-Dawley; Thrombosis; Tirofiban; Tyrosine; Vascular Patency | 2007 |
Application of high-throughput screening to identify a novel alphaIIb-specific small- molecule inhibitor of alphaIIbbeta3-mediated platelet interaction with fibrinogen.
Topics: Antibodies; Blood Platelets; Cell Adhesion; Cell Line; Collagen; Drug Evaluation, Preclinical; Fibrinogen; Humans; Models, Molecular; Molecular Structure; Platelet Membrane Glycoprotein IIb; Protein Structure, Tertiary; Tirofiban; Tyrosine | 2008 |
Selective inhibition of platelets by the GPIIb/IIIa receptor antagonist Tirofiban reduces leukocyte-endothelial cell interaction in murine antigen-induced arthritis.
Topics: Animals; Arthritis, Experimental; Cell Communication; Endothelial Cells; Female; Leukocytes; Mice; Mice, Inbred C57BL; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2007 |
Reduced fibrin deposition and intravascular thrombosis in hDAF transgenic pig hearts perfused with tirofiban.
Topics: Adult; Animals; Animals, Genetically Modified; Antibodies; CD55 Antigens; Complement C3; Complement C4; Creatine Kinase; Disaccharides; Fibrin; Fibrinolytic Agents; Heart; Heart Transplantation; Humans; Male; Myocardium; Swine; Thrombosis; Tirofiban; Transplantation, Heterologous; Tyrosine | 2007 |
Coronary embolism in a patient with mitral valve prosthesis: successful management with tirofiban and half-dose tissue-type plasminogen activator.
Topics: Coronary Thrombosis; Embolism; Heart Valve Prosthesis; Humans; Male; Middle Aged; Mitral Valve; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 2007 |
Long term tirofiban infusion before percutaneous coronary intervention in patients with angiographically massive intracoronary thrombus.
Topics: Angioplasty, Balloon, Coronary; Chi-Square Distribution; Coronary Angiography; Coronary Thrombosis; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Platelet Aggregation Inhibitors; Statistics, Nonparametric; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Effect of platelet glycoprotein IIb/IIIa receptor antagonist on survival of epigastric island flaps in rats with total venous occlusions.
Topics: Abdominal Wall; Animals; Disease Models, Animal; Graft Survival; Laser-Doppler Flowmetry; Male; Necrosis; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Surgical Flaps; Tirofiban; Tyrosine; Venous Insufficiency | 2008 |
High-dose tirofiban administered as bolus-only during percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Eptifibatide; Female; Humans; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Retrospective Studies; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Synthesis and biological evaluation of PEG-tirofiban conjugates.
Topics: Collagen; Cryoprotective Agents; Freezing; Humans; Mediator Complex Subunit 1; Molecular Structure; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polyethylene Glycols; Polymers; Structure-Activity Relationship; Tirofiban; Transcription Factors; Tyrosine | 2008 |
Rescue use of tirofiban for acute carotid in-stent thrombosis.
Topics: Acute-Phase Reaction; Angiography; Carotid Artery Diseases; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Stents; Thrombosis; Tirofiban; Tyrosine | 2008 |
Real-world safety and efficacy of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Artery Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Tirofiban; Tyrosine | 2008 |
Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation.
Topics: Antithrombin III; beta-Thromboglobulin; Blood Platelets; Class I Phosphatidylinositol 3-Kinases; Extracorporeal Circulation; Fibrinogen; Granulocytes; Hemoglobins; Humans; Male; Microscopy, Electron, Scanning; Morpholines; Peptide Hydrolases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoprotein IIb; Protein Kinase Inhibitors; Pyrimidinones; Research Design; Stress, Mechanical; Time Factors; Tirofiban; Tyrosine | 2008 |
Hypercoagulability due to homocystinuria in a case of head and neck reconstruction resolved with combined systemic therapy.
Topics: Carcinoma, Squamous Cell; Fibrinolytic Agents; Head and Neck Neoplasms; Homocystinuria; Humans; Male; Platelet Aggregation Inhibitors; Postoperative Complications; Surgical Flaps; Thrombophilia; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 2008 |
[Acute profound thrombocytopenia associated with tirofiban: clinical approach to diagnosis and therapeutic management].
Topics: Acute Disease; Aged; Female; Humans; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 2008 |
E-page Original Images. Thrombotic lesion of saphenous vein graft resolved by antiaggregant therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Diagnosis, Differential; Graft Occlusion, Vascular; Humans; Male; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Radiography; Saphenous Vein; Tirofiban; Tyrosine | 2008 |
Transcranial Doppler ultrasonography-directed intravenous glycoprotein IIb/IIIa receptor antagonist therapy to control transient cerebral microemboli before and after carotid endarterectomy.
Topics: Aged; Aged, 80 and over; Carotid Stenosis; Combined Modality Therapy; Endarterectomy, Carotid; Female; Humans; Infusions, Intravenous; Intracranial Embolism; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Postoperative Complications; Preoperative Care; Tirofiban; Tyrosine; Ultrasonography, Doppler, Transcranial; Ultrasonography, Interventional | 2008 |
The effect of tirofiban on fibrinogen/agonist-induced platelet shape change and aggregation.
Topics: Adenosine Diphosphate; Blood Platelets; Cell Shape; Fibrinogen; Fibrinolytic Agents; Humans; In Vitro Techniques; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Fibrinogen; Serotonin; Tirofiban; Tyrosine | 2008 |
Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis.
Topics: Animals; Anticoagulants; Arginine; Arteriovenous Shunt, Surgical; Aspirin; Bleeding Time; Chlorides; Ferric Compounds; Guinea Pigs; Hemostasis; Male; Pipecolic Acids; Platelet Aggregation Inhibitors; Sulfonamides; Thrombosis; Tirofiban; Tyrosine | 2008 |
Unplanned surgery after drug eluting stent implantation: a strategy for safe temporary withdrawal of dual oral antiplatelet therapy.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Contraindications; Drug Therapy, Combination; Drug-Eluting Stents; Fibrinolytic Agents; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Preoperative Care; Surgical Procedures, Operative; Ticlopidine; Tirofiban; Tyrosine | 2008 |
Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Electrocardiography; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Platelet Aggregation Inhibitors; Polysaccharides; Risk Assessment; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2008 |
Heparin-induced thrombocytopenia and cardiopulmonary bypass: anticoagulation with unfractionated heparin and the GPIIb/IIIa inhibitor tirofiban and successful use of rFVIIa for post-protamine bleeding due to persistent platelet blockade.
Topics: Anticoagulants; Cardiopulmonary Bypass; Drug Therapy, Combination; Factor VIIa; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Postoperative Hemorrhage; Reoperation; Thrombocytopenia; Tirofiban; Tyrosine | 2008 |
Efficient tirofiban infusion resulting in resolution of intracoronary thrombus.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Electrocardiography; Fibrinolytic Agents; Heptanoic Acids; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine; Tirofiban; Tyrosine | 2008 |
Successful treatment of rotary pump thrombus with the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Adult; Anticoagulants; Aspirin; Female; Heart-Assist Devices; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tirofiban; Tyrosine; Warfarin | 2008 |
Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Risk Factors; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Ventricular Dysfunction, Right | 2008 |
The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Blood Coagulation Factors; Blood Platelets; Calcium Signaling; Collagen; Cytoplasmic Granules; Dose-Response Relationship, Drug; Female; In Vitro Techniques; Lysosomes; Male; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sus scrofa; Thrombelastography; Thrombin; Tirofiban; Tyrosine | 2008 |
Evaluation of triple anti-platelet therapy by modified thrombelastography in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Thrombelastography; Ticlopidine; Tirofiban; Tyrosine | 2008 |
Mechanical reperfusion: treat well, treat on time too.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Emergency Medical Services; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2008 |
Intra-arterial tirofiban infusion for thromboembolism during endovascular treatment of intracranial aneurysms.
Topics: Adult; Aged; Cohort Studies; Embolization, Therapeutic; Female; Humans; Infusions, Intra-Arterial; Intracranial Aneurysm; Male; Middle Aged; Radiography; Retrospective Studies; Thromboembolism; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Intracoronary thrombus aspiration through a guiding catheter in a case with stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Coronary Thrombosis; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stents; Suction; Tirofiban; Tyrosine | 2008 |
Overcoming "resistance" to aspirin and clopidogrel with tirofiban: fact or fiction?
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Ticlopidine; Tirofiban; Tyrosine | 2008 |
Rescue treatment with intra-arterial tirofiban infusion and emergent carotid stenting.
Topics: Carotid Artery, Internal; Carotid Stenosis; Emergency Treatment; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Radiography; Stents; Tirofiban; Tyrosine | 2008 |
Species differences in small molecule binding to alpha IIb beta 3 are the result of sequence differences in 2 loops of the alpha IIb beta propeller.
Topics: Adenosine Diphosphate; Amino Acid Sequence; Animals; Cell Line; Conserved Sequence; Cricetinae; Eptifibatide; Fibrinogen; Humans; Mice; Molecular Sequence Data; Peptides; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Rats; Recombinant Proteins; Sequence Alignment; Tirofiban; Tyrosine | 2009 |
Successful treatment of cardiogenic shock by stenting of the left main coronary artery in acute myocardial infarction.
Topics: Coronary Vessels; Electrocardiography; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Shock, Cardiogenic; Stents; Thrombolytic Therapy; Tirofiban; Tyrosine | 2008 |
Does tirofiban prevent platelet loss in patients after cardiogenic shock during continuous renal replacement therapy?
Topics: Blood Platelets; Critical Care; Humans; Platelet Count; Renal Replacement Therapy; Shock, Cardiogenic; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
[Case report of acute severe thrombocytopenia induced by tirofiban].
Topics: Acute Disease; Humans; Male; Middle Aged; Thrombocytopenia; Tirofiban; Tyrosine | 2008 |
Tirofiban increases soluble guanylate cyclase in rat vascular walls: pharmacological and pathophysiological consequences.
Topics: Animals; Antihypertensive Agents; Aorta; Blood Pressure; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Guanylate Cyclase; Humans; Hypertension; Isosorbide Dinitrate; Male; Muscle, Smooth, Vascular; Nitric Oxide Donors; Nitroprusside; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Tachyphylaxis; Time Factors; Tirofiban; Tyrosine; Up-Regulation; Vasodilation; Vasodilator Agents | 2009 |
Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Artery Disease; Eptifibatide; Female; Hemorrhage; Hospital Mortality; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
The benefits and risks of abciximab, eptifibatide, or tirofiban during PCI: class effects or do they differ?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Artery Disease; Eptifibatide; Hemorrhage; Hospital Mortality; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Risk Assessment; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Acute profound thrombocytopenia after treatment with tirofiban and off-pump coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Acute Disease; Angina, Unstable; Coronary Angiography; Coronary Artery Bypass, Off-Pump; Follow-Up Studies; Heparin; Humans; Infusions, Intravenous; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Platelet Transfusion; Postoperative Complications; Preoperative Care; Risk Assessment; Severity of Illness Index; Thrombocytopenia; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Essential thrombocythemia: a case of acute ST-segment elevation myocardial infarction in a young female.
Topics: Adult; Age Factors; Antisickling Agents; Aspirin; Clopidogrel; Coronary Angiography; Female; Fibrinolytic Agents; Heparin; Humans; Hydroxyurea; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombocythemia, Essential; Ticlopidine; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 2009 |
Effect of IIb-IIIa glycoprotein inhibitors in a partial limb amputation model submitted to warm ischemia in rats.
Topics: Abciximab; Amputation, Surgical; Animals; Antibodies, Monoclonal; Hindlimb; Immunoglobulin Fab Fragments; Limb Salvage; Male; Microcirculation; Models, Animal; No-Reflow Phenomenon; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Rats; Rats, Wistar; Tirofiban; Tyrosine; Warm Ischemia | 2009 |
The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2009 |
Acute inferior myocardial infarction due to cannabis smoking in a young man.
Topics: Adult; Angioplasty, Balloon, Coronary; Coronary Thrombosis; Fibrinolytic Agents; Humans; Male; Marijuana Smoking; Myocardial Infarction; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
First report of tirofiban-induced anemia (found in combination with severe thrombocytopenia).
Topics: Acute Disease; Anemia; Angioplasty, Balloon, Coronary; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Male; Middle Aged; Platelet Aggregation Inhibitors; Severity of Illness Index; Thrombocytopenia; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Tirofiban and activated protein C synergistically inhibit the Instant Blood Mediated Inflammatory Reaction (IBMIR) from allogeneic islet cells exposure to human blood.
Topics: ABO Blood-Group System; Blood Coagulation; Dose-Response Relationship, Drug; Drug Synergism; Humans; In Vitro Techniques; Inflammation; Islets of Langerhans Transplantation; Lymphocytes; Perfusion; Platelet Aggregation Inhibitors; Protein C; Recombinant Proteins; Tirofiban; Transplantation, Homologous; Tyrosine | 2009 |
[MULTISTRATEGY and FATA: merits, limits and troubles of no profit clinical trials in acute myocardial infarction].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clinical Trials as Topic; Drug Therapy, Combination; Drug-Eluting Stents; Electrocardiography; Humans; Immunoglobulin Fab Fragments; Italy; Myocardial Infarction; Platelet Aggregation Inhibitors; Survival Analysis; Tirofiban; Tyrosine | 2009 |
Integrin priming dynamics: mechanisms of integrin antagonist-promoted alphaIIbbeta3:PAC-1 molecular recognition.
Topics: Amidines; Dual Specificity Phosphatase 2; Eptifibatide; Integrins; Intercellular Signaling Peptides and Proteins; Isoxazoles; Models, Molecular; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Thermodynamics; Tirofiban; Tyrosine | 2009 |
Tirofiban administration and percutaneous coronary intervention with stenting of saphenous vein graft thrombosis.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Constriction, Pathologic; Coronary Angiography; Coronary Artery Bypass; Drug Administration Schedule; Embolism; Fibrinolytic Agents; Graft Occlusion, Vascular; Humans; Male; Saphenous Vein; Stents; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Characterization of static adhesion of human platelets in plasma to protein surfaces in microplates.
Topics: Abciximab; Albumins; Antibodies, Monoclonal; Blood Platelets; Collagen; Eptifibatide; Fibrinogen; Humans; Immunoglobulin Fab Fragments; Peptides; Plasma; Platelet Adhesiveness; Platelet Aggregation; Proteins; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Thromboxane A2; Tirofiban; Tyrosine | 2009 |
P-selectin antagonism reduces thrombus formation in humans.
Topics: Adolescent; Adult; Blood; Cells, Cultured; Cross-Over Studies; Double-Blind Method; Humans; Hydroxyquinolines; P-Selectin; Perfusion; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tirofiban; Tyrosine; Young Adult | 2009 |
Acute profound thrombocytopenia after treatment with tirofiban and off-pump coronary artery bypass grafting: is there a paradox?
Topics: Acute Coronary Syndrome; Acute Disease; Cardiopulmonary Bypass; Coronary Artery Bypass, Off-Pump; Humans; Metabolic Clearance Rate; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Premedication; Risk Factors; Thrombocytopenia; Tirofiban; Tyrosine | 2009 |
In vitro inhibition of platelet aggregation in response to increasing concentrations of tirofiban in patients with significant renal insufficiency.
Topics: Adenosine Diphosphate; Adolescent; Adult; Aged; Chi-Square Distribution; Creatinine; Female; Humans; In Vitro Techniques; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet-Rich Plasma; Renal Insufficiency; Risk Factors; Tirofiban; Tyrosine | 2009 |
Triple antiplatelet therapy for clopidogrel resistance with stent malapposition: a case report.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Sirolimus; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Resolution of late sirolimus-eluting stent thrombosis after tirofiban treatment.
Topics: Adult; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Drug-Eluting Stents; Electrocardiography; Fibrinolytic Agents; Humans; Infusions, Intra-Arterial; Male; Sirolimus; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
The GPIIbIIIa antagonist drugs eptifibatide and tirofiban do not induce activation of apoptosis executioner caspase-3 in resting platelets but inhibit caspase-3 activation in platelets stimulated with thrombin or calcium ionophore A23187.
Topics: Apoptosis; Blood Platelets; Calcimycin; Caspase 3; Coagulants; Enzyme Activation; Eptifibatide; Flow Cytometry; Humans; Ionophores; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombin; Tirofiban; Tyrosine | 2009 |
RGD-ligand mimetic antagonists of integrin alphaIIbbeta3 paradoxically enhance GPVI-induced human platelet activation.
Topics: Benzodiazepines; Biomimetics; Blood Coagulation; Blood Platelets; Calcium Signaling; Enzyme Activation; Humans; Immunoglobulin gamma-Chains; Intracellular Signaling Peptides and Proteins; Ligands; Oligopeptides; Phosphatidylserines; Phosphorylation; Piperidines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Protein Conformation; Protein-Tyrosine Kinases; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Secretory Vesicles; src-Family Kinases; Syk Kinase; Time Factors; Tirofiban; Tyrosine | 2010 |
Measuring the right compound at the right time is not always easy.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Platelets; C-Reactive Protein; Dose-Response Relationship, Drug; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Stents; Time Factors; Tirofiban; Tyrosine | 2010 |
Mechanism of platelet functional changes and effects of anti-platelet agents on in vivo hemostasis under different gravity conditions.
Topics: Actin Cytoskeleton; Adenosine Diphosphate; Animals; Aspirin; Blood Platelets; Calcium; Chelating Agents; Contractile Proteins; Egtazic Acid; Filamins; Hemostasis; Humans; Hypergravity; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microfilament Proteins; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Protein Binding; Ristocetin; Thrombosis; Time Factors; Tirofiban; Tyrosine; Weightlessness Simulation | 2010 |
Alveolar hemorrhage following tirofiban treatment. A misleading diagnosis.
Topics: Aged; Diagnostic Errors; Female; Hemorrhage; Humans; Lung Diseases; Platelet Aggregation Inhibitors; Pulmonary Alveoli; Tirofiban; Tyrosine | 2010 |
Vanishing platelets: rapid and extreme tirofiban-induced thrombocytopenia after percutaneous coronary intervention for acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Transfusion; Renal Insufficiency; Severity of Illness Index; Thrombocytopenia; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
Mechanical and chemical thrombolysis of cerebral sinus thrombosis: evolution of a technique.
Topics: Cerebral Angiography; Combined Modality Therapy; Endovascular Procedures; Female; Fibrinolytic Agents; Humans; Sinus Thrombosis, Intracranial; Suction; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine; Young Adult | 2011 |
Letter by Doraiswamy regarding article, "Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring
Topics: Anticoagulants; Aspirin; Clopidogrel; Confounding Factors, Epidemiologic; Double-Blind Method; Drug Resistance; Elective Surgical Procedures; Hemorrhage; Heparin; Humans; Myocardial Revascularization; Patient Selection; Platelet Aggregation Inhibitors; Postoperative Complications; Randomized Controlled Trials as Topic; Research Design; Thromboembolism; Ticlopidine; Tirofiban; Tyrosine | 2010 |
A case of acute stent thrombosis treated successfully with intracoronary tirofiban.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Coronary Thrombosis; Equipment Failure Analysis; Fibrinolytic Agents; Humans; Injections, Intra-Arterial; Male; Middle Aged; Shock, Cardiogenic; Stents; Tirofiban; Tyrosine | 2010 |
Complete thrombus resolution with tirofiban in obstructive mechanical prosthetic mitral valve thrombosis.
Topics: Adult; Anticoagulants; Coronary Thrombosis; Echocardiography, Transesophageal; Heart Valve Prosthesis; Humans; Male; Mitral Valve; Tirofiban; Tyrosine; Warfarin | 2010 |
In vitro evaluation of ultrasound-assisted thrombolysis using a targeted ultrasound contrast agent.
Topics: Animals; Biomarkers; Contrast Media; Dogs; Fibrinolytic Agents; Humans; Image Enhancement; Image Processing, Computer-Assisted; Microbubbles; Phantoms, Imaging; Reproducibility of Results; Serum Albumin; Sodium Chloride; Sonication; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine; Ultrasonics; Ultrasonography; Venous Thrombosis | 2009 |
Tirofiban 'bridging' therapy for patients with drug-eluting stents undergoing non-cardiac surgery.
Topics: Coronary Restenosis; Drug-Eluting Stents; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2010 |
IIb or Not IIb: is there a place for pre-hospital tirofiban in ST-segment elevation myocardial infarction patients?
Topics: Angioplasty, Balloon, Coronary; Electrocardiography; Emergency Medical Services; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; Pulse Therapy, Drug; Risk Assessment; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Creatine Kinase; Fibrinolytic Agents; Follow-Up Studies; Humans; Injections, Intravenous; Middle Aged; Myocardial Infarction; Retrospective Studies; Stroke Volume; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
Pharmacoinvasive strategy for ST-segment elevation myocardial infarction: wading through the treatment options.
Topics: Angioplasty; Anticoagulants; Drug-Eluting Stents; Humans; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine; Ultrasonography | 2010 |
Non-ST-segment elevation myocardial infarction in a patient with essential thrombocythemia treated with glycoprotein IIb/IIIa inhibitor: a case report.
Topics: Electrocardiography; Enzyme Inhibitors; Humans; Hydroxyurea; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Thrombosis; Tirofiban; Tyrosine | 2011 |
Successful surgical management of massive pulmonary embolism during the second trimester in a parturient with heparin-induced thrombocytopenia.
Topics: Adult; Anticoagulants; Cardiopulmonary Bypass; Echocardiography, Transesophageal; Embolectomy; Enoxaparin; Female; Fondaparinux; Heart Arrest, Induced; Heparin; Humans; Infant, Newborn; Live Birth; Male; Polysaccharides; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Trimester, Second; Pulmonary Embolism; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine; Venous Thrombosis; Warfarin | 2010 |
Promoting regeneration of peripheral nerves in-vivo using new PCL-NGF/Tirofiban nerve conduits.
Topics: Animals; Immunohistochemistry; Male; Microscopy, Electron, Scanning; Nerve Regeneration; PC12 Cells; Peripheral Nerves; Polyesters; Rats; Rats, Sprague-Dawley; Tirofiban; Tissue Engineering; Tissue Scaffolds; Tyrosine | 2011 |
Pulmonary embolectomy in heparin-induced thrombocytopenia and thrombosis? Safety of heparin use.
Topics: Anticoagulants; Cardiopulmonary Bypass; Embolectomy; Enoxaparin; Female; Fondaparinux; Heart Arrest, Induced; Heparin; Humans; Polysaccharides; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Trimester, Second; Pulmonary Embolism; Risk Assessment; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine; Ultrasonography; Venous Thrombosis; Warfarin | 2010 |
Shear-dependent suppression of platelet thrombus formation by phosphodiesterase 3 inhibition requires low levels of concomitant Gs-coupled receptor stimulation.
Topics: Aspirin; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Dose-Response Relationship, Drug; GTP-Binding Protein alpha Subunits, Gs; Hemostasis; Humans; Ligands; Platelet Aggregation; Quinolines; Ristocetin; Shear Strength; Tirofiban; Tyrosine; Urea; von Willebrand Factor | 2011 |
Alveolar hemorrhage following tirofiban treatment. A misleading diagnosis.
Topics: Hemorrhage; Humans; Lung Diseases; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pulmonary Alveoli; Pulmonary Wedge Pressure; Tirofiban; Tyrosine | 2010 |
[Efficiency and safety of thrombus aspiration plus intra-infarct-related artery administration of tirofiban during primary angioplasty].
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Tirofiban; Tyrosine | 2010 |
Traumatic dissection of a coronary artery: detection by multislice computed tomography and use of tirofiban as a reversible platelet inhibitor.
Topics: Accidents, Traffic; Aortic Dissection; Coronary Aneurysm; Coronary Angiography; Humans; Male; Myocardial Ischemia; Platelet Aggregation Inhibitors; Thoracic Injuries; Tirofiban; Tomography, X-Ray Computed; Tyrosine; Young Adult | 2011 |
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Antibodies, Monoclonal; Anticoagulants; Cost-Benefit Analysis; Decision Trees; Drug Therapy, Combination; Female; Health Care Costs; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Models, Econometric; Myocardial Revascularization; Peptide Fragments; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Quality-Adjusted Life Years; Recombinant Proteins; Survival Analysis; Tirofiban; Tyrosine; United Kingdom | 2011 |
Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolim
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiovascular Agents; Coronary Angiography; Disease-Free Survival; Drug-Eluting Stents; Female; Humans; Immunoglobulin Fab Fragments; Kaplan-Meier Estimate; Male; Metals; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; ROC Curve; Severity of Illness Index; Sirolimus; Stents; Thrombosis; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2011 |
Heparin versus tirofiban in microvascular anastomosis: randomized controlled trial in a rat model.
Topics: Anastomosis, Surgical; Animals; Disease Models, Animal; Drug Therapy, Combination; Fascia; Fibrinolytic Agents; Follow-Up Studies; Free Tissue Flaps; Head and Neck Neoplasms; Heparin; Microsurgery; Neoplasms, Experimental; Plastic Surgery Procedures; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Rats; Rats, Sprague-Dawley; Skin Transplantation; Therapeutic Irrigation; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine; Wound Healing | 2011 |
Granulocyte-CSF induced inflammation-associated cardiac thrombosis in iron loading mouse heart and can be attenuated by statin therapy.
Topics: Animals; Disease Models, Animal; Endothelial Cells; Fibrosis; Granulocyte Colony-Stimulating Factor; Heart Ventricles; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iron; Macrophages; Male; Mice; Mice, Inbred C57BL; Myocarditis; Simvastatin; Thrombosis; Tirofiban; Tyrosine | 2011 |
Cannabis: a rare trigger of premature myocardial infarction.
Topics: Adult; Angioplasty, Balloon, Coronary; Electrocardiography; Fibrinolytic Agents; Humans; Male; Marijuana Smoking; Myocardial Infarction; Risk Factors; Smoking; Stents; Time Factors; Tirofiban; Tyrosine | 2011 |
The antithrombotic activity of EP224283, a neutralizable dual factor Xa inhibitor/glycoprotein IIbIIIa antagonist, exceeds that of the coadministered parent compounds.
Topics: Animals; Biotin; Disease Models, Animal; Drug Combinations; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oligosaccharides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Rats; Thromboembolism; Tirofiban; Tyrosine | 2011 |
Delineating the roles of the GPIIb/IIIa and GP-Ib-IX-V platelet receptors in mediating platelet adhesion to adsorbed fibrinogen and albumin.
Topics: Adsorption; Antibodies, Monoclonal; Circular Dichroism; Fatty Alcohols; Fibrinogen; Gold; Humans; Platelet Adhesiveness; Platelet Glycoprotein GPIb-IX Complex; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Protein Conformation; Protein Structure, Secondary; Serum Albumin; Silicones; Sulfhydryl Compounds; Tirofiban; Tyrosine | 2011 |
Controversies with On-TIME 2.
Topics: Emergency Medical Services; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Tyrosine | 2011 |
Position of tirofiban in ST segment elevation myocardial infarction treatment: more than an adjunctive therapy.
Topics: Adult; Aged; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Tirofiban; Tyrosine | 2011 |
AMI on the move.
Topics: Accelerated Idioventricular Rhythm; Ambulances; Angioplasty, Balloon, Coronary; Coronary Occlusion; Delivery of Health Care, Integrated; Electrocardiography; Emergency Medical Services; Female; Fibrinolytic Agents; Gene Expression Profiling; Health Services Accessibility; Hemodynamics; Humans; Male; Myocardial Infarction; Outcome and Process Assessment, Health Care; Platelet Aggregation Inhibitors; RNA, Messenger; Telemetry; Tirofiban; Transcription, Genetic; Tyrosine | 2011 |
Dual oral antiplatelet therapy and unplanned surgery: possible role for intravenous platelet glycoprotein receptor inhibitors.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Biliary Tract Surgical Procedures; Cardiovascular Diseases; Cholangitis; Choledocholithiasis; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Humans; Infusions, Intravenous; Male; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2011 |
Intra-arterial adjuvant tirofiban after unsuccessful intra-arterial thrombolysis of acute ischemic stroke: preliminary experience in 16 patients.
Topics: Adult; Aged; Aged, 80 and over; Angiography; Brain Ischemia; Cerebral Hemorrhage; Combined Modality Therapy; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Injections, Intra-Arterial; Injections, Intravenous; Male; Middle Aged; Recovery of Function; Retrospective Studies; Stroke; Thrombolytic Therapy; Tirofiban; Tissue Plasminogen Activator; Treatment Outcome; Tyrosine; Urokinase-Type Plasminogen Activator | 2011 |
RGD mimetics containing phthalimidine fragment as novel ligands of fibrinogen receptor.
Topics: Arginine; Blood Platelets; Drug Design; Drug Evaluation, Preclinical; Fibrinogen; Fluorescein-5-isothiocyanate; Humans; Isoquinolines; Ligands; Oligopeptides; Phthalimides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Receptors, Fibrinogen; Software; Stereoisomerism; Structure-Activity Relationship; Tirofiban; Tyrosine | 2011 |
Acute stent thrombosis during percutaneous coronary intervention. Treatment with tirofiban.
Topics: Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis; Coronary Thrombosis; Fibrinolytic Agents; Humans; Male; Middle Aged; Radiography; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2012 |
IC bolus only versus IV with infusion 2b/3a inhibitors during STEMIs having PCI.
Topics: Angioplasty, Balloon, Coronary; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2012 |
Intra-arterial tirofiban infusion for partial recanalization with stagnant flow in hyperacute cerebral ischemic stroke.
Topics: Acute Disease; Adult; Blood Flow Velocity; Brain Ischemia; Cerebral Angiography; Diffusion Magnetic Resonance Imaging; Female; Fibrinolytic Agents; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Retrospective Studies; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2011 |
Tirofiban versus abciximab: tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates.
Topics: Abciximab; Animals; Antibodies, Monoclonal; Anticoagulants; Disease Models, Animal; Immunoglobulin Fab Fragments; Primates; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2012 |
Changes in BNP, hs-CRP and TIMI risk index with addition of tirofiban during primary percutaneous coronary intervention for acute STEMI: a prospective observational cohort study.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Biomarkers; C-Reactive Protein; Cohort Studies; Drug Administration Schedule; Female; Fibrinolytic Agents; Humans; Intraoperative Period; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk; Severity of Illness Index; Tirofiban; Tyrosine | 2012 |
Direct intracoronary delivery of tirofiban during primary percutaneous coronary intervention for ST-elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2012 |
The illusion of "optimal" platelet inhibition.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Blood Platelets; Cardiovascular Diseases; Coronary Artery Disease; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Thiophenes; Tirofiban; Tyrosine | 2012 |
Pharmacokinetic modeling of the high-dose bolus regimen of tirofiban in patients with severe renal impairment.
Topics: Acute Kidney Injury; Case-Control Studies; Humans; Models, Biological; Platelet Aggregation; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2012 |
Imaging of left main coronary artery thrombus with CT coronary angiography.
Topics: Acute Coronary Syndrome; Anticoagulants; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Coronary Vessels; Echocardiography; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Tirofiban; Tomography, X-Ray Computed; Tyrosine | 2012 |
Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIb/β3 integrin.
Topics: Animals; Antibodies; CHO Cells; Cricetinae; Cricetulus; Eptifibatide; Humans; Ligands; Mice; Mice, Inbred BALB C; Models, Biological; Oligopeptides; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Protein Conformation; Rats; Substrate Specificity; Thrombocytopenia; Tirofiban; Tyrosine | 2012 |
Upstream glycoprotein IIb/IIIa inhibitors for STEMI: use on-time or not at all?
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Thrombosis; Emergency Medical Services; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2012 |
Platelet-mediated mesenchymal stem cells homing to the lung reduces monocrotaline-induced rat pulmonary hypertension.
Topics: Animals; Antibodies; Blood Platelets; Blood Pressure; Bone Marrow Cells; Familial Primary Pulmonary Hypertension; Heart Ventricles; Hemodynamics; Hypertension, Pulmonary; Lung; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Monocrotaline; P-Selectin; Platelet Glycoprotein GPIIb-IIIa Complex; Rats; Rats, Sprague-Dawley; Tirofiban; Tyrosine | 2012 |
Two consecutive open heart operations in a small child with heparin-induced thrombocytopenia type II using anticoagulation with heparin and tirofiban.
Topics: Anticoagulants; Body Size; Cardiac Surgical Procedures; Drug Therapy, Combination; Heart Septal Defects; Heparin; Humans; Infant; Male; Platelet Aggregation Inhibitors; Thrombocytopenia; Tirofiban; Tyrosine | 2012 |
Acute myocardial infarction during the early postpartum period successfully treated with tirofiban.
Topics: Acute Disease; Adult; Coronary Angiography; Electrocardiography; Heart Valve Prosthesis; Humans; Male; Mitral Valve Insufficiency; Myocardial Infarction; Platelet Aggregation Inhibitors; Postpartum Period; Thrombosis; Tirofiban; Tyrosine | 2012 |
Local intraarterial tirofiban after formation of anterograde flow in patients with acute ischemic stroke: preliminary experience and short term follow-up results.
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Feasibility Studies; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Intracranial Hemorrhages; Male; Middle Aged; Stroke; Thrombolytic Therapy; Tirofiban; Tissue Plasminogen Activator; Treatment Outcome; Tyrosine; Urokinase-Type Plasminogen Activator | 2012 |
Huge left atrial appendage thrombus in a patient with atrial fibrillation: successful treatment with tirofiban.
Topics: Aged; Atrial Appendage; Atrial Fibrillation; Female; Humans; Platelet Aggregation Inhibitors; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Profound thrombocytopenia related with tirofiban: will it be enough to only stop medicine?
Topics: Acute Coronary Syndrome; Aged, 80 and over; Angioplasty, Balloon, Coronary; Female; Humans; Immunoglobulins, Intravenous; Platelet Count; Thrombocytopenia; Time Factors; Tirofiban; Tyrosine | 2013 |
Impact of preprocedural TIMI flow on myocardial perfusion, distal embolization and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Electrocardiography; Eptifibatide; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Regional Blood Flow; Regression Analysis; Retrospective Studies; Risk Factors; Survival Rate; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2012 |
Double interruption of antiplatelet therapy and tirofiban "bridging" for lung cancer resection.
Topics: Acute Coronary Syndrome; Aged; Biopsy, Needle; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Drug Substitution; Drug-Eluting Stents; Humans; Lung; Lung Neoplasms; Platelet Aggregation Inhibitors; Retreatment; Ticlopidine; Tirofiban; Tyrosine | 2012 |
Acute myocardial infarction secondary to blunt chest trauma treated with thrombus aspiration.
Topics: Adult; Cardiac Catheterization; Coronary Angiography; Coronary Thrombosis; Diagnosis, Differential; Fibrinolytic Agents; Humans; Male; Myocardial Infarction; Thoracic Injuries; Tirofiban; Tyrosine; Wounds, Nonpenetrating | 2012 |
Tirofiban in Takotsubo cardiomyopathy. Atypical broken heart syndrome with extremely fast recovery: a case report.
Topics: Female; Humans; Middle Aged; Platelet Aggregation Inhibitors; Recovery of Function; Takotsubo Cardiomyopathy; Tirofiban; Treatment Outcome; Tyrosine; Ventricular Dysfunction, Left | 2013 |
Left main coronary artery thrombus resulting from combined protein C and S deficiency.
Topics: Adult; Coronary Angiography; Coronary Thrombosis; Electrocardiography; Fibrinolytic Agents; Humans; Male; Protein C Deficiency; Protein S Deficiency; Tirofiban; Tyrosine | 2012 |
Management of myocardial infarction related to in situ thrombosis.
Topics: Angina Pectoris; Coronary Angiography; Coronary Thrombosis; Diagnosis, Differential; Female; Fibrinolytic Agents; Heparin; Humans; Middle Aged; Myocardial Infarction; Thrombectomy; Tirofiban; Tyrosine | 2013 |
PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty.
Topics: Abciximab; Aged; Amino Acid Substitution; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Platelets; Drug Administration Schedule; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Leucine; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Proline; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Tirofiban-induced acute profound thrombocytopenia after primary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Biomarkers; Erythrocyte Transfusion; Fibrinolytic Agents; Humans; Inferior Wall Myocardial Infarction; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Platelet Transfusion; Severity of Illness Index; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Endovascular stroke therapy: tirofiban is associated with risk of fatal intracerebral hemorrhage and poor outcome.
Topics: Aged; Aged, 80 and over; Cerebral Hemorrhage; Combined Modality Therapy; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Risk; Stroke; Thrombectomy; Tirofiban; Tyrosine | 2013 |
Improved outcomes from transradial over transfemoral access in primary percutaneous coronary intervention for patients with acute ST-segment elevation myocardial infarction and upstream use of tirofiban.
Topics: Aged; Angioplasty, Balloon, Coronary; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Tirofiban; Tyrosine | 2013 |
[Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Monitoring; Electrocardiography; Female; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Preoperative Care; Retrospective Studies; Survival Analysis; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
[Influence of the combination of antiplatelet agents on the occurrence of early left ventricular insufficiency in patients with acute coronary syndromes without persistent ST-segment elevation].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine; Ventricular Dysfunction, Left | 2014 |
Glycoprotein IIb/IIIa antagonists in Takotsubo cardiomyopathy.
Topics: Cardiac Tamponade; Fibrinolytic Agents; Humans; Platelet Glycoprotein GPIIb-IIIa Complex; Takotsubo Cardiomyopathy; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
From treatment to diagnosis of Kounis syndrome in the catherization laboratory: the resolution of vasospastic angina after intracoronary tirofiban and nitrate therapy.
Topics: Acute Coronary Syndrome; Cardiac Catheterization; Coronary Vasospasm; Coronary Vessels; Humans; Hypersensitivity; Male; Middle Aged; Nitrates; Syndrome; Tirofiban; Tyrosine | 2013 |
Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Atrial Fibrillation; Brain Ischemia; Combined Modality Therapy; Comorbidity; Female; Fibrinolytic Agents; Humans; Hypertension; Immunoglobulin Fab Fragments; Infusions, Intra-Arterial; Infusions, Intravenous; Intracranial Hemorrhages; Magnetic Resonance Imaging; Male; Mechanical Thrombolysis; Middle Aged; Neuroimaging; Prognosis; Registries; Retrospective Studies; Risk Factors; Severity of Illness Index; Single-Blind Method; Thrombolytic Therapy; Tirofiban; Tissue Plasminogen Activator; Treatment Outcome; Tyrosine; Urokinase-Type Plasminogen Activator | 2013 |
Tirofiban-induced acute profound thrombocytopenia: what is the optimal approach to treatment?
Topics: Adult; Humans; Immunoglobulins, Intravenous; Male; Platelet Aggregation Inhibitors; Platelet Count; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine | 2015 |
Short-term effect of upstream administration in comparison to deferred injection of tirofiban on patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Aged; Coronary Angiography; Electrocardiography; Female; Humans; Injections; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke Volume; Tirofiban; Tyrosine; Ventricular Function, Left | 2013 |
Glycoprotein IIb/III inhibition during acute percutaneous coronary intervention: tool or talisman?
Topics: Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2013 |
An effect of glycoprotein IIb/IIIa inhibitors on the kinetics of red blood cells aggregation.
Topics: Adult; Antibodies, Monoclonal; Blood Platelets; Cell Communication; Eptifibatide; Erythrocyte Aggregation; Erythrocytes; Fibrinogen; Humans; Kinetics; Ligands; Optics and Photonics; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine; Young Adult | 2014 |
Effects of upstream administration of tirofiban before percutaneous coronary intervention on spontaneous reperfusion and clinical outcomes in acute ST-segment elevation myocardial infarction.
Topics: Aged; Chi-Square Distribution; Combined Modality Therapy; Coronary Circulation; Disease-Free Survival; Drug Administration Schedule; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Reperfusion; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2015 |
[The prospective register study of domestic tirofiban for clinical application in acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aged; Female; Humans; Male; Middle Aged; Prospective Studies; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Multiple coronary thrombi with cisplatin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Coronary Thrombosis; Etoposide; Humans; Male; Percutaneous Coronary Intervention; Stents; Teratoma; Testicular Neoplasms; Tirofiban; Treatment Outcome; Tyrosine | 2014 |
The safety and efficacy of 12 versus 24 hours of tirofiban infusion in patients undergoing primary percutaneous coronary intervention.
Topics: Aged; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Postoperative Care; Retrospective Studies; Time Factors; Tirofiban; Tyrosine | 2015 |
High-bolus dose tirofiban compared with abciximab in primary percutaneous coronary intervention: a propensity score-matched outcome study.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Survival Analysis; Thrombocytopenia; Thrombosis; Tirofiban; Tyrosine | 2015 |
Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies.
Topics: Anesthesiology; Aspirin; Cardiac Surgical Procedures; Cardiology; Clopidogrel; Eptifibatide; Hemorrhage; Humans; Italy; Myocardial Ischemia; Peptides; Perioperative Care; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Societies, Medical; Stents; Surgical Procedures, Operative; Thoracic Surgery; Ticlopidine; Tirofiban; Tyrosine | 2014 |
Instant reocclusion following mechanical thrombectomy of in situ thromboocclusion and the role of low-dose intra-arterial tirofiban.
Topics: Adult; Aged; Aged, 80 and over; Angiography; Brain; Brain Ischemia; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Prospective Studies; Recurrence; Stroke; Thrombectomy; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2014 |
Clinical research of treatment with tirofiban for high-risk non-ST-segment elevation acute coronary syndrome during peri-operative intervention operation period.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Electrocardiography; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Perioperative Period; Risk; Tirofiban; Tyrosine | 2015 |
Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy.
Topics: Absorbable Implants; Adenosine; Adult; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Graft Occlusion, Vascular; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor; Ticlopidine; Tirofiban; Tissue Scaffolds; Tyrosine | 2015 |
Intra-arterial infusion of tirofiban and urokinase for thromboembolic complications during coil embolization of ruptured intracranial aneurysms.
Topics: Adult; Aged; Aneurysm, Ruptured; Combined Modality Therapy; Drug Therapy, Combination; Embolization, Therapeutic; Female; Fibrinolytic Agents; Humans; Infusions, Intra-Arterial; Intracranial Embolism; Intracranial Thrombosis; Male; Mechanical Thrombolysis; Middle Aged; Subarachnoid Hemorrhage; Tirofiban; Treatment Outcome; Tyrosine; Urokinase-Type Plasminogen Activator | 2014 |
Tirofiban induced anemia without thrombocytopenia.
Topics: Aged; Anemia; Coronary Angiography; Coronary Stenosis; Fibrinolytic Agents; Humans; Male; Stents; Thrombocytopenia; Tirofiban; Tyrosine | 2015 |
Acute thrombosis during left main stenting using tap technique in a patient presenting with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Drug Combinations; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Stents; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2015 |
Plasminogen associates with phosphatidylserine-exposing platelets and contributes to thrombus lysis under flow.
Topics: Blood Platelets; Crotalid Venoms; Fibrin; Fibrinolysin; Fibrinolysis; Fibrinolytic Agents; Flow Cytometry; Hemostatics; Hirudins; Lectins, C-Type; Microscopy, Confocal; Oligopeptides; Phosphatidylserines; Protein Binding; Rheology; Shear Strength; Thrombin; Thrombosis; Tirofiban; Tissue Plasminogen Activator; Tyrosine; Urokinase-Type Plasminogen Activator | 2015 |
Can BRIGHT restore the glow of bivalirudin?
Topics: Antithrombins; Female; Fibrinolytic Agents; Heparin; Hirudins; Humans; Male; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Recombinant Proteins; Tirofiban; Tyrosine | 2015 |
[Two catheters for one coronary perforation].
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Aspirin; Cardiac Catheterization; Catheters; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dyslipidemias; Femoral Artery; Heart Injuries; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Percutaneous Coronary Intervention; Premedication; Radial Artery; Stents; Tirofiban; Tyrosine | 2015 |
The effects of tirofiban infusion on clinical and angiographic outcomes of patients with STEMI undergoing primary PCI.
Topics: Aged; Coronary Angiography; Drug Administration Schedule; Female; Fibrinolytic Agents; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Retrospective Studies; Tirofiban; Treatment Outcome; Tyrosine | 2015 |
Platelet Glycoprotein IIb/IIIa Inhibitor Tirofiban Ameliorates Cardiac Reperfusion Injury.
Topics: Animals; Apoptosis; In Situ Nick-End Labeling; Malondialdehyde; Myocardial Reperfusion Injury; Myocardium; Peroxidase; Platelet Glycoprotein GPIIb-IIIa Complex; Rats; Rats, Sprague-Dawley; Tirofiban; Tyrosine | 2015 |
A novel snake venom-derived GPIb antagonist, anfibatide, protects mice from acute experimental ischaemic stroke and reperfusion injury.
Topics: Animals; Bleeding Time; Blood Platelets; Brain Ischemia; Cell Count; Cerebral Hemorrhage; Crotalid Venoms; Dose-Response Relationship, Drug; Fibrin; Infarction, Middle Cerebral Artery; Lectins, C-Type; Male; Mice; Platelet Glycoprotein GPIb-IX Complex; Protective Agents; Reperfusion Injury; Stroke; Tirofiban; Tyrosine; von Willebrand Factor | 2015 |
GDF-15 prevents ventilator-induced lung injury by inhibiting the formation of platelet-neutrophil aggregates.
Topics: Animals; Blood Platelets; Capillary Permeability; Cell Adhesion; Chemotaxis, Leukocyte; Drug Evaluation, Preclinical; Extracellular Traps; Growth Differentiation Factor 15; Lung; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Neutrophils; Platelet Adhesiveness; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Transfusion; Pulmonary Edema; Pulmonary Gas Exchange; Radiation Chimera; RNA, Messenger; Tirofiban; Tyrosine; Ventilator-Induced Lung Injury | 2015 |
Protective effects of tirofiban on ischemia/reperfusion-induced renal injury in vivo and in vitro.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Blood Urea Nitrogen; Cell Line; Chemotaxis, Leukocyte; Creatinine; Cytoprotection; Disease Models, Animal; Kidney; Kidney Diseases; Male; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Rats, Sprague-Dawley; Reactive Oxygen Species; Reperfusion Injury; Tirofiban; Tyrosine | 2015 |
Ventriculostomy-Related Hemorrhage After Treatment of Acutely Ruptured Aneurysms: The Influence of Anticoagulation and Antiplatelet Treatment.
Topics: Acute Disease; Adult; Aged; Aneurysm, Ruptured; Anticoagulants; Aspirin; Cerebral Hemorrhage; Clopidogrel; Endovascular Procedures; Female; Heparin, Low-Molecular-Weight; Humans; Hydrocephalus; Intracranial Aneurysm; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Thromboembolism; Ticlopidine; Tirofiban; Tyrosine; Ventriculostomy | 2015 |
Predictors of No-Reflow Phenomenon in Young Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Topics: Adult; Age Factors; Chi-Square Distribution; Coronary Circulation; Female; Humans; Logistic Models; Lymphocyte Count; Male; Mean Platelet Volume; Middle Aged; No-Reflow Phenomenon; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Count; Retrospective Studies; Risk Factors; Sex Factors; ST Elevation Myocardial Infarction; Time Factors; Time-to-Treatment; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Safety and Efficacy of Intravenous Tirofiban as Antiplatelet Premedication for Stent-Assisted Coiling in Acutely Ruptured Intracranial Aneurysms.
Topics: Administration, Intravenous; Aged; Aneurysm, Ruptured; Cerebral Hemorrhage; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Male; Middle Aged; Platelet Aggregation Inhibitors; Premedication; Retrospective Studies; Stents; Thromboembolism; Tirofiban; Tyrosine | 2016 |
A New Protocol for Anticoagulation With Tirofiban During Flow Diversion.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clinical Protocols; Clopidogrel; Embolization, Therapeutic; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Intracranial Aneurysm; Intracranial Hemorrhages; Intraoperative Care; Male; Middle Aged; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Tirofiban; Tyrosine | 2016 |
Imaging of deep venous thrombosis using radioactive-labeled tirofiban.
Topics: Animals; Disease Models, Animal; Male; Platelet Glycoprotein GPIIb-IIIa Complex; Radionuclide Imaging; Rats; Rats, Wistar; Technetium; Tirofiban; Tyrosine; Venous Thrombosis | 2015 |
Safety and efficacy of a new prophylactic tirofiban protocol without oral intraoperative antiplatelet therapy for endovascular treatment of ruptured intracranial aneurysms.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aneurysm, Ruptured; Embolization, Therapeutic; Endovascular Procedures; Female; Humans; Injections, Intravenous; Intracranial Aneurysm; Intraoperative Care; Male; Middle Aged; Platelet Aggregation Inhibitors; Pre-Exposure Prophylaxis; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Bridge therapy or standard treatment for urgent surgery after coronary stent implantation: Analysis of 314 patients.
Topics: Ambulatory Care; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Stenosis; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Surgical Procedures, Operative; Tirofiban; Tyrosine | 2016 |
Tirofiban counteracts endothelial cell apoptosis through the VEGF/VEGFR2/pAkt axis.
Topics: Apoptosis; Blotting, Western; Cell Culture Techniques; Cell Survival; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Human Umbilical Vein Endothelial Cells; Humans; Integrin beta3; Proto-Oncogene Proteins c-akt; Tirofiban; Tumor Necrosis Factor-alpha; Tyrosine; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
A misleading diagnosis in acute coronary syndrome: tirofiban-induced alveolar hemorrhage.
Topics: Acute Coronary Syndrome; Acute Lung Injury; Adult; Diagnostic Errors; Fibrinolytic Agents; Hemorrhage; Humans; Male; Tirofiban; Tyrosine | 2015 |
Tirofiban as treatment for acute retinal artery occlusion following internal carotid artery flow diverter implantation.
Topics: Acute Disease; Aged; Carotid Artery Diseases; Carotid Artery, Internal; Female; Fluorescein Angiography; Humans; Intracranial Aneurysm; Magnetic Resonance Imaging; Male; Platelet Aggregation Inhibitors; Retinal Artery Occlusion; Stents; Tirofiban; Tomography, Optical Coherence; Tyrosine; Visual Acuity | 2016 |
Diffused alveolar hemorrhage: A rare and severe complication of tirofiban-induced thrombocytopenia.
Topics: Aged; Coronary Occlusion; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Thrombocytopenia; Tirofiban; Tyrosine | 2016 |
Gene mutations of platelet glycoproteins and response to tirofiban in acute coronary syndrome.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Angina, Unstable; Antibodies, Monoclonal; Eptifibatide; Female; Genotype; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Mutation; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Polymerase Chain Reaction; Prospective Studies; Tirofiban; Tyrosine | 2016 |
[A large-scale, multicenter, retrospective study on efficacy of bivalirudin use during peri-percutaneous coronary intervention period for Chinese patients with coronary heart disease].
Topics: Aged; China; Coronary Disease; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Peptide Fragments; Percutaneous Coronary Intervention; Recombinant Proteins; Retrospective Studies; Stroke; Tirofiban; Tyrosine | 2016 |
Tirofiban induces vasorelaxation of the coronary artery via an endothelium-dependent NO-cGMP signaling by activating the PI3K/Akt/eNOS pathway.
Topics: Animals; Coronary Circulation; Coronary Vessels; Cyclic GMP; Dose-Response Relationship, Drug; Endothelium, Vascular; In Vitro Techniques; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Signal Transduction; Tirofiban; Tyrosine; Vasodilation; Vasodilator Agents | 2016 |
In Reply: Safety and Efficacy Issues of Tirofiban Use in Endovascular Procedures: What Are the Actual Indications?
Topics: Endovascular Procedures; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Letter: Safety and Efficacy Issues of Tirofiban Use in Endovascular Procedures: What Are the Actual Indications?
Topics: Endovascular Procedures; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Thrombus remnant despite intra-arterial thrombolysis for thrombus formation during endovascular treatment of ruptured cerebral aneurysms: Does it harm?
Topics: Adult; Aged; Aged, 80 and over; Aneurysm, Ruptured; Cerebral Angiography; Endovascular Procedures; Female; Fibrinolytic Agents; Humans; Intracranial Aneurysm; Male; Middle Aged; Stents; Thrombolytic Therapy; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Impact of Target Arterial Residual Stenosis on Outcome After Endovascular Revascularization.
Topics: Aged; Cerebral Angiography; Combined Modality Therapy; Computed Tomography Angiography; Diagnosis, Differential; Endovascular Procedures; Female; Humans; Infarction, Middle Cerebral Artery; Intracranial Arteriosclerosis; Magnetic Resonance Angiography; Male; Middle Aged; Prevalence; Recurrence; Retrospective Studies; Risk Factors; Smoking; Thrombectomy; Tirofiban; Treatment Outcome; Tyrosine; Vasospasm, Intracranial | 2016 |
Drug Targets for Cardiovascular-Safe Anti-Inflammatory: In Silico Rational Drug Studies.
Topics: Anti-Inflammatory Agents; Aspirin; Binding Sites; Caffeic Acids; Celecoxib; Coumaric Acids; Cyclooxygenase 1; Cyclooxygenase 2; ERG1 Potassium Channel; Eugenol; Heart; Humans; Inflammation; Integrin alpha2; Protein Structure, Tertiary; Tirofiban; Tyrosine | 2016 |
Diagnosis and Treatment Algorithm for Blood Flow Obstructions in Patients With Left Ventricular Assist Device.
Topics: Algorithms; Equipment Design; Equipment Failure; Female; Fibrinolytic Agents; Heart-Assist Devices; Humans; Male; Middle Aged; Retrospective Studies; Thrombectomy; Thrombosis; Tirofiban; Tyrosine | 2016 |
The association of the coronary thrombus burden with all-cause mortality and major cardiac events in ST-segment elevation myocardial infarction patients treated with tirofiban.
Topics: Aged; Cause of Death; Coronary Thrombosis; Female; Hemorrhage; Hospital Mortality; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Recurrence; Retrospective Studies; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Amides and neolignans from the aerial parts of Piper bonii.
Topics: Alkaloids; Amides; Benzofurans; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Flavonoids; Glycosides; Humans; Inhibitory Concentration 50; Lignans; Molecular Structure; Piper; Piperidines; Plant Components, Aerial; Platelet Aggregation; Platelet Aggregation Inhibitors; Structure-Activity Relationship; Tirofiban; Tyrosine | 2016 |
Metallaphotoredox-catalysed sp(3)-sp(3) cross-coupling of carboxylic acids with alkyl halides.
Topics: Carbon; Carboxylic Acids; Catalysis; Molecular Structure; Nickel; Oxidation-Reduction; Tirofiban; Tyrosine | 2016 |
Rescue mechanical thrombectomy using a retrievable stent for thromboembolic occlusion occurring during coil embolization of ruptured intracranial aneurysms.
Topics: Adult; Aged; Aneurysm, Ruptured; Blood Vessel Prosthesis; Embolization, Therapeutic; Female; Humans; Infusions, Intravenous; Intracranial Aneurysm; Male; Mechanical Thrombolysis; Middle Aged; Retrospective Studies; Stents; Thrombectomy; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
Aspirin, but Not Tirofiban Displays Protective Effects in Endotoxin Induced Lung Injury.
Topics: Acute Lung Injury; Animals; Endotoxins; Male; Mice; Mice, Inbred C57BL; Neutrophils; Tirofiban; Tyrosine | 2016 |
Safety and Preliminary Efficacy of Early Tirofiban Treatment After Alteplase in Acute Ischemic Stroke Patients.
Topics: Aged; Brain; Brain Ischemia; Drug Administration Schedule; Female; Fibrinolytic Agents; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Stroke; Thrombolytic Therapy; Time Factors; Tirofiban; Tissue Plasminogen Activator; Tomography, X-Ray Computed; Treatment Outcome; Tyrosine | 2016 |
Platelet Integrin αIIbβ3 Inhibitor Rescues Progression of Apoptosis in Human Platelets.
Topics: Adult; Apoptosis; Blood Platelets; Female; Humans; Male; Membrane Potential, Mitochondrial; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Reactive Oxygen Species; Thrombin; Tirofiban; Tyrosine | 2016 |
In-Silico Analysis of Amotosalen Hydrochloride Binding to CD-61 of Platelets.
Topics: Bleeding Time; Blood Platelets; Computer Simulation; Furocoumarins; Hemorrhage; Humans; Photosensitizing Agents; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2016 |
Validated spectrofluorimetric methods for the determination of apixaban and tirofiban hydrochloride in pharmaceutical formulations.
Topics: Calibration; Drug Compounding; Limit of Detection; Pyrazoles; Pyridones; Reproducibility of Results; Solutions; Solvents; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Tirofiban; Tyrosine | 2017 |
A Naphthalenic Derivative ND-1 Inhibits Thrombus Formation by Interfering the Binding of Fibrinogen to Integrin
Topics: Abciximab; Animals; Antibodies, Monoclonal; Cardiovascular Diseases; Disease Models, Animal; Eptifibatide; Fibrinogen; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Integrin alpha2; Integrin beta3; Mice; Naphthalenes; Peptides; Platelet Aggregation; Rats; Thrombocytopenia; Thrombosis; Tirofiban; Tyrosine | 2016 |
Aspiration thrombectomy and intracoronary tirofiban via GuideLiner
Topics: Cardiac Catheterization; Chemotherapy, Adjuvant; Coronary Angiography; Coronary Thrombosis; Fibrinolytic Agents; Humans; Male; Mechanical Thrombolysis; Middle Aged; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
An Anti-Coagulation Conundrum: Implantation of Total Artificial Heart in a Patient with Heparin-Induced Thrombocytopenia Type II.
Topics: Anticoagulants; Cardiopulmonary Bypass; Heart, Artificial; Heparin; Humans; Platelet Aggregation Inhibitors; Thrombocytopenia; Tirofiban; Tyrosine | 2017 |
Stentriever Thrombectomy Failure: A Challenge in Stroke Management.
Topics: Aged; Aged, 80 and over; Arterial Occlusive Diseases; Carotid Artery Diseases; Cerebral Angiography; Computed Tomography Angiography; Endovascular Procedures; Female; Fibrinolytic Agents; Humans; Infarction, Middle Cerebral Artery; Infusions, Intra-Arterial; Intracranial Hemorrhages; Magnetic Resonance Angiography; Male; Middle Aged; Mortality; Prospective Studies; Stents; Stroke; Thrombectomy; Thrombolytic Therapy; Tirofiban; Tissue Plasminogen Activator; Treatment Failure; Treatment Outcome; Tyrosine; Ultrasonography, Doppler, Transcranial | 2017 |
Preliminary Study of Tirofiban Infusion in Coil Embolization of Ruptured Intracranial Aneurysms.
Topics: Adult; Aged; Aneurysm, Ruptured; Embolization, Therapeutic; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Intracranial Aneurysm; Male; Middle Aged; Retrospective Studies; Tirofiban; Treatment Outcome; Tyrosine | 2018 |
High-dose bolus tirofiban versus low-dose bolus in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Postoperative Complications; Retrospective Studies; Thrombosis; Tirofiban; Tyrosine | 2017 |
Early Thrombosuction and Tirofiban Use in Knee and Below-Knee Arterial Thrombosis.
Topics: Aged; Aged, 80 and over; Arteries; Embolism; Female; Hemorrhage; Humans; Knee Joint; Leg; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Thrombectomy; Thromboembolism; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
Bridging with Tirofiban during Oral Antiplatelet Interruption: A Single-Center Case Series Analysis Including Patients on Hemodialysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Coronary Artery Disease; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Intraoperative Care; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Renal Dialysis; Retrospective Studies; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
[Long-lasting thrombocytopenia induced by glycoprotein IIb/IIIa inhibitor].
Topics: Aged; Humans; Male; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Severity of Illness Index; Thrombocytopenia; Time Factors; Tirofiban; Tyrosine | 2017 |
Intravenous administration of tirofiban versus loading dose of oral clopidogrel for preventing thromboembolism in stent-assisted coiling of intracranial aneurysms.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Clopidogrel; Endovascular Procedures; Female; Fibrinolytic Agents; Humans; Intracranial Aneurysm; Male; Middle Aged; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Tirofiban; Tyrosine; Young Adult | 2017 |
Force-activatable biosensor enables single platelet force mapping directly by fluorescence imaging.
Topics: Animals; Biosensing Techniques; Blood Platelets; Cell Adhesion; Dogs; Drug Evaluation, Preclinical; Equipment Design; Humans; Integrins; Optical Imaging; Platelet Activation; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2018 |
Effects of Tirofiban on Random Skin Flap Survival in Rats.
Topics: Animals; Graft Survival; Male; Models, Animal; Oxidative Stress; Plastic Surgery Procedures; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Rats; Rats, Sprague-Dawley; Surgical Flaps; Tirofiban; Tyrosine | 2018 |
Comparison on Anticoagulation and Antiplatelet Aggregation Effects of Puerarin with Heparin Sodium and Tirofiban Hydrochloride: An In Vitro Study.
Topics: Adult; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Female; Heparin; Humans; Isoflavones; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Tirofiban; Tyrosine | 2018 |
Low-Dose Tirofiban Improves Functional Outcome in Acute Ischemic Stroke Patients Treated With Endovascular Thrombectomy.
Topics: Aged, 80 and over; Brain Ischemia; Cerebral Hemorrhage; Combined Modality Therapy; Endpoint Determination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Recurrence; Registries; Risk Factors; Stroke; Thrombectomy; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
Efficacy and safety of quadruple therapy including tirofiban in the treatment of Chinese NSTE-ACS patients failing to receive timely percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; China; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Multicenter Studies as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Time Factors; Tirofiban; Tyrosine | 2017 |
Safety and preliminary efficacy of intravenous tirofiban in acute ischemic stroke patient without arterial occlusion on neurovascular imaging studies.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Brain; Brain Ischemia; Cerebral Angiography; Cerebral Hemorrhage; Computed Tomography Angiography; Diffusion Magnetic Resonance Imaging; Female; Fibrinolytic Agents; Humans; Incidence; Male; Middle Aged; Proof of Concept Study; Stroke; Time Factors; Time-to-Treatment; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
Perioperative Management of Dual Antiplatelet Therapy.
Topics: Aspirin; Elective Surgical Procedures; Hemorrhage; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine; Tirofiban; Tyrosine | 2018 |
Impact of pre-procedural dual antiplatelet therapy on periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions with adjunctive tirofiban.
Topics: Aged; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2018 |
Protein kinases are involved in the cardioprotective effects activated by platelet glycoprotein IIb/IIIa inhibitor tirofiban at reperfusion in rats in vivo.
Topics: Animals; Cardiotonic Agents; Enzyme Activation; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Phosphatidylinositol 3-Kinases; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Kinase C-epsilon; Protein Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Tirofiban; Tyrosine | 2018 |
Effect of intra-coronary administration of tirofiban through aspiration catheter on patients over 60 years with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Topics: Aged; Aged, 80 and over; Angiography; Angioplasty, Balloon, Coronary; Catheters; Drug Administration Routes; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Perfusion Imaging; Myocardium; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2018 |
Acute Myocardial Infarction in Nephrotic Syndrome.
Topics: Adult; Anterior Wall Myocardial Infarction; Coronary Angiography; Coronary Vessels; Fibrinolytic Agents; Humans; Hypertension; Injections, Intra-Arterial; Male; Nephrotic Syndrome; Nitroglycerin; ST Elevation Myocardial Infarction; Thrombectomy; Tirofiban; Treatment Outcome; Tyrosine; Vasodilator Agents | 2015 |
Prophylactic administration of tirofiban for preventing thromboembolic events in flow diversion treatment of intracranial aneurysms.
Topics: Embolization, Therapeutic; Humans; Intracranial Aneurysm; Platelet Aggregation Inhibitors; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2021 |
A meta-analysis of randomized controlled trials investigating tirofiban combined with conventional drugs by intracoronary administration for no-reflow prevention.
Topics: Humans; Percutaneous Coronary Intervention; Pharmaceutical Preparations; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tirofiban; Treatment Outcome; Tyrosine | 2021 |
Walking on a thin line between potent platelet inhibition for myocardial infarction and risk of hemorrhagic complications. Tirofiban induced subconjunctival hemorrhage.
Topics: Adult; Blood Platelets; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine; Walking | 2021 |
Primary Percutaneous Coronary Intervention with High-Bolus Dose Tirofiban: The FASTER (Favorite Approach to Safe and Effective Treatment for Early Reperfusion) Multicenter Registry.
Topics: Aged; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Reperfusion; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2022 |
Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens.
Topics: European Union; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2022 |
Tirofiban potentiates agonist-induced platelet activation and degranulation, despite effectively inhibiting aggregation.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Blood Platelets; Chemokine CCL5; Humans; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Thrombin; Tirofiban; Tyrosine | 2022 |
Safety Profile and Complication Rates in Emergency Off-label Use of Tirofiban in Interventional Neuroradiology : An Observational Dual Center Study.
Topics: Adult; Aged; Aged, 80 and over; Fibrinolytic Agents; Humans; Ischemic Stroke; Middle Aged; Off-Label Use; Platelet Aggregation Inhibitors; Retrospective Studies; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2023 |
[Role of platelets aggregation in the process of ductus arteriosus closure of newborn pups].
Topics: Animals; Animals, Newborn; Antibodies, Monoclonal; Blood Platelets; Cesarean Section; Dogs; Ductus Arteriosus; Female; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pregnancy; Tirofiban; Tyrosine | 2022 |
PLATELET SUPPRESSION BY TIROFIBAN AMELIORATES PULMONARY COAGULATION AND FIBRINOLYSIS ABNORMALITIES IN THE LUNGS OF MOUSE ANTIBODY-MEDIATED TRANSFUSION-RELATED ACUTE LUNG INJURY.
Topics: Acute Lung Injury; Antibodies; Fibrin; Fibrinolysis; Humans; Lung; Male; Platelet Aggregation Inhibitors; Tirofiban; Transfusion-Related Acute Lung Injury; Tyrosine | 2023 |